Review

Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications

Md Nurul Huda, Md Nafiujjaman, Isaac G. Deaguero, Jude Okonkwo, Meghan L. Hill, Taeho Kim,* and Md Nurunnabi*

Cite This: https://doi.org/10.1021/acsbiomaterials.1c00217

Read Online

ACCESS | Metrics & More | Article Recommendations

ABSTRACT: Exosomes are cell-derived vesicles containing heterogeneous active biomolecules such as proteins, lipids, mRNAs, receptors, immune regulatory molecules, and nucleic acids. They typically range in size from 30 to 150 nm in diameter. An exosome's surfaces can be bioengineered with antibodies, fluorescent dye, peptides, and tailored for small molecule and large active biologics. Exosomes have enormous potential as a drug delivery vehicle due to enhanced biocompatibility, excellent payload capability, and reduced immunogenicity compared to alternative polymeric-based carriers. Because of active targeting and specificity, exosomes are capable of delivering their cargo to exosome-recipient cells. Additionally, exosomes can potentially act as early stage disease diagnostic tools as the exosome carries various protein biomarkers associated with a specific disease. In this review, we summarize recent progress on exosome composition, biological characterization, and isolation techniques. Finally, we outline the exosome's clinical applications and preclinical advancement to provide an outlook on the importance of exosomes for use in targeted drug delivery, biomarker study, and vaccine development.

KEYWORDS: Exosome, clinical translation, drug delivery, biomarker, diagnosis, vaccine

1. INTRODUCTION

With recent development and progress, biomarkers are an emerging tool for drug discovery and development. Given that the exosome embodies various proteins and lipids that are cell derived, these specific proteins, receptors, signaling molecules, and lipids can be identified and potentially used for diagnostic measures of abnormalities on the cellular level when compared with a healthy control.[1] Therefore, exosome-mediated detection technologies have emerging potential in the early stage disease diagnosis field. Early detection via biomarker identification is considered a robust tool for efficient treatment of various chronic diseases such as cancer, autoimmune, infectious, and inflammatory diseases.[2−4] Besides, biomarkers are being widely used as diagnostic tools, personalized medicine platforms, and substitute end points for clinical research.[5]

Over the past decade, there have been many exciting developments in drug delivery. Synthetic biopolymers stand out among these innovations due to their ability to act as a drug delivery platform with improved abilities in drug targeting and controlled release.[6] Also, a range of exosome-mediated drug formulations is being developed and currently undergoing preclinical and clinical trials. Unfortunately, drug-loaded synthetic polymers will opsonize with other biomolecules

(protein) in the bloodstream which can result in three distinct issues: toxicity, immunogenicity, and mononuclear phagocyte system (MPS) rapid clearance.[7,8] In the hopes of addressing these issues, the exosome has been singled out as a potential candidate as a bioinspired, bioengineered, and biomimetic drug delivery solution.[9,10]

Exosomes usually range from 30 to 150 nm. The intraluminal vesicle (ILV) is a circular lipid bilayer vesicle released from cells that differs from other extracellular vesicles such as microvesicles and apoptotic bodies, in composition and biogenesis.[11,12] First described as small vesicles by which maturating sheep reticulocytes discard obsolete cellular components,[13,14] further studies have shown that exosomes and other secreted extracellular vesicles are the prominent and universal form of cell-to-cell communication.[15] When exosomes are released, they are immediately internalized by surrounding cells or enter systemic circulation for intercellular

Figure 1. Exosome biogenesis begins with the formation of intraluminal vesicles (ILs) in late endosomes following cargo sorting. Both ESCRT-dependent and ESCRT-independent lipid-driven pathways are involved in creating multivesicular bodies. Exocytic MVCs fuse with the plasma membrane in Rab GTPases regulated miRNAs; exosome content depends on the cell type and cells' physiological and pathological conditions. Here we illustrate the components of exosomes identified in multiple proteomic studies and different cell content. Adapted from Gurunathan et al. ref 49. Copyright 2019 MDPI and modified to accompany our review on exosome biogenesis and composition.

communication.[16] Exosome secretion is a constitutive mechanism involved in both pathological and physiological conditions, regulating exosome surface markers and contents.[1,17] Exosomes can transport biologically active molecules, including proteins, fragmented DNA, antigens, and nucleic acids that regulate gene expression and cellular function in target cells.[18−22] As such, exosomes mediate autocrine, paracrine, and endocrine effects, classifying them as potential therapeutics.[18] For example, mesenchymal stem cells (MSCs) and other progenitor cells used in cell therapy mediated cytoprotective, angiogenic, and regenerative effects that can be recapitulated by the exosomes they release.[23] Indeed, exosomes have been found and investigated in numerous bodily fluids, including bile acid, blood, breast milk, urine, cerebrospinal fluid, and saliva, suggesting that exosomes play a prominent role in physiological regulation response and disease progression.[1,11,24−26] Recently, exosomes' pathophysiological role in diseases, especially cancers, neurodegenerative, inflammatory, and infectious diseases, has emerged.[26−29] Exosomes function as diagnostic biomarkers, imaging tools, therapeutic targets, tissue repairing agents, and drug delivery platforms and can be used in vaccine development. This would eventually lead to preclinical and clinically trials as avenues of new investigation as a result of their unique biological and pathophysiological characteristics.[30−35] However, thus far, there is no review currently available about the progress of exosome research and potential applications in a clinical setting. In this review, we have laid out a comprehensive study on the status of exosome clinical trials and their preclinical application to various diseases. More information on exosome classification, biological composition, relevant markers can be found at http://www.isev.org (International Society for Extracellular Vesicles), http://microvesicles.org (Vesiclepedia, a compendium for EVs with continuous community

annotation),[36] http://www.exocarta.org (ExoCarta, a web-based compendium of exosomal cargo),[37] and http://exrna.org (extracellular RNA communication program). Also, we state how exosome surface engineering can act as translational medicine agents due to advancement in bioengineering techniques such as cationic pullulan, cationic linkers (DBCO-amine/dye), aptamer-based DNA tether, and click chemistry.[38−41]

2. EXOSOME COMPOSITION, BIOGENESIS, AND MECHANISM OF ACTION

About 98% of all potential therapeutic medicines related to central nervous system (CNS) diseases have failed to reach the market due to an inability to cross the blood−brain barrier (BBB).[42] While drug formulations have managed to overcome the barrier,[43,44] they have their own drawbacks, including significant toxicity and rapid clearance by the mononuclear phagocyte system (MPS).[7] Similar immediate clearance phenomena are observed in animal models for targeted drug delivery, cell therapy, and tumor therapy.[45,46] On the contrary, exosomes (30−150 nm) and cell origin vesicles offer intrinsic characteristics of an ideal drug delivery method for an intracellular platform.[47,48] Exosomes as delivery vesicles provide (i) good tolerance in the body because of their wide distribution in bodily fluids (like milk, urine, blood, saliva, etc.),[4,50−53] (ii) proper internalization in distant cells,[54] (iii) reliable delivery of cargo such as proteins,[55] mRNA,[56] lipids,[57] drugs,[6] and nucleic acids, and (iv) an extended circulation half-life via i.v. injections.[58] Thus, naturally occurring exosomal intrinsic properties enable targeted delivery and diminish the rapid clearance of drugs.[59−61] In Figure 1, we illustrate what a typical exosome contains. From our understanding, the composition varies in its protein, lipid, and nucleic acid content depending on cell origin, cell homeostasis, and its

current pathological condition. On their surface, exosomes carry immune regulatory molecules, membrane trafficking molecules, and tetraspanin. These molecules either help the exosome to bind or pass through the recipient membrane for delivering its cargo. Exosomes carry multiple forms of these molecules inside them, including nucleic acids, signaling molecules, chaperons, and enzymes to bring the message to the neighboring cells. These chemical messengers can both modulate cell physiology and carry information about any foreign invaders. Exosomes originating from immune cells can activate or inactivate T-cells, depending on immune cell physiological conditions. This is why we found multiple studies on exosome proteomics and lipidomics that explore exosome composition for either biomarker study or targeted drug delivery. Exosomes also play a crucial role in cell–cell communication using protein chaperones, cDNA, nucleic acid, and mRNA content to connect with neighboring and distant cells.[62] Exosomes deliver their protein, lipid, and cytoplasmic content to recipient cells through membrane fusion and modify physiological and pathological functions of targeted cells.[63] The exosome's cargo is determined by its cell origin, cell physiological condition, and intercellular release site.[1] Exosome biogenesis begins with early endosomal maturation to microvesicles (MVB) and late endosomes to exosomes, during which endosomal membrane transforms into intraluminal vesicles (ILVs) in the lumen of the organelles through multiple pathways.[64] The most studied endosomal pathways are associated with endosomal complexes ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III, and AAA ATPase Vps4 associated complex for transport.[65–68] In ESCRT RNAi screening, a total of 23 ESCRT and ESCRT-associated proteins have been identified in HeLa cells.[69] In another study after shRNA transfection, secreted exosome trapped with anti-CD63 beads and screen identified seven ESCRT proteins with a role in exosome secretion.[70] One research study showed that the depletion of both ESCRT-0 protein Hrs and ESCRT-1 protein STAM1 resulted in reduced exosome secretion.[69]

On the contrary, knockdown of ESCRT-III and associated proteins like VSP4B, VTA1, and ALIX increased exosome secretion.[69] In the same study, after further investigation, the authors found that Hrs, TSG101, and STAM1 depletion decreased exosome secretion, whereas VPS4B knockdown increased production. Those proteins were purified by ultracentrifugation and analyzed via Western blot (WB) and qRT-PCR.[69–71] The endosomal membrane transiently recruited ESCRT proteins from the cytoplasm, where their function is to sort the transmembrane protein from MVB. ESCRT-0 binds with a ubiquitin-protein programmed for degradation, executing a sorting of MVB in the first set of steps.[62] Knockdown of ESCRT-0 protein Hrs from dendritic cells results in fewer exosomes secreted, which can be measured by the exosomal level of ubiquitinated proteins: TSG101 and VPS4B.[72] ESCRT-I and -II promote the budding process and start the enzymatic deubiquitous cargo protein before forming (ILVs) microvesicles in the intracellular compartment.[73] The ESCRT-3 complex drives the final stage of membrane invagination and separation.[74]

An integral membrane protein of the lysosome has been suggested to play a role in exosome formation. A higher amount of exosome secretion was observed after transfection of COS cells with SIMPLE lipopolysaccharide-induced TNF factor (LITAF) and mutation of SIMPLE interfered with proper MVB formation.[75] Also, syndecans, the membrane

proteins carrying heparan sulfate chains, are mediated by their binding to syntenin. Syntenin is a multivalent soluble protein that binds ALIX to build a link between syndecans and ESCRT machinery.[76] Another study determines that the syndecan–syntenin–ALIX mechanism in MCF-7 cells was responsible for 1–50% of the secreted exosomes.[77] In addition to proteins, lipids also play an essential role in vesicular transport,[78,79] and both act intrinsically for vesicle transportation like membrane deformation, fission, and fusion.[80] The exosome membrane is enriched in sphingomyelin, tetraspanin, integrin, cholesterol, immune regulatory molecules, and ceramide, whereas inside it contains chaperons, mRNA, cDNA, and proteins.[49,81,82] Exosomes released from a cell are taken up through catherin-independent endocytosis or micropinocytosis by neighboring cells.[19,83–85] Once internalized by recipient cells, exosomes release their cargo, resulting in the altered regulation of the recipient cell's various biological functions.[86,87] The biogenesis of exosomes is often described as either an ESCRT-dependent or ESCRT-independent mechanism,[88] but these pathways might interplay.[89] Current research also suggests that these pathways may work synergistically in the different subpopulations of exosomes depending on the origin of the various biogenesis machinery.[90] Phospholipids and sphingolipids are also involved in the formation of exosomes.[91–93]

For example, following epidermal growth factor (EGF) stimulation, EGF receptor (EGFR) was not sorted into the ILVs of ESCRT-depleted cells, suggesting diversity in exosome formation pathways.[90] The late endosomal lipid marker, bismonoacylglycerophosphate (BMP), also known as lyso-bisphosphatidic acid (LBPA), was found to colocalize with EGF-containing exosomes. However, other studies have suggested that LBPA-carrying MVBs are distinct from EGF, provided that MVBs are developed after EGFR stimulation (EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular endosome subpopulation).[94,95] Multiple studies have been done on both ESCRT-dependent and -independent pathways of exosome biogenesis.[69,96–98] Finally, the comparatively smaller size and unified shape allow exosomes to successfully escape clearance by the MPS, prolonging their circulation time and implying their cell–cell communication superiority. Remember, the biogenesis pathways work synergistically, meaning that the subpopulation of exosomes depends on a different mechanism. The cell homeostasis and physiological conditions are also essential factors to consider, which control exosome release and secretion pathways.[99,100] For example, silencing of ALIX protein modulates exosome cargo selection rather than affecting their secretion. Decreasing ALIX expression in shRNA-expressing cells increases the content of MCH class II content on the exosome surface.[69] Another study by Hoshino et al. showed the exosome populations were reduced by Hrs knockdown in head and neck squamous cell carcinoma cells, using NTA analysis.[101] Epithelial cells can secrete exosomes apically and basolaterally to eliminate unfavorable lipid and proteins from entering into the lumen.[102] Another study suggests that inflammation induced by IL-1β can be counteracted by primary bone marrow macrophages-derived exosomes carrying MHC II membrane protein.[103] The study also confirms that MHC II expression is lower in healthy tissue than in inflamed regions. Exosomes will play a vital role in the future of precision and personalized-based medicine against cancer, infectious, rare, and immune diseases.

Figure 2. Schematic summary of standard laboratory methods for exosome purification. Four different isolation techniques are demonstrated here: Polymeric precipitation[116] (top left), column for size-exclusion chromatography[123] (top right), density gradient chromatography[110] (bottom right), and differential ultracentrifugation[110] (bottom left). Temperature maintained at 4 °C for most of the protocol.[110]

3. EXOSOME ISOLATION AND CHARACTERIZATION

Recently, exosomes gained much attention for their intrinsic properties such as cell–cell communication, immune response, and antigen presentation across various disease models.[104] Like cells, exosomes are composed of a lipid bilayer that can facilitate loading both hydrophobic and hydrophilic drugs.[57] Exosomes are widely distributed in human blood, serum, urine, and bodily fluid. They typically have low immunogenicity and a longer half-life than many other available drug delivery vehicles.[105] Furthermore, the exosomes have advantages over similar polymeric vehicles due to their inherited surface markers and receptors with its target cells, thus increasing targeted drug delivery to specific tissue/cells.[106] Important points to remember: because of the variation in the size of different cell-secreted vesicles, the exosome's (30–150 nm) related purification and isolation processes are critical. The size of the particle plays a crucial role in targeted drug delivery. It is essential to use around 100–200 nm particles for the exosome delivery method.[104–106] Robust methods of purifying exosomes from cell culture media rely on minimizing copurifying protein aggregates and other membranous particles. Thankfully, different laboratory-based isolation protocols are available, such as differential ultracentrifugation,[107] size-exclusion chromatography,[108,109] immunoaffinity-based capture,[110,111] exosome precipitation,[112] polymer precipitation,[113]

microfluidic-based isolation,[114] and commercially available kits that scientists use to yield exosomes.

When a heterogeneous mixture (suspension) is centrifuged, more abundant and denser particulate constituents in the suspension will precipitate first (Figure 2). Centrifugation is employed to isolate and purify exosomes and enzyme hydrodynamic properties of polymeric particles such as proteins and nucleic acids.[115−117] Depending on the centrifugation force, exosomes can be separated according to their size and viscosity. Ultracentrifugation (UC) is a centrifugation process optimized for high centrifugal forces up to 1000000g. There are two branches of ultracentrifugation: analytical and preparative.[118] Analytical ultracentrifugation is an isolation process depending on particulate material physicochemical properties and molecular interactions of polymeric materials. Preparative ultracentrifugation plays a crucial part since it is used to separate small particles such as viruses, bacteria, subcellular organelles, and exosomes.[49,111,118] Ultracentrifugation-based isolation is considered the benchmark and the most studied isolation method in published research.[119] In brief, the culture supernatants were cleared of cell debris, large proteins, dead cells, and large vesicles by sequential centrifugation at 300 g for 10 min (to remove cells), then 1000g for 20 min (to remove apoptotic bodies), and finally, 10000g for 30 min (to remove microvesicles), followed by filtration using either 220 or 450 nm syringe filters. Then,

Figure 3. Validation of exosome enrichment from human cell-free sera. (A) TEM micrographs of exosomes in ultracentrifugation (UC) and ExoQuick (EQ) preparations. Data for six independent patient samples are shown (P1−P6). Exosomes confirmed by size (30−100 nm) and appearance. Scale bar in each image represents 100 nm. (B) Immunoblot of CD63 in unprocessed cell-free serum alone (−), UC, and EQ exosome preparations. Adapted from Prendergast et al. ref 124. Copyright 2018 PLoS.

the cleared samples were spun at 100000g for 1−2 h to pellet the exosomes.[120] To avoid contamination by the FBS-derived exosomes, FBS was spun at 100000g for 2 h to remove exosomes before the cell culture experiment.[48,121] Differential filtration is also applied to separate exosomes from cell culture medium or serum. First, dead-end (normal) filtration uses a 100 nm membrane filter, depleting floating cells and large cell debris. Second, the filtrate undergoes tangential flow filtration via 500 kDa molecular weight cutoff (MWCO) hollow fibers.[122] Then concentrated samples are further filtered using biofiltration. Size-exclusion chromatography (SEC) separation technique is also applied to exosome isolation. In SEC, stationary phase gels like sucrose or Sepharose are utilized to sort differential molecular size.

Samples with small radii will get trapped in the pore opening, letting larger particles go down fast. When this technique is performed using organic solvents, it is called gel permeation chromatography (GPC).[125] The main application of GPC is found in polymer analysis.[125] When size-exclusion chromatography is performed utilizing an aqueous solvents column, the method is called gel filtration.[123] The disadvantages of these methods are (i) the susceptibility of the chromatography column to contamination, (ii) the need to collect and analyze a larger fraction of exosomes to obtain a larger exosome subpopulation, and (iii) the length of time for post exosome isolation.[115] Immunomagnetic isolation uses antibody-labeled magnetic beads and captures exosomes with stained antibodies using a magnetic field.[111] To isolate and purify polymers from other unwanted materials, polymeric precipitation is a technique used to form a mesh-like net structure that embeds exosomes between 60 and 180 nm. Polymeric precipitation isolation methods have advantages in detecting biomarkers of identified exosomes.[113] Several immune isolation assays based on either magnetic beads or microfluidic devices have been able to use antibody-based affinity capture for rapid exosome isolation.[126,127] These methods depend on the availability of specific exosomal surface proteins or antibodies for discrimination between the exosomes of interest and other vesicles' sizes in the fluids.[126,128,129] In Figure 3, we try to rationalize from a recent study, where authors have compared the ultracentrifugation method with the commercially available isolation kit ExoQuick.

The study confirms how the commercial kit more precisely isolates exosomes. A immunoblot of purified exosomes isolated by ExoQuick shows a wider band than that of the exosomes isolated by UC. Finally, we will mention the commercial kits available for exosome isolation. Some of the prevalent kits typically used such as ExoQuick, Ultra exosome precipitation solution (EXQ)[130] by System Biosciences, total Exosome Isolation for serum or plasma (TEI),[131] exoRNeasy Serum/Plasma midi kit (EXR),[132] and RIBO exosome isolation reagent (REI)[133] yield relatively pure isolation.

Exosome characterization is very challenging due to the heterogeneity of the exosome population, different isolation techniques, the mixed-size-distribution, and the difficulty in cargo profiling. For exosome characterization, general instrumental methods used for particle size, hydrodynamic diameter, and surface zeta potentials are nanoparticle tracking analysis (NTA)[134] and dynamic light scattering (DLS).[135] For morphology characterization, available techniques are scanning electron microscopy (SEM)[134] and transmission electron microscopy (TEM).[135,136] Western blot analysis[136,137] and mass spectrometry[136,138] have been widely used for biological characterization and proteomics. The electron microscopy technique is the gold standard for characterization of exosome morphology. However, morphology observed by TEM contradicts that of the morphology observed by SEM. TEM images show that exosomes are cup-shaped, whereas SEM images show that they are roughly round shaped. One drawback of the TEM/SEM technique is that the system requires a thin sample; therefore, sample preparation is tedious, affecting exosome properties. The nanoparticle tracking analysis (NTA) technique is another way of determining sizes of exosomes. NTA utilizes Brownian movement of the exosomes to determine the size and particle concentration.[139] DLS is also based on a similar principle where the hydrodynamic radii of the exosome solution determine the fluctuations in reflected laser transmission caused by the Brownian motion of the particles. Different molecular profiling approaches were applied for proteomic analysis of exosomes. In particular, two-dimensional gel electrophoresis (2DGE) and liquid chromatography coupled tandem mass spectroscopy (LC-MS) are predominantly used.[140−143] However, compared to proteomic analysis, lipid and metabolite analysis of exosomes is

Figure 4. Exosome drug-loading techniques. (A) Exosome-secreting cells or exosomes incubated with the desired cargos. Cargos diffuse across the cell and exosomal membrane and are subsequently packaged within the exosomes. (B) Desired nucleic acids can be loaded into exosomes via a transfection-based strategy. Transfected with vectors, the donor cell generates RNAs/proteins and packages these products into exosomes using endogenous expression and sorting machinery of the donor cell, respectively. Exosomes can be directly transfected with small RNAs for cargo loading purposes. (C) Cargos can be loaded into exosomes directly through physical treatments. Electroporation, sonication, and surfactant treatment generate pores on the exosomal membranes that facilitate cargo loading. Freeze−thaw treatment, extrusion, and dialysis enhance cargo loading into exosomes during membrane recombination processes. Adapted from Fu et al. ref 146. Copyright 2020 Elsevier.

underutilized. The main limitation of proteomics and lipidomics is the risk of contamination of other extracellular vesicles, mainly caused by the isolation techniques. Exosome isolation purification can be determined by Western blotting (WB) or RT-qPCR. Both techniques develop bands from protein or RNA purified from exosomes. Fluorescent imaging is another characterization assay that uses lipophilic dye such as PKH67, Dil, DiD, or DiR embedded in the lipid bilayer of

the exosomes. For drug delivery application, characterization assays such as NTA, WB, TEM, and RT-qPCR are enough to demonstrate various physical and composition properties. For biomarker analysis, WB or PCR are used to identify specific protein/metabolite expression in pathogenic exosomes.

This section provided an overview of exosome isolation techniques and characterization methods that are opening a new window toward developing safer and more advanced

strategies and devices for more cost-effective, time-saving, and efficient isolations of exosomes from biological fluids.

4. EXOSOME DRUG-LOADING TECHNIQUES

One of the most promising forms of targeted drug delivery revolves around implementing insoluble drug loading in lipid-based systems for enhanced accumulation in the diseased tissues. Exosomes gained much interest in the scientific community of drug delivery because they can carry various molecules, including carbohydrates, proteins, lipids, and nucleic acids.[24] Besides, the exosomes themselves can vary in size from 30 to 150 nm in diameter, depending on the type. This variability in the potential transport vehicles creates opportunities for the loading and targeting of a diverse array of biomolecules to provide therapy to targeted organs in the body[144] (Figure 4). A reliable means to load small hydrophobic molecules has been found using sonication, which works by causing shear forces in the exosome that allow drug molecules to accumulate in the lipid layer of its membrane.[145] Effective methodologies have utilized a direct probe and a set, consisting of 30 s of sonication and 30 s of rest, repeated six times.[145] This method was used to load macrophages with paclitaxel (PTX), a potent chemotherapeutic agent and an eminently hydrophobic compound. The study showed the most significant relative particle size (287.7 ± 0.7 nm) that displayed the highest encapsulation efficiency (EE) ($28.29 \pm 1.38\%$). This method's efficiency was significantly higher than other loading methods of the same drug, including electroporation or incubation, with neither reaching above 6% EE.[145] Similarly, the catalase for Parkinson's study used an almost identical method, producing only moderate sizes (179.0 ± 10.6 nm unloaded, 183.7 ± 13.8 nm exoCAT loaded) but also received the highest relative loading capacity (<200 μg catalase/mg exosome). The nature of this loading method allows for drug fusion to the membrane, which may inhibit total controlled release due to an initial burst phase. Incubation has been attempted in the previous study, which involved shaking for 1 h at 37 °C. This resulted in a significantly smaller particle (132.2 ± 2.3 nm) with a spare loading capacity ($1.44 \pm 0.38\%$).[48] In the same article, the authors had showed that the catalase in the Parkinson's study was added to 250 μL of exosomes for a final concentration of 0.1 mg/mL complete protein. Before the addition of catalase, the macrophages were diluted in PBS (0.15 mg/mL total protein). The sample was then incubated at room temperature for 18 h. Sizing was 108 ± 14.3 nm, and loading was measured by enzymatic activity, which was rated very low (>20 μg catalase/mg exosome). A side note is that postloading sizes of incubated exosomes were relatively similar; however, this may be due to this method's deficient efficacy level. SEM images show that this method creates abnormal nonspherical shapes, which may have unintended effects in a therapeutic context. The freeze−thaw loading cycle was attempted in the catalase for Parkinson's study, which involved adding the exosomes and catalase identically to the incubation loading, allowing them to incubate for 30 min, then to freeze at −80 °C rapidly, and then to thaw at room temperature (RT). This cycle was repeated three times and was somewhat successful, with an average size of 147.0 ± 10.0 nm unloaded, 158.0 ± 11.0 nm loaded, and ∼100 μg of catalase/mg of exosome. Continuous freeze−thaw cycles have been shown to cause fluctuations in fluorescence due to lipid-dilution ratio changes. Extrusion is performed by placing the catalase mixture in an Avanti lipids extruder with 200 nm

pore diameter and then purifying it using gel-filtration chromatography with Sepharose 6 BCL. Sizing was consistent and small (134.0 ± 7.5 nm unloaded, 154.8 ± 11.0 nm loaded), and loading ($190-200$ μg catalase/mg exosome) was the second most effective drug-loading method after sonication.[48] Morphology data show a spherical and consistent shape. Electroporation was attempted in the PTX study with abysmal results. The exosomes and PTX were added to a chilled 4 mm electroporation cuvette, subsequently electroporated using an Eppendorf evaporator at 1000 kV for 5 ms, and then incubated at 37 °C for 30 min to allow for the recovery of the exosomal membrane.[147] This method resulted in an average size of 145.3 ± 1.0 nm, but encapsulation was low ($5.3 \pm 0.48\%$). In brief, exosomes could be loaded with drugs either *in vitro* in purified exosomes or *in vivo* during biogenesis (Figure 4).

Transfection is a technique for loading proteins, peptides, and nucleic acids into exosomes. Using specific transfecting agents such as plasmids or tethers, the cell can be transduced to ectopically express desired proteins, lipids, or nucleic acids which will later undergo exocytosis from the cell via exosomes. For example, Bellavia et al. transduced human embryonic kidney 293 (HEK293) cells using BCR-ABL siRNA and later collected exosomes from cell medium.[148] Yang et al. has also shown that different transfecting cells with mRNA can produce a 50-fold higher exosome amount compared to the naive cell culture technique. These exosomes carrying PTEN mRNA restore tumor-suppression function in the brain, increase animal survival, and enhance tumor-growth inhibition.[149] Except for nucleic acids, we can introduce specific proteins or lipids via transfection techniques. For example, HEK293 cells were transfected with CD9-human antigen R (HuR) to facilitate the loading of miR-155 into exosomes.[150] Another study showed that HEK293 cells transfected with vascular stomatitis virus glycoprotein (VSVG) enabled exosomes to penetrate the plasma membrane of recipient cells.[151] Further, exosome cargo can also modulate by expressing cargo-sorting proteins onto exosome surfaces via cell transfection. This cargo loading technique is promising; yet, its cargo loading efficiency is low due to cargo selectivity and chemical impurity due to transfection.

Electroporation is another technique for loading DNA, mRNA, siRNA, and RNAi into exosomes. In this technique, the electric field is applied to increase permeability for small molecule drugs and large molecule biologics through the membrane of exosomes. For drug loading, the exosome and payload (drug/protein) need resuspension in an electroporation buffer. The electroporation buffer can be trehalose pulse medium (TPM; 50 mM trehalose (Sigma-Aldrich, Cat. No. T0167) in PBS) or (1.15 mM potassium phosphate, pH = 7.2, 25 mM potassium chloride, 21% Optiprep) or cytomix electroporation buffer (120 mM KCl, 0.15 mM $CaCl_2$, 10 mM KPO_4, 25 mM HEPES, 2 mM EGTA, and 5 mM MgCl2, adjusted to pH 7.6 with KOH).[152,153] Then electroporation is carried out using a GenePulser Xcell electroporator (e.g., from Bio-Rad). All samples are filtered using omega membrane Nanosep centrifugal devices ($100-3000$ MWCO, depending on the size of payload) to remove the excess payload of drug, DNA, or mRNA. Measuring the volume of samples being loaded into the electroporation buffer is also important. Depending on the loading protein, the voltages and capacitances of the electroporator will differ.[154] Some studies report that electroporation leads to exosome aggregation,

resulting in a lower loading efficiency. That is why it is recommended to filter the electroporated sample with a 450/220 μL filter.

Surfactant treatment is another technique for exosome drug loading. Surfactants such as saponin or triton are used to increase the membrane permeability of the exosome through simple incubation methods.[155,57] Incubation with surfactant can be used to facilitate the loading of the antioxidant and catalase into exosomes, and provide neuroprotective efficiency of post-intranasal administration in a Parkinson's disease (PD) animal model.[48] Although the surfactant enhances higher loading efficiency within the exosome, some limitations exist in the technique. Surfactants may inactivate/degrade the potential function of therapeutic or loading cargo, and excessive surfactant may cause *in vivo* hemolysis. Additional purification methods may need to be implemented after incubating with the surfactant.[155]

Hypotonic dialysis is another drug-loading method widely used for exosome drug loading. The basic principle is that an exosome and drug mixture is placed in a dialysis tube and continuously stirred to allow for drug loading. This method can load 11-fold higher drug content than a room temperature incubation loading method.[156] This loading system is also suitable for reducing intra-exosomal pH by rehydrating and dehydrating the exosome in acidic citrate and ethanol buffer. This pH gradient of exosome helps to load miRNA and siRNA.[157] Some studies report that the dialysis loading method may induce protein degradation due to the pH change of the exosomes.[158] Therefore, this method is considered as a highly effective drug-loading method; yet, proper validation is needed to identify the experimental conditions and exosomal cargo selection.

Today, numerous drug-loading techniques have been developed in light of the exosome's intrinsic properties for drug loading and delivery (see Figure 4 and discussion earlier in this section for details). In incubation methods, drug-loading efficiency depends on the proportion of drug and exosome protein concentration. The loading efficiency of incubation methods is poor, and certain factors influence efficiency. First, in gradient-based cargo diffusion, the concentration of cargo is curved due to the saturated concentration of the drug, indicating the enhanced drug-loading profile. Second, the membrane integrity of the exosome restricts most of the hydrophilic drug to the influx. To increase the loading efficiency, we need physical triggering methods such as sonication, extrusion, electroporation, surfactant treatment, dialysis, etc. Multiple studies conducted in parallel demonstrate that drug-loading efficiency increased with these physical treatment methods compared to the general incubation methods.[48,159] Despite higher drug-loading efficiency, the physical methods have many disadvantages for drug delivery application of exosomes. First, surfactant treatment may introduce impurities in the exosome, which may cause toxicity during therapy. Second, electroporation may destabilize the exosome membrane integrity or cause severe aggregation. Third, dialysis treatment may cause the inactivation or degradation of the protein loaded. Fourth, the ultracentrifugation method provides us with a mixture of extracellular vesicles, e.g., ranging from 30 to 150, which is satisfactory for biomarker analysis but not for drug delivery where we need a precise range of particles. Fifth, the freeze−thaw method, due to multiple freezing and thawing cycles, can cause degradation of the exosome membrane and a leaky structure. Transfection

is another way to increase the loading efficiency of protein, lipids, and nucleic acid via transducing cells or exosomes with nucleic acids or proteins expressed by a plasmid. However, this technique is costly and time-consuming, making it unstable for small-scale research purposes. Overall, exosome loading techniques can improve desirable cargo but introduce impurities that affect exosomal properties. Therefore, we need to use particular loading techniques depending on the exosome application and consider the implications of the introduced impurities for drug loading. The purification of exosomes is laborious due to their intrinsic biological properties, making them more difficult to use for drug loading. Engineered exosomes provide an alternative means to overcome drug-loading issues. If we can develop or utilize current techniques such as plasmid, tether, or bio-ortholog click chemistry, we can generate the desired exosomes from cell culture. In this way, we can avoid drug-loading steps and have stabilized exosome treatment that can be used to combat cancer, immune, and rare diseases. We can also consider how to remove natural exosomal cargo during exocytosis, allowing us to load more therapeutic payload during the drug-loading step. However, the optimization of exosome loading strategies is limited by our insufficient understanding of exosome biology, structure, biogenesis, and lagging exosome-related research and development tools.[60] We need a standardized drug-loading protocol for getting uniform and stable results in drug delivery applications both in preclinical and clinical studies.

5. PRECLINICAL RESEARCH DEVELOPMENTS

5.1. Role of Exosomes in the Immune System.
Exosomes play an important role in immune regulation, eliciting both positive and negative "unwanted" immune responses, including tolerance and evasion.[160−162] Individually, exosomes can act as immunoregulating agents by modulating immune activation, antigen presentation, suppression, and surveillance.[163−166] The exact mechanisms for many of these actions are not entirely understood. Several studies have begun to reveal how these vesicles play necessary and frequently pivotal roles in initiating various immune responses.[167−169] The inflammatory response is often signaled by exosomes, meaning that these vesicles play a crucial role in several pathological states, including cancer, diabetes, obesity, and neurodegenerative disease.[28,170−174] For example, microRNAs regulate cell gene expression after transcribing, and exosomes deliver microRNAs to recipient cells. A study by Alexander et al. shows dendritic cell-derived exosomes delivering miR-155 and miR-146α to recipient dendritic cells to promote endotoxin-induced inflammation in mice.[171] In neurodegenerative Alzheimer's disease, exosomes carry pathological misfolded proteins to neighboring neurons, thus promoting a cascade of exosomes carrying pathological misfolded proteins to other neighboring neurons, initiating disease onset and propagation.[175] The study of exosome cargo release may lead to the identification of biomarkers for many of these diseases. Since exosome cargo is a continuously excreted substance via fluids, saliva or urine collection may be valuable pathological screening tools for biomarker identification.[176] We will discuss exosome biomarker applications in more detail in section 5.4 of this review. Exosomes also play an essential part in cardiovascular disease recovery by promoting tissue repair and regeneration.[177,178] Exosomes originating from immune cells play a significant role in prompt immune response and

Figure 5. Recent studies confirm that exosomes can pass through the blood–brain barrier (BBB)[201−204] in both directions. This means that specific exosomes detected in the cerebrospinal fluid (CSF) or in the blood from the brain can be released into the bloodstream and vice versa. Each cell type releases a specific type of exosome(s) that is released and communicates with neighboring cells, acting as the messenger. This characteristic makes exosomes attractive as new sources of biomarkers and therapeutic targets suitable for use in clinical practice, such as a liquid biopsy that could replace current invasive diagnostic methods. Exosomes also have a potential role in drug delivery for brain disease models, and their membrane markers can be used to identify their cellular origin.

inflammation, unlike stem cells and cardiomyocytes.[179] Although these mechanisms are not well studied and only a small number of exosomes directly related to immune response regulation have been discovered, what is known is that exosomes demonstrate cardioprotective effects against post-infarction and atherosclerosis. One example of exosome-based manipulations may found in a study published in *Allergy*,[180] where B cell-derived exosomes with pMHC II found on FDCs could stimulate CD4+ T-cells, which aided their development. Scientists believe that pMHC II found on the FDCs likely allowed the exosomes to engage the T-lymphocytes, modulating immune memory to expand their collection of antigens. Activation of the immune system may also be triggered by exosome activity.[181] Dendritic cell (DC) exosomes classified as "mature" are significantly more effective than their younger counterparts when inducing specific antigen T-cell activation.[181] This phenomenon is most likely due to distinct differences in protein composition that accumulate as the cell matures.[181] These changes can help in tumor suppression; however, these same effects have occasionally been hijacked by tumor cells, allowing for uncontrolled growth without a proper response. Recently, a study found that tumor cells can bypass the typical immune response by upregulating

the surface expression of programmed death-ligand 1 (PD-L1), allowing the tumor to mask itself by eliciting the immune checkpoint response.[120] Effective quantification of PD-L1 could be used as a possible tool for helping in tumor treatment decisions based on the amount observed at specific sites.[182] This line of investigation closely follows the migration and composition of these vesicles. Peptide transfer acting as a form of cell-to-cell communication via exosome migration can have profound biological effects.[183] For example, prion proteins from the exosome walls may be transferred to uninfected cells by fusing with their uninfected counterparts.[184] In pregnant women, placenta-derived exosomes circulate T-cell activating markers including Fas ligands and HLA-DR. These exosomes also show greater suppression of JAK3 and CD3-zeta (T-cell coreceptor) than prepregnant circulating placenta exosomes.[185] Dendritic and lymphoid cell-derived exosomes regulate immune activation. Tumor-derived exosomes (TEX) have also been considered as a vaccine platform due to their effects on T-lymphocytes, suppression CD3-zeta, and JAK3 expression. Thus, TEX expressing tumor antigens can suppress T-cell signaling and induce apoptosis for potential use as a tumor vaccine.[186] In another study, the authors compare the molecular profile of TEX with healthy controls circulating

Figure 6. LPS injection induces changes in extracellular vehicles (exosomes) and miRNAs in the cerebrospinal fluid (CSF). (A) Representative transmission electron microscope (TEM) image showing the presence of EVs in the CSF in two independent experiments. (B) NanoSight quantification of the number of particles in the CSF at 0, 1, 2, 4, and 6 h after i.p. LPS injection ($n = 3-5$). (C) Size distribution of the EVs *in vivo* in the CSF before (black; $n = 5$) and 6 h after (gray; $n = 3$) LPS treatment determined by NanoSight analysis. (D−G) Quantitative real-time polymerase chain reaction analysis of miR-1a (D), miR-9 (E), miR-146a (F), and miR-155 (G) ($n = 4$). RNA was isolated from pooled CSF (50 μL) from different mice ($n = 3$). Data information: Data in (B, D−G) are displayed as mean $\pm$ SEM and analyzed by Student's t test. Significance levels are indicated on the graphs: *$0.01 \leq P < 0.05$; **$0.001 \leq P < 0.01$. Adapted from Balusu et al. ref [213]. Copyright 2016 EMBO Press.

exosomes. They found that TEX downregulates both CD3-zeta and JAK3 expression of activated T-cells and Fas/FasL-dependent apoptosis. TEX were incubated with activated T-cells, CD56(+) CD16(+) NK (natural killer) cells or conventional CD4(+) CD25(neg) T-cells res. Also, the authors showed how TEX promotes CD4(+) CD25(neg) T-cell proliferation but suppresses it when they transform into CD4(+) CD25(hi)FOXP3+ (FOXP3 is forkhead box P3) Treg cells (regulatory T-cells). Therefore, TEX has immuno-suppressive properties that depend on the T-cell activation state.[187] Tumor cells escape the immune checkpoint by upregulating PD-L1, which interacts with the program death-1 (PD-1) T-cell receptor.[188,189] Anti-PD-1 or anti-PD-L1 antibodies have shown promising results in treating tumors.[190] Along the same lines, metastatic melanomas releasing exosomes containing PD-L1 can suppress CD8 T-cells, preventing proliferating tumor growth via IFN-ϒ stimulation.[183] This study unveiled a mechanism for how tumor cells suppress the immune system initially and how exosome PD-L1 is a potential target for anti-PD-1 therapy. In autoimmune diseases studies, T-cell regulation is a key mediator of diseases treatment, and some of the mechanisms are suppressed by Treg cells, apoptosis of overactivated T-cells by cytokines destitution, immune checkpoints such as PD-1, and CTLA-4 expression.[191,192] Multiple previously published reviews and research articles conclude that exosomes released from immune cells play both preventive and developmental roles in autoimmune diseases.[193,194] Mesenchymal stromal cell (MSC) exosomal immune properties are well studied. Zhang

et al. showed that MSC-derived exosomes induced production of CD4+CD25+Foxp3+ Treg or CD4+CD25+ T-cells via allogeneic APC-enriched CD11C+ cells through T-cell activation.[195] This activation is both exosome and APC dependent.

Exosomes' intrinsic properties of cell-to-cell communication allow for the transfer of potentially toxic proteins without the need for direct contact. However, this type of communication may also be used in a manner beneficial to the immune system by allowing for a more robust and adaptable transfer of antigenic markers between cells, which would bypass the need for a more abrasive communication route. Overall, understanding of the role that exosomes play in the immune system response is still in its infancy. A great deal of research must be done to gain insight into the complex interactions that elicit the varied responses discovered. This field's foundation will need to focus on mechanistic and response-oriented inquiry to understand how these vesicles can be fully utilized.

5.2. Role of Exosomes in Blood−Brain Barrier (BBB) Penetration.

The BBB is a protective mechanism that helps maintain a stable chemical environment in the brain.[196,197] No other body organ or tissue is as protective and dependent on maintaining the internal environment as the brain.[196] For blood and proteins to reach the brain through brain capillaries, these products must cross three barriers, (i) the endothelium of the capillary wall, (ii) external capillaries of the wall covered by relatively thick basal lamina, and (iii) the bulbous "feet" of the astrocytes clinging to the capillaries (Figure 5). Nutrients such as glucose, electrolytes, and essential amino acids can

J

Figure 7. Systemic inflammation activates the exosomal machinery in the choroid plexus. (A) Representative confocal images of CD63, RAB5, and ANXA2 (red) in the choroid plexus (CP) at 0, 4, and 8 h after LPS treatment. Hoechst (blue) was used to stain the nucleus. The dotted line indicates the ependymal cells that line the ventricle, and the square boxes indicate the zoomed inset images displayed at the right corner of each image. Scale bars, 100 μm. (B, C) Representative TEM images show the presence of MVBs in the CPE cells before (B) and 6 h after (C) LPS administration *in vivo*. Black arrowheads point to exosomes present in MVBs. Scale bars, 9 μm. (D–F) Quantification of number of MVBs per cell section (D), number of exosomes per MVB (E), and number of exosomes per cell section (F), based on TEM analysis of several adjacent cells (0 h, $n = 20$; 3 h, $n = 21$; 4 h, $n = 13$; 6 h, $n = 23$). (G–J) Quantitative real-time polymerase chain reaction (qPCR) analysis of miR-1a (G), miR-9 (H), miR-146a (I), and miR-155 (J). Data are presented as relative expression normalized with housekeeping miRs by the TaqMan qPCR assay (0 h, $n = 4$; 1 h, $n = 5$; 6 h, $n = 5$; 24 h, $n = 3$). (K) NanoSight analysis of CSF isolated from LPS-injected mice followed by icv injection of vehicle or GW4869, a neutral sphingomyelinase inhibitor that inhibits exosome secretion ($n = 8$). (L) qPCR analysis of the expression of miR-1a, miR-9, miR-146a, and miR-155 in the choroid plexus of mice injected with LPS and then icv injected with vehicle (black) or GW4869 (gray) ($n = 4$). (M) NanoSight analysis of the supernatant of choroid plexus explants from PBS- or LPS-injected mice ($n = 6$). Data information: Data in (D–M) are displayed as mean ± SEM and analyzed by Student's t test. Significance levels are indicated on the graphs: *$0.01 \leq P < 0.05$; **$0.001 \leq P < 0.01$; ***$0.0001 \leq P < 0.001$; ****$P < 0.0001$. Adapted from Balusu et al. ref 213. Copyright 2016 EMBO Press.

penetrate the BBB via passive diffusion through the endothelium cell membrane.[198−200] On the contrary, small nonessential amino acids and potassium ions are prevented from entering the brain. They are actively pumped out from the brain through endothelium capillary action.[198] Transport across the BBB is catalyzed by transport processes such as carrier-mediated/receptor-mediated transport, and active efflux transport.[205−207] Efflux transport protects the brain from

endogenous substances such as neurotransmitters and hormones and is also vital for drug transportation to a diseased brain region.[208] At places of high glutamate presence in the diseased brain, the brain's glutamate levels are regulated by the BBB through the use of excitatory amino acid transporters (EAATs 1−4).[205] Because of the limited ability of most drug delivery methods, an alternate approach is required. Thus, exosomes may work as a cloak, which can have elevated drug-loading amounts and better-targeted delivery.[48] Recent advances in exosome research regarding their intercellular communication and their organotrophic behavior opened a new door in targeted drug delivery research.[209,210] For cell−cell communication, the surface of the exosome is enriched with cell-adhesion targeting molecules (tetraspanin and integrin), antigen-presenting molecules (MHC I and II), membrane trafficking molecules, and receptor proteins.[211] For example, tetraspanin proteins CD9, CD63, and CD81, isolated from brain endothelial HCMEC/D3 cells, play a crucial role in communication between primary astrocytes and cortical neurons.[201] Exosomes derived from neuronal glioblastoma (GBM) and neuroectodermal cells cannot cross the BBB, whereas exosomes derived from endothelium cells that have a tetraspanin marker as CD63 can.[212] Also, endothelium cell exosomes can pass through the BBB using cell-specific proteins via receptor-mediated endocytosis.[212] Hypoxic GBM U87 cells release exosomes through VEGF-A induced BBB permeability for tumor invasion, endangering brain health integrity. Authors found GBM exosomes alter/reduce the expression of claudin-5 and promote BMVECs.[204] In zebrafish, exosome-loaded doxorubicin, and paclitaxel, show promising ability to cross the BBB, whereas neither of the drugs showed brain uptake by themselves.[201] In Figure 6,[213] the authors show that the CSF can carry exosomes and constituents, observed by TEM imaging. Interestingly, NTA analysis confirms an exosome population increase in CSF due to systemic LPS injection compared to control CSF. This experiment validates our conclusion that the exosome number increases due to the disease state. miRNA analysis also confirms that exosomes can carry payloads such as miRNA and mRNA proteins. These data validate the exosome's capability of drug delivery of active biologics to the brain in a disease condition.

In HIV patients, the role of amyloid beta (Aβ) deposition is one of the characteristics, and the BBB plays a critical role in Aβ homeostasis within the brain. It was reported that HIV-1 infection increases exosome release from brain endothelial cells and higher Aβ cargo in the brain compared to a healthy control.[214] This study concludes that exosomes carried cargo across the BBB and successfully delivered it to the brain. Aβ plaques accumulation is also a pathological characterization of Alzheimer's disease.[215] The review by Badhwar et al. summarized how blood exosomes could be a potential source of biomarkers for Alzheimer's disease. The authors compiled about 26 previously published studies on blood exosome biomarkers and other sources such as neuron, astrocyte, and brain vasculature exosomes biomarker screening. This study provides a correlation of blood exosomes with exosomes derived from other brain fluid sources.[216] Parkinson's disease (PD) is another deadly brain disease and a common movement disorder. Dopamine administration is one of the main treatments used for PD. Qu et al. have reported that dopamine loaded in blood exosomes showed and improved therapeutic results in the PD mouse model and reduced systemic toxicity compared to free dopamine administration.

Blood exosome (40−200 nm) shows a promising targeted drug delivery approach for PD treatment.[217] In Figure 7, the study shows that the authors investigated the correlation of miRNA expression due to peripheral inflammation in the brain region. The authors also found systemic TNF injection increases the total amount of exosomes released and found a significant increase in the expression of miR146a and miR155 due to LPS injection in vivo.[213]

From the above discussion, we found that exosomes can cross the BBB and carry payloads back and forth from the inner and outer lumens. Thus, exosomes provide another avenue for therapeutic drug delivery to fight against brain diseases and brain-related cancers that are untreatable with current therapeutic agents.[212,217]

5.3. Role of Exosomes as a Drug Delivery Vehicle. Currently, the most preferred drug delivery systems are based on biodegradable liposomes or biological exosomes. Because of novel developments through exosomal research, several exosome-based drug formulations are currently in clinical trials, and recently some have been approved for clinical use.[218] Exosome bilayer-based drug delivery benefits the payload alternation of its biodistribution and higher encapsulation capacity.[218] Biological exosomes are also commonly used as drug delivery vehicles because of their overall bioavailability, improved drug encapsulation coupled with a controlled release, longer circulation time, and lessened toxicity.[219−221] Biodegradable nanoparticles like exosomes have successfully encapsulated bioactive molecules such as curcumin,[222] paclitaxel,[223] neurotoxin-I,[224] and dexamethasone,[225] all of which improve biodistribution and controlled release. Additionally, biodegradable nanoparticles are also utilized as drug delivery vesicles for multiple disease models of cancers,[226,227] diabetes,[228] and brain diseases such as Alzheimer's,[229] prions,[230] and Parkinson.[48] Most of these medications have translated into clinical trials, and some have already been introduced to the American market.[231]

On the other hand, liposomes, PLGA, PLA, or poly(lactic-co-glycolic acid) are the most common and well-studied nanoparticles (NPs) for targeted drug delivery applications.[232−235] Many liposomal and PLGA NPs mediated formulations have been successfully translated to the clinic and have obtained FDA approval: Doxil (liposomal doxorubicin),[236] DaunoXome (liposomal daunorubicin),[237] Onivyde (liposomal nanoformulations of irinotecan),[238] Cimzia (a PEGylated blocker of tumor necrosis factor-alpha (TNF-α)),[239] Neulasta (PEGylated form of filgrastim),[240] Vivitrol (PLGA L/G 75:25 with active ingredient naltrexone),[241,242] and Signifor LAR (PLGA with active ingredient pasireotide pamoate, treatment for acromegaly).[243,244] One of the main challenges in translating polymer-based formulation is the behavioral difference between in vivo models compared to in vitro. To overcome the existing challenges in biocompatibility, diffusion, cell internalization, and tissue transportation, further studies are needed to thoroughly investigate utilizing different animal models.[245] These biodegradable polymeric vehicles accumulate in the reticuloendothelial system (RES), including the liver, spleen, kidney, lymph nodes, and bone marrow. Polymeric NPs are cleared by resident APCs, like macrophages, via direct interaction and increase immunosuppression and risk of infection.[232,246,247] Plasma proteins also play a pivotal role in clearing polymer-based drug formulations from the RES via opsonization.[248,249] Liposome and PLGA NPs also interact with immune cells in the blood and resulting in

antibody production against NPs different functional components due to repeated injection.[45,250−252] This phenomenon is called the "accelerate blood clearance (ABC)" phenomenon. Dams et al. first observed the ABC phenomenon that when animal models were administered with empty PEGylated liposomes, it influenced biodistribution and pharmacokinetic behavior of the second dose of PEGylated liposomes after 7 days.[253] Some polymeric NPs also induce an innate immune response due to subsequent activation of the complementary system known as complement activation-related pseudoallergy (CARPA).[254] CARPA has been observed from clinically approved liposome formulations (e.g., DaunoXome and Doxil).[255] Another challenge, specifically for tumor-targeting polymeric NPs, arises from the complexity and heterogeneity of the tumor's microenvironment, resulting in the accumulation of NPs in neighboring healthy cells.[256,257] Lastly, polymeric and biodegradable nanoparticle delivery systems' development and marketability, even with their ability to evade the host immune system with extended circulation, stability, and low toxicity, have remained elusive.[258]

To overcome the limitations of most biodegradable/polymeric nanoparticles,[259] exosome-mediated drug delivery[210] provides superior features including long circulation half-life,[260] enhanced cell-specific targeted delivery,[145] increased biocompatibility,[104,261] reduced/low toxicity,[262,263] ability to stimulate an immune response against pathogens,[161] antitumor modulation,[161] antigen presentation,[264] etc. Exosomes have been utilized as a drug delivery vesicle in multiple studies using low-molecular-weight drugs, active biologics (lipids, nucleic acids, siRNA, proteins), and larger antibodies.[41,201,265−269] For example, the exosome-mediated delivery systems using curcumin have already shown great potential over conventional drug delivery systems.[270] Curcumin, an antioxidant that has chemotherapeutic properties, is a natural polyphenol found in the rhizomes of turmeric.[271−273] Alvarez-Erviti et al. reported expressing a neuron targeting a protein on the exosome surface with postloading using siRNA, followed by injection into the mouse bloodstream. The authors have achieved specific gene knockdown in the brain and proof of the exosomal capability of crossing the BBB without inducing any immune response.[268] Another ongoing challenge in delivery science is targeting the subcellular compartment of specific cells. For instance, targeting nuclease and delivering the CRISPR-Cas9 system are very attractive to the scientific world and have a higher precision for gene editing. Scientists can deliver large plasmids, including the CRISPR-Cas9 expression vectors loaded in exosome, to mesenchymal stem cells.[269] This study validates that exosomes can deliver cargo to recipient cells and gives insight into *in vivo* gene editing potentials against multiple diseases.[269] Delivery of antibodies and active biologics is also a promising platform in the drug delivery field. Wan et al. has reported on the modification of aptamer-based DNA on exosomal surfaces by DNA hybridization chain reaction, enhancing exosome functionality and showing potential for broader biomedical applications such as targeted drug delivery, cell-free therapy, and gene knockdown.[41] Acquired drug resistance is a challenging mechanism against cancer chemotherapeutics, and it has been reported that exosomes play a critical role in this drug-resistance transfer among cancer cells. Lv et al. has shown that drug-sensitive MCF-7 cells (MCF-7/s) become drug resistant after treatment with exosome isolates from the docetaxel-resistant variant MCF-7 cell line (MCF-7/DOC).[274] The authors also found that P-glycoprotein (P-GP)

expression is higher in exosomes from MCF-7/s cells after treatment with MCF-7/doc exosomes, indicating P-GP has a role in drug-resistance transfer among the cells. In 1996, Raposo et al. first observed the role that exosomes play in adaptive immune system stimulation via antigen presentation.[275] Exosomes also carried and presented MHC I/II to modulate the antigen-specific CD8+ and CD4+ via direct and cross-presentation.[276] Bianco et al. showed that immature dendritic cell-derived exosomes inhibit inflammation in a murine footpad model via inflammatory cytokines IL-10 and IL-4.[277] Another study by Chen et al. showed mesenchymal stem cell-derived (MSC) exosomes increased the concentration of anti-inflammatory factor TGF-β and suppressed the secretion of pro-inflammatory factor IL-1β and TNF-α.[278] Besides, MSC exosomes also induced the transition of Th1 to Th2 cells and reduced the potential to differentiate into interleukin 17-producing effector T-cells (Th17). Thus, MSC exosomes have the intrinsic properties of modulating the tumor microenvironment's immune response and providing immune protection via exosomes. T- and B-cell-derived exosomes also play a vital role in immune modulation. For example, mouse B-lymphoma cell-derived exosomes carry heat shock protein 70, modulating the antitumor immune response in T-cells.[279] In another study, dendritic cell-derived exosomes primed with acid-eluted tumor peptides eradicated tumors in mice.[280] Exosomes from T-cells also improved the immune response with the help of communication with endothelium cells by destroying tumor stroma and preventing tumor metastasis.[281] Immune modulation is achieved by bioactive lipids and proteins of the exosome and exosome mRNA. Aucher et al. reported that human macrophage exosomes functionally inhibit cancer cells proliferation by delivering miRNAs to hepatocarcinoma cells (HCCs).[282] Another study based on MSC-derived exosomes showed that the paclitaxel-loaded exosome inhibits *in vitro* tumor growth.[283] The study by Pascucci et al. showed the effect of murine MSC SR4987 line exosomes loaded with paclitaxel (PTX) and delivered to the human pancreatic cell line CFPAC-1, which possessed intense antiproliferation activity against CFPAC-1.[283] PTX-loaded MSC exosomes showed higher cell target specificity as well. Rani et al. also reported that MSC-derived exosomes play a crucial role in its paracrine function.[266] Another study by Kalimuthu et al. showed paclitaxel (PTX) loaded with MSC-derived exosomes could accelerate anticancer treatment against breast cancer (MDA-MB-231) cells observed both *in vitro* and *in vivo*.[265] Exosomes have been extensively studied for brain drug delivery to improve brain disease and inflammation treatment. A study by Yan et al. has shown that exosomes derived from mouse brain endothelial cell line (bEND3) loaded with doxorubicin significantly reduced growth and proliferation of U-87 MG cancer cells compared to embryos treated with buffer control or drug only. Chemotherapy is the standard and most effective method for cancer treatment, and the above discussion validates that exosome-chemotherapeutic drug delivery reduces side effects through a targeted drug delivery strategy which reduces the overall drug dose needed for the treatment.[284] Zhuang et al. demonstrated that exosomes encapsulated with curcumin (Exocur) and STAT3 inhibitor JSI124 (Exo- JSI124) via LPS induced brain inflammation via microglia cells in a mouse model. The authors have reported the delivery method of Exocur and Exo-JSI124 induced apoptosis of microglial cells.[285] Additionally, exosome-mediated drug delivery systems have been utilized for

curcumin delivery, which forms a complex with curcumin that enhances both loading efficiency and the safe transportation for patients in clinical trials.[286] Other great applications of exosomes involve their immune-protective and regenerative effects. MSCs are derived from multiple sources such as bone marrow, adipose tissue, cord blood, and other sources and are getting much attention as potential candidates for regenerative medicine.[287−289] Cardiosphere-derived cells (CDCs) derived exosomes produce a range of cardioprotective measures such as antioxidant, antifibrotic, antiapoptotic, and anti-inflammatory effects.[290,291] Another highlight of exosomes research is delivery of siRNA.[292,293] For example, Shtam et al. demonstrated that HeLa cell-derived exosomes delivering siRNA for RAD51 and RAD52 activate apoptosis of recipient cancer cells.[294] Wahlgren et al. also showed that peripheral blood exosome-mediated siRNA delivery efficiently silences the target MAPK gene in lymphocytes and monocytes.[295] Another interesting finding is that analysis of protein and mRNA confirms exosomal-mediated siRNA delivery, targeting successful knockdown of BACE1, a therapeutic target of Alzheimer's disease.[296] Also, a recent study by Haney et al. reported that catalase loaded into exosomes can cross the BBB, improving the disease outcomes in a Parkinson's mouse model.[48] Recent studies have also found that the targeted delivery of streptavidin-FasL (SA-FasL) via exosomes could substantially enhance the therapeutic effects of the SA-FasL protein while minimizing its potential off-target effects often caused by its solubility when doses are delivered by injection.[297] Regarding exosome-mediated vaccine development and delivery, Li et al. reported that the exosomes can transfer TNF-ϒ and induce antiviral activity.[298] Exosomes derived from DCs also show promising potential for targeted immune responses against tumor cells and increased the therapeutic effect compared with cell and noncell based therapeutic strategies.[299] Specifically, mature and activated DC-derived exosomes carry MHC I and MHC II molecules and costimulatory molecules such as CD40, CD80, and CD86 and deliver cargo to active cytotoxic T- and natural killer (NK) cells *in vitro* and *in vivo* via potent antigen-specific T- and B-cell responses.[300,301] Genetically engineered autologous or allogeneic T-cells expressing chimeric antigen receptors (CARs) or T-cell receptors (TCRs) as cellular immunotherapy may also be considered as a promising cancer treatment method.[302] Lu et al. recently reported that exosomes from hepatocellular carcinoma (HCC) antigen-modified DCs could be used as cell-free vaccines for HCC and opens the window for HCC immunotherapy.[303] Another study by Geis-Asteggiante et al. demonstrated myeloid-derived suppressor cells (MDSC) derived exosomes using protein mRNA and miRNA, can induce immune suppression function.[304] Di Bonito et al. used an engineered exosome with the E7 protein of human papilloma virus (HPV). The E7 protein elicited a strong and effective antigen-specific cytotoxic T-lymphocyte (CTL) immunity.[305] A DNA vector expressing HPV-E7 and fused at the C-terminus of an exosome-anchoring protein named Nef^{mut} was injected into mice.[306] In this study, the authors provide evidence that injection of Nef^{mut}/E7 DNA induces similar antigen-specific cytotoxic T-lymphocytes like mice implanted with TC-1 tumor cells. Integrin $\alpha v\beta 6$ can convert the latent transforming growth factor (TGF)-β to promote the development of Treg cells.[307] The authors demonstrated that the delivery of cardiovascular exosomes carrying integrin $\alpha v\beta 6$ promotes the generation of the donor

antigen-specific immune tolerance. On the same line, another study showed DC-mediated exosomes promote heart allograft survival.[308] The authors have finally demonstrated that donor-derived peripheral exosomes carrying MMP1a promoted allograft heart survival via inducing donor antigen-specific Treg to attenuate the T helper (Th)2 pattern inflammation.[309]

Exosomes offer enormous promise as a contemporary yet promising area for small and large biological molecules' therapeutic drug delivery. As a drug delivery vehicle, exosomes provide an added advantage over polymeric vehicles due to the lack of accumulation of exosomes in the RES, especially the liver, which helps them avoid first-pass metabolic effects before reaching target sites.[297] It is also essential to note that exosome-mediated drug delivery offers a comparatively longer circulation half-life, induces a robust immune response against pathogens, and facilitates subcellular-specific targeted delivery of therapeutics (e.g., to mitochondria and nucleus).[15] However, there is a need for additional investigations into how exosomes react to the body's immune responses before these therapies are accepted as permanent therapeutic methods.[27] This section demonstrates the exosome's robust immune response, drug delivery capacity to any specific target, and carrying of extensive biologics and antibodies, and discusses how scientists can utilize the exosome platform for designing an adjuvant vaccine and therapeutic delivery. Surface modification and engineered exosomes added a plethora of applications for drug delivery, disease diagnosis, and facilitate immunotherapy. Nevertheless, significant effort is required to develop exosome as a personalized therapeutic modality based on patient disease history.

5.4. Exosome as a Disease Biomarker. The National Institutes of Health Biomarkers Definitions Working Group in 1998 defined a biomarker as a quantifiable measure of a normal biological process, pathological process, or pharmacological response to a therapeutic administration.[310] Currently, both invasive and noninvasive methods are employed for biomarker identification. For example, serum analysis of blood samples from cancer patients is well established for monitoring the location and stage of cancer. Exosomes reignite the field of biomarker study. Naturally, the question arises, why do exosomes have advantages in biomarker screening applications? First, MHC-expressing exosomes have the ability of antigen presentation via both direct and indirect pathways.[127,311] Second, exosomes contain cell-specific surface markers that carry protein and RNA cargo, and are highly stable in storage conditions.[312,313] The exosome was initially considered an unnecessary protein excreted from cells. However, recent studies confirm the importance of exosomes in cell−cell communication by transporting microRNA, mRNA, and proteins. The membrane bilayer and luminal content of exosomes are protected from extracellular proteases. Multiple exosome sources contribute to the biomarker study; they are urine, saliva, cerebrospinal fluid, blood, body fluid, amniotic fluid, ascites, and cells used to identify and validate biomarker screening. Exosomes contain a variety of lipids, nucleic acids, mRNA, proteins of cytosolic, cell signaling, and membrane trafficking, reflecting the cell type and condition. In a PubMed search conducted on January 20, 2021, 4767 papers were generated related to exosomes and biomarker studies. As a biomarker, exosomes are getting more attention from various groups of scientists as more evidence is emerging that exosomes contain protein and nucleic acids associated with cancer, liver, kidney, neurodegenerative, infectious, and

metabolic diseases. Exosomes are easy to analyze and can be stored at −80 °C for 1 week to 1−2 years (depending on the exosome source) for future use.[314] More information on exosome biomarkers can be found at http://www.exocarta.org (ExoCarta, a web-based compendium of exosomal cargo) and http://exrna.org (extracellular RNA communication program). Biomarker screening studies utilize multiple tools to analyze specific markers relevant to the disease model. Protein, mRNA, and microRNA content of exosomes are used as a diagnostic tool for biomarker analysis. Most general approaches are flow cytometry (FACS), immunohistochemistry, biochemical analysis (microarray studies, RT-qPCR, Western blotting), surface resonance Raman spectroscopy (SERS), and principal component analysis (PCA). These assays are based on the type of exosome source and disease-specific biomarker.

Proteins found in exosomes from both healthy and disease states are diverse and resemble various disease conditions related to cancer, liver, renal, kidney, and brain diseases. Several proteins have been identified as a diagnostic marker for exosomes. Scaffolding membrane proteins Tetraspanin are enriched on the exosome surface. The study shows plasma CD63+ expression elevated in patients with melanoma compared with a healthy control.[315] Recent research also stated that a higher level of CD63$^+$ in different cancer types consolidates as a potential biomarker for cancer.[316] CD81, another biomarker, was found to be higher in chronic hepatitis C patients and associated with fibrosis and inflammation.[317−319] In a lung cancer diagnostic biomarker study, authors found a higher expression of CD151, CD171, and tetraspanin 8 in serum exosome blood collected from 581 cancer patients (431 with lung cancer and 150 controls).[320] This study suggests exosomal protein is a promising biomarker for nonsmall-cell lung carcinoma (NSCLC). Glypican-1 (GPC1)-positive exosomes serve as potential biomarkers in early stage pancreatic cancer. Exosomes isolated from systemic circulation of 250 pancreatic patients showed a higher correlation of GPC1 in cancer patients than the healthy control.[321] In another biomarker proteomic study, urine exosomes collected from a mouse liver damage model were utilized. The authors demonstrated that CD26, CD81, S1C3A1, and CD10 could be used as a potential biomarker for hepatic damage.[322] On the same line, a urine exosome biomarker study revealed that some specific markers are most frequently associated with ALG2-interacting protein X (ALIX), CD24, CD9, flotillin-1, HSP70, tumor susceptibility gene 101 (TSG101), lysosome-associated membrane protein 1 (LAMP1), gp330 precursor, uromodulin, pro-epidermal growth factor precursor, MME neprilysin, and beta-galactosidase precursor.[323−329] In a gastric cancer biomarker study, the authors found that metastatic AZ-P7a cells release let-7 miRNA, which activates CD-97-associated pathways to promote oncogenesis.[330−332] Many studies prove that glioblastoma (GBM) is malignant, and exosome mRNA content provides us more insight into GBM and how biomarker identification will lead to an effective treatment.[333] Studies show MiR-21 plays a key role in GBM pathways. Also, exosomal marker noncoding RNA (RNU6−1) and microRNA (miR-320, miR-574−3p) are significantly associated with GBM diagnosis. More evidence shows an exosome role in carcinogenesis pathways such as ERK, PI3K/AKT, STAT3, and PTEN.[333−336] Breast cancer is a highly prevalent disease, and early diagnosis gives a better outcome of treatment. Serum exosome microRNA or noncoding RNA analysis shows promising results in breast cancer biomarker identification.[337] In another study, the authors found exosomal miRNA-21 with 105 expressions higher tissue of metastasis patients than nonmetastasis and healthy donors, which implies that liquid biopsy based on circulating exosomes can be a complementary diagnostic biomarker tool for a breast cancer study.[338] Another plasma exosome analysis study revealed that exosomal microRNA MiR-21 and MiR-1246 are more significantly elevated in human breast cancer patients and can serve as a plasma biomarker for breast cancer.

Exosomes harbor different proteins, lipids, and nucleic acids that are present in most body fluids. It has been proven that exosomes play a role as a critical signal transduction promoter to recipient cells via transporting proteins, lipids, mRNA, microRNA, etc. Research on exosomal biology and functions makes it ideal as a biomarker screening tool. Compared with traditional biomarker specimens such as serum or urine, exosome offers higher sensitivity and specificity to their excellent stability. The use of biomarker screening utilizing exosomes will expand since they are found in mammalian cells and a diverse range of pathological microorganisms.[339−341] In conclusion, exosomes for use as biomarkers are in a very early stage of discovery, and their potential clinical value waits to be fully explored.

5.5. Exosome Applications in Medical Imaging and Tracking.

Exosomes were thought to be waste materials from cells until they were revealed to transfer various biomolecules to various cavities.[342] To engage in intercellular communication by overcoming the natural biological barrier (e.g., blood−brain barrier), exosomes have become an emerging effective diagnostic and therapeutic nanocarrier.[13,343] However, there is a limited understanding of how and where exogenously administered exosomes are distributed *in vivo*.[344] The current method to assess exosome-mediated delivery success is to evaluate therapeutic symptoms or repeated post-mortem histopathological examination. Therefore, real-time, noninvasive exosome imaging is a prerequisite to making exosomal therapy clinically relevant. In recent years, scientists have developed an efficient labeling and tracking method of exosomes using various imaging modalities (Figure 8). The imaging tools can provide information on exosomes such as biodistribution, migration capability, physiological functions, and *in vivo* behavior, and enhance the opportunities to find an optimal administration route for exosome-mediated drug delivery.[345] Optical imaging is a widely used imaging and diagnostic technique that is cost-effective, highly sensitive, and includes images at the molecular level. There are mainly two types of optical imaging: fluorescent imaging and bioluminescence imaging. Fluorescence imaging is based on a fluorescence probe that is excited upon the laser irradiation, by which it produces fluorescent signals observed by the optical imaging system. Fluorescence imaging is noninvasive and is used in real time with the use of nonionizing light sources.[346] There are two ways to label exosomes with fluorescent materials (e.g., proteins, dyes, or nanoparticles). (1) Indirect labeling is to have parent cells express a fluorescence protein, including green fluorescent protein or red fluorescent protein, to excrete the exosomes with their biological mechanism of visualization capability passed down to their daughter cells. (2) Direct labeling is another type of labeling in which fluorescence dyes (or nanoparticles) are used to label the secreted exosomes after isolation via surface modification or physical interaction to observe their biodistribution and tissue

Figure 8. Exosome visualization using various imaging modalities. Fluorescence dye-labeled or luciferase-expressing exosomes visualize the biodistribution or tissue uptake under optical imaging systems (fluorescence imaging or bioluminescence imaging). Gold nanoparticles (GNPs) labeling exosomes observe the whole-body tracking in deep tissues under computer tomography (CT) or photoacoustic imaging (PAI). Superparamagnetic iron oxide nanoparticles (SPIONs) labeled exosomes show the active cell migration or homing to target regions *in vivo* under magnetic resonance imaging (MRI) or magnetic particle imaging (MPI).

uptake.[347,348] Anchordoquy et al. demonstrated that lipophilic carbocyanine DiOC18(7) (DiR) dyes can be used to successfully labeled exosomes derived from breast cancer cells, and the resulting the biodistribution in tumor-bearing xenografts could be observed. In comparison with DiR dye-labeled liposomes, they found most exosomes accumulated in the liver and spleen after 1 h of intravenous injection. They also observed higher fluorescence sensitivity of exosomes than liposomes within tumor regions.[349] Bioluminescence imaging utilizes the natural light emission process from some living organisms that bioluminesce (e.g., firefly, bacteria). Bioluminescence images are generated by detecting photons emitted internally from enzyme-catalyzed reactions with an optical imaging system.[350] The Takakura group from Kyoto University constructed exosomes with intense luciferase activity via indirect labeling. In their study, B16-f10 murine melanoma cells were transfected with the plasmid expressing a fusion protein of gLuc-lactadherin. The secreted exosomes from the cells were collected by the ultracentrifugation isolation method. After a 4-h systemic injection, they found the exosomes accumulated first to the liver and then to the lungs with fast clearance from systemic circulations.[351] Because of the penetration depth limitation of light in optical imaging,

Figure 9. *In vitro* and *in vivo* photoacoustic imaging and magnetic resonance imaging of exosome-loaded nanocomposites (V_2C-TAT@Ex-RGD). (A) *In vitro* PAI images and the quantitative curve of PA intensity of the V_2C-TAT at different concentrations. (B) *In vivo* PA images of mice 12 h after intravenous injection of PBS, V_2C-TAT (10 mg/kg), and V_2C-TAT@Ex-RGD (V2C-TAT, 10 mg/kg). (C) Quantification of the PA signals from the tumor sites from different groups treated with (1) PBS, (2) V2C-TAT (10 mg/kg), and (3) nanocomposites (V_2C-TAT, 10 mg/kg). (D, E) *In vivo* PA images and the responding signal intensities of mice at different times after intravenous injection of nanocomposites (V_2C-TAT, 10 mg/kg). (F) T1-weighted MR images of mice 24 h after intravenous injection of PBS, V_2C-TAT (V_2C-TAT, 10 mg/kg), and nanocomposites (V_2C-TAT, 10 mg/kg). (G) Quantification of the MR signals from the tumor sites from different groups. Adapted from Cao et al. ref 358. Copyright 2019 American Chemical Society.

other whole-body imaging modalities are needed. Computed tomography (CT) is a crucial imaging technique for disease diagnostics with a high temporal and spatial resolution based on measuring X-ray absorptions throughout the body. X-ray CT imaging has been widely used in the clinic to visualize bone structures and has now been adapted to quantify cell tracking with gold nanoparticle labeling.[352] A recent publication showed that stem cell-derived exosomes labeled with gold nanoparticles could track the migration and homing patterns in brain disorders.[353] Betzer et al. studied the efficient labeling of glucose-coated gold nanoparticles to exosomes and demonstrated the enhanced exosomal accumulation at the lesion site using CT imaging on a mouse model of focal brain ischemia after 24 h of intranasal administration.[354] Gold nanostructures can be potentially used for photoacoustic imaging (PAI) of tracking of exosomes, using strong light absorption to generate sound waves. On the basis of a "light in/sound out" approach, PAI can efficiently combine optical imaging's spectral contrast and the anatomical penetration depth of ultrasound imaging (up to multiple centimeters).[355]

Another whole-body imaging technique is magnetic resonance imaging (MRI), which offers advantages with radiation-free, high spatial resolution. To be detected by MRI, exosomes are required to be labeled with super-paramagnetic iron oxide nanoparticles (SPIONs). In one study, Hu et al. utilized the electroporation technique to allow melanoma exosomes to be loaded with SPIONs and detected by MRI. They revealed that the SPION-exosome exhibited a much more efficient homing and retention in sentinel lymph nodes than the free SPION 48 h after initial footpad injection.[356] Furthermore, in a newer magnetic imaging modality, magnetic particle imaging (MPI), SPIONs can create a linearly quantifiable signal that is difficult to achieve in MRI without any tissue background signal. In a recent study, Jung et al. labeled SPIONs in MDA-MB-231 cancer cells' culture in hypoxic conditions and showed hypoxic cancer cells take up these exosomes more avidly. They showed these exosomes are quantitatively visualized with MPI signals from SPIONs to monitor the whole-body distribution and *in vivo* targeting of exosome-mediated drug (Olaparib) delivery to tumors.[357] Exosomes play a pivotal role in analyzing cancer biology and brain diseases. It is crucial to diminish false-positive exosomal signals from exosome labeling as an imaging tool.

Besides, exosome-based multimodal imaging can be considered more effective and specific for noninvasive disease diagnostics. Cao et al. reported that nucleus-targeted exosome engineered vanadium quantum dots nanocomposites showed effective multimodal (PAI and MRI) image-guided efficient cancer therapeutic potency.[358] Besides, nanocomposites showed good biocompatibility and long circulation time. As a result, it can target a high number of cancer cells and have demonstrated efficacy in escaping the endosome and advancement into the nucleus. Because of their NIR absorbance and good photostability, nanocomposites-treated mice exhibited a 2.11-fold higher PAI signal in the tumor site than the control group. In contrast, because of the 3d1 electronic configuration of quadrivalent vanadium (V) and the quantum mechanical confinement, nanocomposites displayed 3.73-fold higher *in vivo* T_1 MRI contrast than the control groups. Their overall results indicated that nanocomposites could be attractive agents for multimodal imaging (Figure 9).[341] New exosomal imaging techniques will be developed for preclinical and clinical settings with continuous development in the field of exosome research.

5.6. Role of Exosomes in Vaccine Development and Delivery.
Almost all living organisms, including viruses and bacteria, shed exosomes in the extracellular matrix. As mentioned before, exosomes carry larger proteins, lipids, and nucleic acids in their cargo. Lipids, proteins, membrane trafficking, nucleic acid-like signal transducers, anti-apoptosis molecules, and T-cell stimulations found on the exosome surface also has some immune-modulatory effects. Exosomes also contain a high level of triacylglycerol (TAG), cardiolipin, and cholesterol (CE), and where TAG and CE are found in the lipid droplet core and cardiolipin in mitochondria.[65] Both cell-specific and ubiquitous proteins are selectively expressed in exosomes from their native cells. They also include cytosolic proteins such as tubulin, flotillin, and membrane transport proteins such as annexin, actin, and Rab proteins 1. Exosomes also carry heat shock proteins such as HSP20, HSP27, HSP70, and HSP90, involved in loading and binding antigen peptide onto MHC molecules, antigen presentation, maturation dendritic cells, and translocation of NF-$\kappa\beta$ into the nucleus through CD91.[359,360] Another abundant protein family present on the exosome surface is tetraspanin like CD9, CD63, CD81, and CD82, interacting with multiple proteins such as integrin and MHC class I and II.[361] Exosomes that are released from viral cells also carry viral miRNA, proteins, and even the entire virion. For example, the major oncoprotein of EVB (a gamma herpesvirus), latent membrane protein 1 (LMP1), was identified in exosomes isolated from EVB infected cells.[362] Immune modulating cells such as macrophages and monocytes abundant with exosomes can modulate antigen presentation and affect myeloid cell differentiation and proliferation. During antigen presentation, B-cell-derived exosomes first interact with antigens and modulate T-cell activation and cytokine secretion.[363,364] The study also shows that immune-derived exosomes take cytokines such as TGF-β, IL-1α, TNF, and IL-1β. On the contrary, infected cell-derived exosomes can carry viral molecules and microbials.[365]

Exosomes also play a critical role in the chronic inflammatory process. For example, DC-derived exosomes behave as antigen-presenting molecules and can perpetuate Th2 cells' response to DC to regulate immunity and inflammation.[366] Mast and B-cell-derived exosomes also drive Th2 responses and promote the Th2 environment.[367]

Exosomes also play a role in processes such as angiogenesis, stromal cell activation, and tumor growth metastasis. The release of exosomes is increased when a cell is under stress, particularly at stress conditions due to disease-related changes.[368] In the current therapeutic paradigms, cancer cells become nonresponsive to chemotherapeutics and radiation after repeated exposures, and exosomes are one of the major players in cancer progression. For example, pancreatic cell-derived exosomes carrying tetraspanin-8 promote vessel branching. Tetraspanin-8 also modulates uptake and binding of cancer exosomes by endothelial cells.[369] In the tumor microenvironment, cancer-associated fibroblasts (CAF) differentiate into myofibroblasts to facilitate tumor progression. The study shows CAF exosomes promote or activate multiple signaling pathways. For example, Desrochers et al. have shown that CD81-positive exosomes from stromal cells activate several signaling pathways in breast cancer tumors. This activated signaling promotes cancer cell motility, metastasis, and tumor growth.[370] Mature and activated DC-derived

exosomes carry MHC I and MHC II molecules and costimulatory molecules such as CD40, CD80, CD86, among others which activate natural killer (NK) cells and cytotoxic T-cells *in vitro* and *in vivo* via potent antigen-specific T- and B-cell responses.[301,371] Therefore, exosomes play both an immune activation and a cancer progress role depending on the cell type origin. However, exosomes also suppress immune cell activation. Studies show that cancer exosomes also elevate the differentiation of mature dendritic cells without its antigen presentation to the myeloid cell, which produces TGF-beta for T-cell suppression.[372] Thus, exosomes use signaling between tumor cells and surrounding cells to promote the tumor microenvironment. In an infectious disease, the pathogen faces a hostile situation and invades cell signaling. Along the same line, the study shows pathogen use of exosomes for differentiation, growth control, transmission, and virulence coordination to infection. For example, exosomes from malaria are actively taken up by endothelium and monocytes, altering vascular properties, promoting virulence via malaria exosomes, and stimulating DNA-sensing pathways via microRNA.[373] Parasite or virus-infected cells or parasites themselves release exosomes to activate immune cells via antigens to present to APC. In contrast, exosomes from microbial molecules carrying leishmania GP63 or HIV Nef can activate apoptosis of immune effector cells like helper T-cells and effector B-cells or inhibit T-cells.[374]

Vaccines deliver the natural or inactive form of proper antigens adjuvant; partial viral particles typically elicit a potent immune response. In cancer immunotherapy, a tumor-associated antigen (TAA) can be a potential delivery particle as a vaccine. For vaccine applications, some TAA targeting proteins such as HER2, p53, CEA, RAS, MUC1, etc., are immunosuppressive and poorly antigenic.[375] For example, Hartman et al. has proposed to generate recombinant adenoviral vectors expressing the extracellular domain (ECD) of carcinoembryonic antigen (CEA) or HER2 linked to the C1C2 domain of lactadherin in addition to native unlinked ECD versions of CEA and HER2. The authors found adenoviral expression of a C1C2-modified CEA/ECD, and HER2/ECD resulted in higher expression of the protein in the exosome fraction in transgenic murine model than the control. This study signifies low immunogenicity of soluble TAAs in cancer patients and opens the cancer vaccine platform via improving antitumor immune response.[376] Recently, exosomes are getting much more attention due to their intrinsic properties as drug carriers and immunomodulators. Anticoli et al. has used engineered exosomes with the E7 protein of the human papilloma virus (HPV). The study demonstrates that E7 protein elicited solid and effective antigen-specific cytotoxic T-lymphocyte (CTL) immunity. Genetically engineered autologous or allogeneic T-cells expressing chimeric antigen receptors (CARs) or T-cell receptors (TCRs) as cellular immunotherapy agents are promising as a new treatment method for multiple ranges of cancers.[302] Despite T-cell efficiency, T-cell therapies show unique toxicities such as cytokine release syndrome (CRS) and CAR-T-related encephalopathy syndrome (CRES). Previous studies also showed human T-cell-derived exosomes in cytotoxic T-lymphocyte (CTL)−target cell interactions.[377,378] CTL-derived exosomes containing CTL surface membrane molecules (CD3, CD8, and the TCRs) result in tumor cell death as a consequence of interactions between the TCR and proper antigen/MHC combination. The authors' data validate that

CAR-containing exosomes derived from CAR-T cells can be used as cancer-targeting agents and can improve the therapeutic efficacy of a potential cancer vaccine platform.[262] Another study by Li et al. demonstrates an exosome derived from *Toxoplasma gondii* that modulates the immune response. The exosomes were isolated from *T. gondii* and incubated with macrophage RAW264.7 cells. After *T. gondii* exosomal treatment, production of IL-12, TNF-α, and IFN-γ in macrophage cells increased, and the level of IL-10 decreased, as determined using an enzyme-linked immunosorbent assay (ELISA). The authors have concluded that *T. gondii* exosome-modulated macrophage activation *in vitro* triggers humoral and cellular immune responses and results in partial protection against acute parasite infection in mice. The results suggest that exosomes may serve as a potential candidate against toxoplasmosis.[379]

Roier et al. showed how outer membrane vesicles form in Gram-negative bacteria emerging in the research field and significantly impact future applications such as outer membrane vesicle (OMV)-based vaccines. OMVs derived from heterologous *H. influenza* strains were thoroughly characterized for size distribution and quantity of vesicle production among strains Rd KW20, Hib strain Eagan, and NTHi 2019-R strain. The presence of vaccine candidate 13 ATP-binding cassettes (ABC) transporter proteins and 8 lipoproteins in *H. influenzae* OMVs supports their potential to act as a vaccine against *H. influenzae* infections. In contrast, the presence of essential virulence factors such as serine protease HtrA and vaccine candidates OMP 26 and protein D indicates that OMVs in *H. influenza* pathogenesis have potential vaccine application via exosome.[380] This above discussion demonstrates that the exosomes can play an important role in immune modulation, serve as potential vaccine development platforms, and be used as a delivery vehicle. Exosomes can increase the efficiency of vaccines to generate antibodies against multiple diseases and are a versatile platform for developing more vaccines.

In the preclinical study discussion, we found exosomes play a critical role in both physiological and pathological conditions, as they can carry pathogenic messages that indicate disease condition. Therefore, exosomes can be utilized as a biomarker and a disease marker to target for therapeutic efficiency. Preclinical studies of exosomes for use as a biomarker, in early detection and drug delivery methods, and in vaccine development platform make them suitable candidates in clinical settings. We believe exosomes can link bridges between our knowledge gaps in different disease conditions. The preclinical data show that exosomes have the potential for application in cancer immunotherapy, infectious disease, and brain disease treatment.

6. EXOSOMES IN CLINICAL TRIALS

The wide range of biological content found and released from exosomes in physiological conditions has various applications in biomedical and drug delivery contexts, such as finding new biomarkers, creating new imaging tools, and developing therapeutic carriers for cancers and brain disease. Up until January 2021, we have found 205 clinical trials related to exosomal research. Out of 205 trials, around 87 trials involve cancer-related studies, 18 include brain pathologies, and 100 include diabetic, cardiovascular, lung, or kidney diseases, including a novel coronavirus study.

Table 1. Exosome Clinical Applications in Cancer Research

no.	disease or conditions	interventions and exosome source	therapeutic and disease model	clinical trial identification	status and clinical phase
1	metastasis (stage IV), melanoma (stage IIIc)	biological blood test	exosome for developing theranostic tools	NCT02310451	unknown and not applicable
2	pancreatic cancer	endoscopic ultrasound-guided portal venous blood sampling exosome	feasibility and safety of sampling portal venous blood, detecting CTCs, and analyzing mRNA markers	NCT03821909	recruiting and not applicable
3	colon cancer	curcumin, curcumin conjugated with plant exosome	exosome-loaded curcumin on the immune modulation, cellular metabolism, and phospholipid profile of normal vs malignant	NCT01294072	active, not recruiting, Phase 1
4	early lung cancer	CT chest scans and blood, exosome detection	We are using peripheral blood exosomes in identifying early biomarkers for lung cancer.	NCT03342253	not yet recruiting and not applicable
5	sarcoma	blood samples	evaluate cancer pathogenesis, progression, and treatment efficiency of the serum-derived exosomes	NCT03800121	recruiting and not applicable
6	prostate cancer	urine exosomes	validate a non-DRE exosome gene expression test of prostate cancer in a prostate needle biopsy	NCT02702856	completed and not applicable
7	pancreatic cancer, benign pancreatic disease	blood sample from patients and healthy controls	exosome purification for such as proteomics and RNA sequencing	NCT02393703	active, not recruiting and not applicable
8	clear cell renal cell carcinoma	urine samples	detecting tumor exosomes in urine, a new biopsy tool for early diagnosis	NCT04053855	not yet recruiting
9	lung metastases osteosarcoma	blood sample	identifying the levels and mutations of circulating exosomal RNA with or without lung metastasis	NCT03108677	recruiting and not applicable
10	proteinosis gallbladder carcinoma	exosomes from blood specimens	correlations between exosome biomarkers and gallbladder carcinoma	NCT03581435	recruiting and not applicable
11	metastatic and ductal (stage IV) pancreatic adenocarcinoma, pancreatic cancer AJCC v8	mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA	mesenchymal stromal cells-derived exosomes with krasg12d siRNA (exosomes) in treating participants with pancreatic cancer with krasg12d mutation	NCT03608631	not yet recruiting and Phase 1
12	breast neoplasms	tumor-derived exosomes	evaluating the use of tumor-derived exosomes as a marker for response to therapy in women receiving neoadjuvant chemotherapy	NCT01344109	withdrawn and not applicable
13	cholangiocarcinoma benign biliary stricture	cholangiocarcinoma derived exosomes	characterize the ncRNAs of cholangiocarcinoma obtained exosomes as a diagnostic tool and evaluate the prognostic and predictive value of cholangiocarcinoma exosome levels in plasma, before and after surgical resection	NCT03102268	recruiting and not applicable
14	pancreatic ductal adenocarcinoma (PDAC)	portal vein blood sample	Test 3 CTC isolation methods and analyses by flow cytometry for onco-exosomes in pancreatic cell lines' culture media	NCT03032913	completed and not applicable
15	sleep apnea syndromes, obstructive cancer	blood samples	to evaluate exosomal PD-1/PD-L1 expression in patients	NCT03811600	not yet recruiting and not applicable
16	gastric cancer	gastric cancer-derived exosomes	characterize gastric cancer-derived exosomes' molecular profile as diagnostic tools and evaluate gastric cancer exosomes levels in plasma prognostic and predictive value	NCT01779583	unknown and not applicable
17	bone metastases	circulating tumor exosome	identify deregulated miRNAs, subsequent bioinformatics analysis to identify their potential role in tumor progression	NCT03895216	recruiting and not applicable
18	oropharyngeal cancer	exosomes from blood and saliva	detect specific HPV proteins in the blood or saliva exosomes to help improve the detection of OPSCC	NCT02147418	recruiting and not applicable
19	larynx, lip, oral cavity, pharynx	metformin hydrochloride, placebo, cancer exosomes	identify the role of metformin hydrochloride and exosomes in cancer cells' metabolic activity and surrounding supportive tissues	NCT03109873	active, not recruiting and early Phase 1
20	carcinoma ovarian cancer, benign gynecologic diseases	ovarian cancer exosomes	analyze the expression of microRNA and long noncoding RNA of exosomes by next-generation sequencing	NCT03738319	recruiting and not applicable
21	oral mucositis, head, and neck cancer	grape extract exosomes, drug; lortab; fentanyl patch, mouthwash	the ability of plant (grape) exosomes to prevent oral mucositis of head and neck cancer	NCT01668849	active, not recruiting and Phase 1
22	nonsmall-cell lung cancer (NSCLC)	plasma exosome, liquid biopsy	plasma exosome, new radiotherapy combining with immunotherapy	NCT02890849	unknown and not applicable

Table 1. continued

no.	disease or conditions	interventions and exosome source	therapeutic and disease model	clinical trial identification	status and clinical phase
23	nonsmall-cell lung cancer (NSCLC)	plasma exosomes radiotherapy	plasma exosome level before and after radiotherapy, PD-L1 mRNA levels in Pexo, and radiotherapy practice combined with immunotherapy	NCT02869685	unknown and not applicable
24	nonsmall-cell lung cancer	dendritic cell-derived exosome	Phase I trials showed no induction of T-cells could be monitored in patients.	NCT01159288	completed and Phase 2
25	rectal cancer	blood sample from participants, neoadjuvant chemoradiation therapy	characterize exosomal biomarker levels in patients and compare exosomal expression rates before, during, and after chemoradiation therapy	NCT03874559	recruiting and not applicable
26	breast cancer leptomeningeal metastasis	CSF and blood	use of proteomic profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal metastases	NCT03974204	not yet recruiting and not applicable
27	metastatic castrate-resistant prostate cancer	blood samples, abiraterone and enzalutamide	detection of arv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre- and post-treatment with selective androgen pathway inhibitors	NCT03236688	active, not recruiting and not applicable
28	bladder cancer	urine samples	urine samples analysis compared to the results of cystoscopy	NCT04155359	not yet recruiting
29	lung cancer (diagnosis)	exosomes from plasma, human bronchial epithelium and cancer cells	serum exosomes noncoding RNA as a biomarker's sensitivity and specificity for the determination of lung cancer	NCT03830619	recruiting and not applicable
30	carcinoma, nonsmall-cell lung	blood samples	feasibility identifying EML4-ALK fusion transcripts and T790 M EGFR mutation from exosomes in NSCLS patients' circulation	NCT03336675	active, not recruiting and not applicable
31	cancer	blood and urine	HSP70-exosome can be used for the early diagnosis of patients with a solid malignant tumor	NCT02662621	recruiting and not applicable
32	thyroid cancer	urine sample, urine exosomal thyroglobulin and galectin 3	identifying urinary exosomal proteins, including thyroglobulin and galectin 3	NCT03488134	active, not recruiting and not applicable
33	new tumor diagnostics from human plasma samples	plasma samples	protein profiling on the isolated exosomes and isolate nucleic acids from exosomes for analysis	NCT04081194	recruiting and not applicable
34	prostate cancer	genetic analysis for the detection of prostasomes	purification of prostasomes from prostate cancer patients and their ability to determine the grade of the prostate tumors	NCT03694483	recruiting and not applicable
35	prostate cancer	Exodx Prostate Intelliscore, urine samples	investigating a new and validated urine test that predicts the likelihood of high-grade prostate cancer on an initial prostate biopsy	NCT03031418	recruiting and not applicable
36	colon cancer, liver tumors	blood draws, colectomy or hepatectomy, fibroscan test	novel ways of diagnosing colon cancer and predicting its propensity to spread to other organs such as the liver	NCT03432806	recruiting and not applicable
37	prostate cancer	Exodx prostate (intelliscore), urine samples	Validated urine test to predicts the likelihood of high-grade prostate cancer on an initial prostate biopsy	NCT03235687	active, not recruiting and not applicable
38	pancreatic carcinoma and intraductal papillary mucinous neoplasm	optical coherence tomography, blood samples	how well ultrahigh-resolution optical coherence tomography works to detect micrometer-sized early stage pancreatic cancer in participants with pancreatic cancer	NCT03711890	not yet recruiting and not applicable
39	prostatic neoplasms	drug: 18F-dcfpyl PET/CT	identify the sensitivity and specificity of 18F-dcfpyl PET/CT, basis, and characterize ctdna and exosome	NCT03824275	recruiting and Phase 2, Phase 3
40	prostate cancer	urine and serum exosomes	investigate the relationship between urinary exosome and the aggressiveness of prostate cancer	NCT03911999	recruiting and not recruiting
41	triple-negative breast cancer	Merck 3475 Pembrolizumab, intraoperative radiation therapy (IORT), serum exosomes	assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes, and serum exosomes	NCT02977468	recruiting and Phase 1
42	renal fibrosis, kidney transplant failure	kidney transplantation urine exosomes	urinary exosomes and the degree of graft fibrosis to determine biomarkers	NCT03870542	recruiting and not applicable
43	no small lung cancer	blood and serum sample, high-dose radiotherapy, cisplatin-doublet therapy, and radiotherapy	markers (molecular and immunological) of ICD or antitumor immunity (exosomal or molecular) can be detected in the serum	NCT02921854	completed and not applicable
44	thyroid cancer	urine exosome protein biomarker	evaluate new therapeutic mechanism and medications for poorly differentiated or anaplastic thyroid cancer.	NCT02862470	active, not recruiting and not applicable

T

Table 1. continued

no.	disease or conditions	interventions and exosome source	therapeutic and disease model	clinical trial identification	status and clinical phase
45	oncology	interstitial tissue fluid of pancreatic cancer site	a short OMICS analysis of PDAC (all stages confounded) uses a "modified EXPEL" procedure	NCT03791073	recruiting and not applicable
46	lymphoma, T-cell	MK-3475, copanlisib, blood samples, peripheral blood lymphocytes PD-1 expression, peripheral blood T-cell and NK cell	PD-1 and PD-L1 expression on tumor tissue; tumor-infiltrating lymphocytes and gene expression as prognostic and predictive biomarkers	NCT02535247	recruiting and Phase 1, Phase 2
47	ovarian cancer ovarian neoplasms	blood samples	to see if monocytes taken from the blood of people with ovarian cancer can kill tumor cells	NCT02063464	completed and not applicable
48	lung cancer	blood samples	diagnosis stages I–IV lung cancer drug efficacy, surgical effect evaluation, recurrence monitoring, prognosis judgment, medication guidance, and molecular classification differentiation via analyzing blood ctDNA	NCT03317080	recruiting and not applicable
49	carcinoma, hepatocellular, kidney and colorectal neoplasms, melanoma	blood samples collected before, after, and during radiotherapy, blood sample exosome	This study will follow-up immune cell populations secreted factors and released nanovesicles in the blood back, during, and after high-dose radiation therapy.	NCT02439008	terminated and not applicable
50	thyroid cancer	metformin, hydrochloride, radioactive iodine, placebo, saliva, and serum samples	Metformin hydrochloride works against radioactive iodine treatment of differentiated thyroid cancer.	NCT03109847	recruiting and Phase 2
51	prostate cancer	whole-body MRI, blood exosomes	compare diagnostic concordance of whole-body multiparametric magnetic resonance imaging (MRI) with current conventional multimodality reference standard imaging	NCT02935816	unknown and not applicable
52	pancreatic neoplasms	diagnostic test: MRI/MRCP, serum, and blood	MRI/MRCP to screen for early stage pancreatic cancer or precursor lesions by analyzing blood samples from pancreatic cancer	NCT03250078	recruiting and not applicable
53	prostate cancer	urine sample	validate the performance characteristics of the mir Scientific Sentinel CS test and mir Scientific Sentinel PCA test	NCT04100811	not yet recruiting and not applicable
54	pancreatic cancer, pancreatic diseases, pancreatitis	blood draw, cyst fluid, tumor tissue collection, functional DNA repair assays	Blood samples were analyzed for various biomarkers; first biomarkers like proteins and proteases, exosomes, stromal elements, circular RNAs, and circulating tumor DNA	NCT03334708	recruiting and not applicable
55	lip, oral cavity squamous pharynx, larynx, squamous carcinoma	nivolumab, IDO1 inhibitor BMS-986205, therapeutic conventional surgery	change in exosome composition and abundance in the peripheral blood	NCT03854032	recruiting and Phase 2
56	metastatic colorectal cancer	toripalimab, stereotactic body radiotherapy	use of stereotactic body radiation therapy in combination with ICI in colorectal cancer patients with oligometastatic	NCT03927898	recruiting and Phase 2
57	soft tissue sarcoma	MDM2, AMG-232, radiation therapy	side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma	NCT03217266	recruiting and Phase 1
58	nonsmall-cell lung cancer	olmutinib	evaluate the efficacy of olmutinib (Olita) in patients with T790M-positive nonsmall-cell lung cancer confirmed using DNA extracted from the exosomes in bronchoalveolar lavage fluid	NCT03228277	completed and Phase 2
59	recurrent inflammatory breast carcinoma, HER2/neu negative, stage IV breast cancer, stage IV	ipilimumab, laboratory biomarker analysis, nivolumab	ctDNA and immune signature assessed by exosome analysis in blood samples	NCT02892734	terminated has result and Phase 2
60	renal cell cancer	urine and serum samples	Metastatic renal cell cancer (RCC) treatment uses five kinase inhibitors sunitinib, everolimus, temsirolimus, sorafenib, and pazopanib, which are now approved for clinical application.	NCT02071719	terminated and not applicable
61	advanced solid tumor, advanced/metastatic colorectal cancer	drug: AL3810	study of personalized medicine evaluation system establishment for liver cancer, gastric cancer, and nasopharynx cancer	NCT03260179	Phase 1
62	prostate cancer	drug: steroids switch, blood samples exosomes	the change of prednisone to dexamethasone in CRPC patients that progress biochemically to AA + prednisone can improve	NCT02928432	completed and Phase 2
63	recurrent lung nonsmall-cell carcinoma, stage II, IIA, IIB, IIIA, and IIIB cancer AJCC v7	image-guided radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis	Radiation dose is delivered on the body, pass into the tumor, and through the body.	NCT01629498	recruiting and Phase 1, Phase 2
64	prostate cancer	samples with DNA, human tissue, body fluids, and fresh blood tissue	This study is to collect healthy and cancerous tissues.	NCT00578240	active, not recruiting and not applicable
65	metastatic triple-negative breast carcinoma, stage IV breast cancer AJCC v6 and v7	enobosarm, laboratory biomarker analysis, pembrolizumab	Giving pembrolizumab and enobosarm may work better than pembrolizumab alone in treating androgen receptor-positive triple-negative breast cancer.	NCT02971761	active, not recruiting and Phase 2
66	tumors refractory solid tumors, cancer, neoplasms, recurrent solid tumors	IT-141	deliver more drugs via exosomes to the tumor with reduced toxicity on healthy tissues.	NCT03096340	recruiting and Phase 1

U

Table 1. continued

no.	disease or conditions	interventions and exosome source	therapeutic and disease model	clinical trial identification	status and clinical phase
67	pancreatic cancer, pancreatic resectable and pancreatic ductal adenocarcinoma	ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine	combination of paclitaxel protein-bound (also known as nab-paclitaxel), gemcitabine, and cisplatin, effective in individuals with untreated metastatic pancreatic cancer	NCT03410030	recruiting and Phase 1, Phase 2
68	prostate cancer, obesity	robotic radical prostatectomy	how fat cells communicate with prostate cancer cells to look at how exosomes communication	NCT04167722	recruiting and not applicable
69	recessive dystrophic epidermolysis bullosa	drug: rigosertib sodium other: quality-of-life assessment	how rigosertib sodium works in treating patients with recessive dystrophic epidermolysis bullosa (RDEB) with locally advanced squamous cell carcinoma	NCT04177498	not yet recruiting and early Phase 1
70	rectal neoplasm, malignant carcinoma, adenocarcinoma	radiation, capecitabine-irinotecan combination, plasma exosome	research on biomarkers for predicting the efficacy and toxicities of neoadjuvant chemo-radiotherapy for locally advanced rectal cancer based on tissue and plasma exosomal RNA	NCT04227886	recruiting and not applicable
71	HER2-positive breast cancer	acquisition of blood samples and tumor tissue samples (biopsies)	blood tests for anti-HER2 treatments, instead of invasive tissue biopsies	NCT04288141	recruiting and not applicable
72	lung cancer	blood exosome	Molecular and cellular biomarkers (exosomes antigens, circulating tumor cells, the panel of mutations in circulating free DNA) and radiomic signature are complementary to assist early detection of lung cancer LDCT	NCT04315753	recruiting and not applicable
73	prostate cancer obesity	exosome from biological samples	The investigators will be collecting prostate and fat tissue from participants undergoing radical prostatectomy to culture and study in the laboratory.	NCT04167722	recruiting and not applicable
74	metastasis breast cancer genomic analysis	tissue and blood samples	metastatic breast cancer with genetic tests including WES, RNaseq, ctDNA, and exosomes	NCT04258735	recruiting and not applicable
75	prostate cancer	liquid biopsies sample	correlation of the Exodx Prostate test results with the outcome of prostate biopsies.	NCT04357717	recruiting and not applicable
76	lung cancer	exosome antigen analysis	molecular and cellular biomarkers (exosomes, protein signatures, circulating tumor cells - CTCs, microRNA)	NCT04323579	recruiting and not applicable
77	cancer	distress exosome from patients	benefits of these psychological interventions on changes in exosomes	NCT04298398	not yet recruiting and not applicable
78	prostate cancer	urine and semen biomarkers	perform urinary and seminal genome, exosomes, methylome, and transcriptome analysis to identify novel molecular signatures associated with prostate cancer imaging endotypes	NCT04340245	not yet recruiting and not applicable
79	colorectal cancer	blood sample exosomes	exosome protein marker for the diagnostic tool	NCT04394572	not yet recruited and not applicable
80	lung cancer	blood and serum sample	The exosome is a liquid biopsies diagnosis tool for lung cancer.	NCT04529915	active, not recruiting
81	untreated advanced NSCLC patients	plasma exosomes	performance of exosomes loaded with EML4-ALK fusion in NSCLC diagnosis	NCT04499794	recruiting,
82	squamous cell carcinoma of the head and neck	serum, cell fluid exosomes	use of the hemopurifier to clear immunosuppressive exosomes in combination with pembrolizumab (Keytruda)	NCT04453046	recruiting, not applicable
83	NSCLC patients	plasma exosomes, pabolizumab, nafulizumab.	plasma exosomes PD-L1 and mRNA as biomarkers after therapeutic efficacy against NSCLC	NCT04427475	recruiting, not applicable
84	lung cancer	blood exosomes	blood exosomes analysis to determine hypoxia as potential biomarkers for early detection	NCT04629079	recruiting, not applicable
85	breast, digestive, gynecologic cancer circulating tumor DNA, exosomes	blood samples	blood exosome as an early biomarker for digestive and gynecological/breast cancer	NCT04530890	not yet recruiting and not applicable
86	prostate cancer	blood sample	blood exosome biomarker for early detection	NCT04556916	not yet recruiting and not applicable
87	pancreas adenocarcinoma	venous sampling	Tumor cells secrete exosome and long RNA, small RNA, miRNA, tRNA, piRNA analysis as a biomarker.	NCT03711890	recruiting and not applicable

V

6.1. Exosomes for Use in Clinical Trials for Cancer Patients. In cancer-related trials, there are about 87 clinical trials in the pipeline. The trials include using exosomes for various processes, such as studies on angiogenesis, tumor growth metastasis, and stromal cell activation, and facilitating cancer progression.[368] When a tumor starts growing, it quickly becomes hypoxic, which triggers the regulation factors of both pro-angiogenic and antiangiogenic cytokines like vascular endothelial, fibroblast, pericytes, and endothelial growth factors (EGF).[381,382] Exosomes are one of the key players in cancer progression, drug resistance,[383] and prognosis.[384,385] For example, pancreatic cell-derived exosomes carrying tetraspanin-8 promote vessel branching. Tetraspanin-8 also modulates the binding and uptake of cancer exosomes by endothelial cells.[30] Al-Nedawi et al. found lung cancer exosomes delivered mutated EGF receptor to pulmonary endothelial cells, activating EGF receptor, and signaling through AKT and MAP kinase pathways. This activation is misleading to VEGF secretion and endothelial cell response to tumor progression.[386] Therefore, cancer cell-derived exosomes can provide effective treatment of antiangiogenic therapy.[387] Lucero et al. demonstrated glioblastoma (GBM) cell-derived exosomes deliver angiogenic mRNA and translate it to protein into recipient cells.[388] Authors identified possible GBM exosomal mRNA as a liquid biopsy biomarker, which shows a trace of post-transcriptional gene silencing. Another study found colorectal exosomes deliver angiogenic mRNA to endothelial cells and enhance proliferation of tubular formation.[389] With angiogenic mRNA transfer via interaction with $\alpha 4$ and $\beta 1$ integrins, angiogenesis is stimulated via eNOS and the PI3K/AKT signaling pathway. Table 1 shows clinical trials based on the use of exosomes as a diagnostic tool, biomarkers, and therapeutic intervention for cancer research. Early detection is a powerful tool to fight against cancer progression. In early detection statistics, there was more than a 70% mortality decrease due to early detection and identification of novel markers of cancer. Exosomes have been used as a biomarker for cancer for decades. That is why we found more than 50 clinical studies of multiple phases looking for biomarkers like protein expression, mRNA, tumor-circulating exosomes, and tumor-derived exosomes—the first study was based on exosomes role as a therapeutic tool for those with advanced unresectable or metastatic melanoma. Exosomes from senescent melanoma cells will be utilized to study the process of drug resistance and relapse, as a therapeutic tool for melanoma for personalized medicine for patients. Another study in Table 1 (No. 4), in early lung cancer research, uses a blood sample exosome of lung cancer patients for identifying biomarkers (NCT03542253).[390] No. 8 in the table will use urine exosomes, utilizing clear cell renal cell carcinoma to identify diagnostic biopsy tools for early detection (NCT04053855). Another study on proteinosis gallbladder carcinoma uses the blood exosome as a biomarker for a correlation study (NCT03581435).[391] In breast neoplasm, tumor-derived exosomes are used as diagnostic and prognostic markers against receiving neoadjuvant chemotherapy (NCT01344109).[392] In gastric cancer, gastric cancer-derived exosomes are used as diagnostic tools for early detection (NCT01779583).[393] In bone metastasis, scientists also utilize circulating tumor exosomes to identify deregulated miRNAs as a biomarker for use in subsequent bioinformatic tool development (NCT03895216).[394] Another study on carcinoma ovarian cancer was based on the analysis of miRNA and lncRNA expression in exosomes.[395] These biomarkers will be employed as biomarkers for early detection as well (NCT0373831).

Other examples include a lung cancer study (NCT03830619), prostate cancer biomarker correlation study (NCT03911999), renal fibrosis study based on urine exosome biomarkers (NCT03870542), nonsmall lung cancer biomarker study for early detection (NCT02921854), and a colorectal cancer biomarker study using blood exosome samples (NCT04394572). These clinical studies have been in multiple phases, and success in these studies will accelerate current cancer treatment many folds. Another cancer research topic uses exosomes in a clinical study to deliver and measure certain drugs' effectiveness in cancer treatment. For example, a review of MK-3475 (Pembrolizumab) on the triple-negative breast tumor microenvironment analyzing both primary tumor, normal breast stroma, circulating lymphocytes, and serum exosomes are in Phase 1 (NCT02535247). Another study on NK and T-cell non-Hodgkin lymphoma, using MK-3475 alone or in combination with copanlisib, analyzes PD-1 expression of peripheral blood lymphoma and T-cell exosomes in Phases 1 and 2 (NCT02535247). Another study on thyroid cancer (NCT03109847) targets the side effects of radioactive iodine treatment of differentiated thyroid cancer, aiming to mitigate them using Metformin hydrochloride validated by serum and saliva exosomes in Phase 2. Another exciting research study is based on patients with stage II−IV squamous cell cancer of the head and neck using Nivolumab and BMS986205, designed to analyze the abundance of exosomes and composition in the peripheral blood for identifying exosomal biomarkers. This study is in Phase 2 with clinical identification number NCT03854032. The last review we will discuss here is colorectal cancer patients with oligometastasis. The study used Ripalimab plus stereotactic body radiotherapy for clinical therapeutic intervention. It is also a Phase 2 study and identification number NCT03927898.[396] Other drug analysis studies based on exosome applications include a study on MDM2 inhibitor AMG-232 treating soft tissue sarcoma (NCT03217266) and another on evaluating the efficacy of Olmutinib using DNA extracted from exosomes of bronchoalveolar lavage fluid on T790M-positive nonsmall-cell lung cancer (NCT03228277). These drug efficiency studies using exosomes give the researcher a suitable and versatile option for treatment. Most of these drug testing studies are either in Phase 1 or 2 and show promising data. Additional exciting applications of exosomes are in vaccines and cancer imaging. In the previous section, we discussed exosomes' immune modulation capabilities and antitumor properties. We found some studies of exosomes for use in vaccine applications. One study used tumor antigen-loaded dendritic cell-derived exosomes as vaccination candidates for nonsmall-cell lung cancer immunotherapy. This is a Phase 2 study with successful Phase 1 data on lung cancer patients and identification number NCT01159288. In the case of imaging and early detection, exosomes also play a promising role. For example, a study combined CT and exosome diagnosis in early lung cancer and found exosomal micro-A was highly expressed in early stage lung cancer tissues and was significantly higher than para-cancerous tissues (NCT03542253). The subsequent study dealt with metastatic, castrate-resistant prostate cancer using the detection of ARv7 in the plasma through blood sample analysis (NCT03236688). Another study used ultrahigh-resolution optical coherence tomography in detecting micro-

Table 2. Clinical Application of Exosomes in Brain-Related Diseases Research

no.	disease and conditions	interventions and exosome source	therapeutic use in the study	trial identification number	status and clinical phase
1	cerebrovascular disorders	mesenchymal stem cell exosomes	MSC-derived exosomes enriched by miR-124	NCT03384433	not yet recruiting and Phase 1, Phase 2
2	lymphoma, B-cell, aggressive non-Hodgkin (B-NHL)	blood samples	Exosome carries therapeutic targets (CD20, PDL-1) and could act as "decoy-receptors" for immunotherapy and identify aggressive B-NHL.	NCT03985696	recruiting and not applicable
3	Parkinson's disease (PD), LRRK2 kinase inhibitor sunitinib	PD patients and controls proteomes	Exosome proteomes derived from PD patients versus controls, if LRRK2 expression and phosphorylation are significantly lowered in exosomes of treated with the potent LRRK2 kinase inhibitor sunitinib.	NCT01860118	completed and not applicable
4	macular degeneration, senile	optical coherence tomography, color retinography, Fundus autofluorescence imaging	The L-DOPA regulates the cell's exosomal and endosomal pathways, decreases the RPE's exosome release significantly.	NCT02863640	terminated and not applicable
5	Parkinson's disease, age-related macular degeneration	optical coherence tomography, Fundus autofluorescence imaging	Estimate the prevalence of ARMD in Parkinson's patients and explore a possible causal link between L-DOPA treatment and ARMD	NCT03415984	completed and not applicable
6	malignant glioma of brain	IGF-1R/AS ODN, biodiffusion chamber	compared to traditional treatment alternatives for tumor recurrence, including a boost of further radiation and more chemotherapy	NCT01550523	completed and Phase 1
7	malignant glioma neoplasms	drug: IGF-1R/AS ODN	within 24 h of craniotomy, implanted for 48 h, surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN	NCT02507583	active, not recruiting and Phase 1
8	healthy subjects, systemic autoimmune diseases	exosomes from plasma and urine sample	to constitute a healthy volunteers cohort to compare with systemic autoimmune diseases cohort into molecular clusters instead of clinical entities by determining molecular profiles using several "omics" techniques	NCT02890147	completed and not applicable
9				NCT02890134	unknown and not applicable
10				NCT02890121	completed and not applicable
11	mild cognitive impairment, neurocognitive disorder, vascular dementia, Alzheimer's, dementia, age-related cognitive decline	neurocognitive battery, EEG with event-related potential (ERP), amyloid PET CT, blood, MRI, blood samples	study of older HK Chinese adults with cognitive impairment, with subjective cognitive decline and mild cognitive impairment.	NCT03275363	recruiting and not applicable
12	mild cognitive impairment	curcumin, behavioral: aerobic yoga, non-aerobic yoga, placebo	study the clinical benefits of curcumin, inhibit several potential disease pathways in Alzheimer's diseases, and determine how physical exercise programs impact individuals with early memory problems	NCT01811381	recruiting and not applicable
13	relapsing multiple sclerosis	blood sample	autoreactive T-lymphocytes an early hallmark of MS, a link inflammation and neurodegeneration in a complex and inter-regulated circuit and the presence of a link between metabolism and immune responses	NCT04121065	not yet recruiting and not applicable
14	neuralgia	exosome analysis, focused transcranial ultrasound	exosomes loaded anti-inflammatory and growth factor targeted delivery	NCT04202783	recruiting and not applicable
15	refractory depression, anxiety disorders, neurodegenerative diseases	exosomes	safety and efficacy of exosome deployment with concurrent transcranial ultrasound	NCT04202770	recruiting and not applicable
16	multiple organ dysfunction syndrome	MSC-derived exosomes	safety and efficacy of exosomal of MSC	NCT04356300	not yet recruited and Phase 1, Phase 2
17	long-term memory decline, mild cognitive impairment	neural exosomes	identify changes in neuronally derived exosome levels induced by training	NCT04253587	not yet recruiting and not applicable
18	Alzheimer's disease	allogenic adipose mesenchymal stem cells exosome	low/mild and high MSCs-Exos administered for nasal drip dosage	NCT04388982	not yet recruited and Phase 1 and 2

X

Table 3. Exosome Clinical Study Applications for Different Disease Models Other than Brain and Cancer

no.	disease and conditions	interventions and exosome source	therapeutic used in the study	trial identification number	status and clinical phase
1	ulcer	plasma-derived exosomes	The objective is to evaluate the effect of autologous exosome rich plasma on cutaneous wound healing.	NCT02565264	enrolling by invitation and early Phase 1
2	myocardial infarction	exosomes in peripheral blood of patients	expression of miRNA with healthy volunteers, explore its relationship with the development of myocardial infarction	NCT04127591	not yet recruiting, and not applicable
3	sepsis	drug; antibiotics, blood exosomes	to compare peripheral blood dendritic cell-derived exosome changes in patients with sepsis with healthy controls	NCT02957279	unknown and not applicable
4	oolycystic ovary syndrome	ginger exosomes, aloe exosomes placebo	Ginger or aloe plants exosomes will treat and improve the condition of polycystic ovary syndrome.	NCT03493984	recruiting and not applicable
5	preeclampsia, cardiovascular disease	exosomes from maternal blood and placental tissue in patients diagnosed with preeclampsia	The functional role of exosomal cargo in normal and pathological pregnancies and point toward novel therapeutic intervention strategies	NCT04154332	not yet recruiting and not applicable
6	diabetes mellitus type 1	mesenchymal stem cells exosomes	Intravenous infusion of cell-free umbilical cord-blood-derived MSC exosomes may reduce the inflammatory state and improve the β-cell mass.	NCT02138331	unknown and Phase 2, Phase 3
7	atrial fibrillation	epicardial fat biopsy	Investigates the role of epicardial fat-derived exosomes in patients who suffer from atrial fibrillation.	NCT03478410	recruiting and not applicable
8	kidney transplantation	urinary exosomes	Prevalence of NCC activation three months after transplantation inpatient treated by CNI.	NCT03503461	completed and not applicable
9	healthy	high salt diet followed by a low salt diet and vice versa	Changes in the epithelial sodium channel (ENaC) of the kidney are reflected in the urinary exosomes	NCT02823613	active, not recruiting and not applicable
10	hemodynamic instability autophagy	blood and urine specimens	Exosomes purified in blood and urine and proteomics studies to analyze autophagy and apoptosis-related biomarkers of exosomes by bioinformatics.	NCT03267160	active, not recruiting and not applicable
11	macular holes	exosomes derived from mesenchymal stem cells from the human umbilical cord	Exosome isolation sequential ultracentrifugation confirmed via spectral-domain optical coherence tomography (OCT) and the minimum linear diameter (MLD).	NCT03437759	recruiting and early Phase 1
12	blood coagulation, platelet function	exosomes from red blood cells	Analyze the effect red blood cell exosomes units have on blood coagulation and platelet function.	NCT02594345	completed and not applicable
13	healthy	erythropoietin, placebo	The diagnostic value of differentially regulated exosome proteins could be further validated against the existing IEF EPO WADA accredited tests.	NCT03700515	recruiting and not applicable
14	preeclampsia	umbilical cord mesenchymal stem cell exosomes	To identify miRNAs 136, 494, and 495 genes expression in the exosomes between peripheral blood, and umbilical cord mesenchymal stem cells.	NCT03562715	completed and not applicable
15	sepsis with multiple organ dysfunction (MOD)	exosomes from macrophage coculture with human cells, blood, and urine	Proteomics studies in exosomes from cell culture and clinical specimens. Analyze ubiquitination, autophagic, and apoptosis-related biomarkers of exosomes by bioinformatics.	NCT03222986	recruiting and not applicable
16	prehypertension	urine exosomes	to characterize changes in urine electrolytes and exosome protein	NCT04142138	not recruiting yet and not applicable
17	exercise physiology	age, genes, training, tick-borne disease, and endurance	investigate potential relationships between age, training intensity, training volume, genes, exosomes, and history of tick-borne disease and physiological variables and endurance performance	NCT03569566	enrolling by invitation and not applicable
18	overweight children with type 2 diabetes risk	exosomes from blood samples	microRNA profiling in circulating exosomes and in blood peripheral mononuclear cells in preadolescents with high risk to develop T2D.	NCT03027726	completed and not applicable
19	diabetic retinopathy (DR)	hematological examination, ophthalmic examination, serum exosomes	significant associations between DR progression and different exosomal miRNA using various statistical methods.	NCT03264976	not recruiting yet and not applicable

Y

Table 3. continued

no.	disease and conditions	interventions and exosome source	therapeutic used in the study	trial identification number	status and clinical phase
20	spinal disease	urine and blood exosomes	Exosomes have the potential of being simple biomarkers that can diagnose postoperative delirium and predict cognitive decline.	NCT04120272	not yet recruiting and not applicable
21	CKDu, arterial stiffness	arterial stiffness assessment, serum, and urine biomarker	to characterize their disease profile using analysis serum and renal urine biomarkers, exosomes, proteomics, and DNA adducts.	NCT02226055	completed and not applicable
22	normal cellular metabolism	somatostatin glucagon, exosome derived from the arterial-venous supply of tissues	study the exosomes derived from the arterial-venous supply of tissues related to the TCA cycle activity.	NCT02748369	active, not recruiting and Phase 1
23	hypertension	urine samples	The study is to determine the concentrations and variabilities of urinary exosomal sodium channels and plasma angiotensins.	NCT03034265	completed and not applicable
24	chronic kidney failure, dialysis related complication	mixed online hemodiafiltration, high flux bicarbonate dialysis, plasma exosomes	quantitative microRNA changes in plasmatic exosome/microvesicles assessed by quantitative real-time PCR, quantitative changes in C-reactive protein, neutrophil gelatinase associated lipocalin, interleukin-6, ferritin	NCT03202212	completed and Phase 1, Phase 2
25	uveitis, vasculitis, ocular inflammatory disease	optic fluid, exosomes present in vitreous and AC fluid in the eye	kinds of cytokines, lymphokines, biomarkers, proteome, and exosomes present in vitreous and AC fluid in the eye with uveitis or other retinal diseases	NCT00331331	completed and not applicable
26	port-wine stain	biopsy sample from port-wine stain birthmark, blood exosomes	blood samples to characterize exosomes and metabolites from port-wine stain	NCT02051101	active, not recruiting and not applicable
27	diabetes mellitus, type 1 diabetes diabetes.	insulin deprivation in type 1 diabetic patients, blood exosomes	transient insulin deprivation in adolescents and T1DM adults alter the circulating blood exosome contents and metabolome	NCT03392441	active, not recruiting and not applicable
28	type 1 diabetes mellitus, type 2 diabetes	human blood samples, beta-cell exosomes	In this study, beta-cell-derived exosomes will be detected and characterized in human blood samples.	NCT03106246	unknown
29	sepsis	blood and serum exosome	miRNA expression levels in exosomes, serum, and blood cells	NCT03280576	complete and not applicable
30	obesity	early time-restricted feeding, structured weight loss program, urine exosome	Urine exosomes will be analyzed in 12-h bins to determine how meal timing affects these end points differentially during the daytime and nighttime.	NCT03459703	recruiting and not applicable
31	Barrett's esophagus, gastroesophageal reflux, esophageal adenocarcinoma	blood exosomes	measure for a biomarker called microRNA (miRNA) using exosomes.	NCT02464930	unknown and not applicable
32	childhood chronic kidney disease	urine exosomes	molecular value (ADMA and urine exosome miRNA)	NCT03227055	recruiting and not applicable
33	chronic ulcer	conditioned media, opical antibiotic combinations, exosome from cell medium	study to see the therapeutic potentials of conditioned medium stem cell as an additional growth factor in chronic skin ulcer healing and to compare the success of chronic ulcer healing	NCT04134676	not yet recruiting and Phase 1
34	COPD, emphysema chronic bronchitis airway obstruction smoking, tobacco, gender	exosomes from lung cells	alterations at the epigenetic, mRNA, microRNA, proteome, metabolome, and microbiome level will perform from multiple lung compartments	NCT03049202	recruiting and not applicable
35	hypertension	sodium phosphate sevelamer, sodium bicarbonate, sodium chloride plasma and urine sample	changes in NaPi-IIa assessed from urinary exosomes	NCT02822131	completed and not applicable
36	thyroid disease, heart failure	urine sample	Investigators will enroll clinical and subclinical thyroid disease with quarterly follow-up and then detect urine exosomal proteins NT-proBNP.	NCT03984006	recruiting and not applicable
37	drug-resistant epilepsy	blood sample	expression profile of miRNAs in the plasma as well as in the exosomes.	NCT03419000	recruiting and not applicable
38	panic disorder	serum sample	changes in exosomal micromas (miRNAs) from serum samples taken before and after cbt from panic disorder (PD) patients	NCT04029740	recruiting and not applicable
39	diabetes	dual energy X-ray, adipose tissue biopsy, blood sample	new biomarkers of adult-onset autoimmune diabetes	NCT03971955	recruiting and not applicable
40	aging, cognitive, ketones, blood sugar	Jardiance 25 mg, plasma exosomes	the study is an increased expression of receptors and mediators of ketone metabolism in plasma exosomes.	NCT03852901	recruiting and Phase 1
41	diabetes mellitus, type 2 diabetes, cardiovascular diseases	dapagliflozin 10 mg, saxagliptin 5 mg, urine exosomes	in addition to dapagliflozin (additive effect), saxagliptin may improve EPC number and function even more than dapa alone, compared to placebo.	NCT03660683	recruiting and Phase 4

Z

Table 3. continued

no.	disease and conditions	interventions and exosome source	therapeutic used in the study	trial identification number	status and clinical phase
42	insulin resistance	rosiglitazone versus placebo, response to amiloride infusion and furosemide infusion, urine exosomes	the difference in the ENac abundance in exosomes in the urine measured after 8 weeks of treatment with either rosiglitazone or placebo	NCT00285805	completed and not applicable
43	childhood obesity, adolescent obesity	behavioral: exercise, serum exosomes	looking for circulating exosome-derived miRNA in plasma	NCT03762629	recruiting and not applicable
44	fibrosis, kidney transplant failure, kidney allograft, and rejection	observational (a urinary biomarker for kidney allograft fibrosis), urine exosomes	urinary exosomes are isolated and analyzed for transglutaminase type 2	NCT03487861	recruiting and not applicable
45	obstructive sleep apnea, morbid obesity, epigenetic disorder	CPAP, bariatric surgery, blood sample, exosome mRNA	differences in miRNA profile among patients with morbid obesity with or without OSA.	NCT03995836	completed and not applicable
46	HIV infection, tuberculosis Infection	detection of molecular biomarkers, plasma exosomes	description of miRNA expression profile in a cohort of patients with an HIV infection and tuberculosis and correlate it with their clinical evolution	NCT03941210	recruiting and not applicable
47	obstructive sleep apnea of adult, hypoxia, sleep disorder, stroke, endothelial dysfunction, oxidative stress	drug lowering cerebral blood flow (CBF) and normoxia sleep, urine exosomes, placebo, and intermittent hypoxia sleep. blood sample	vascular biomarkers exosome analysis or urinary prostaglandins before and after sleep under normoxia and intermittent hypoxia exposure with cerebral blood flow changes	NCT03255408	not yet recruiting and Phase 1 and 2
48	muscular dystrophy, neuromuscular diseases, X-linked genetic diseases, inborn	cardiosphere-derived cell exosomes	evaluating the safety and efficacy of a cell therapy called cap-1002.	NCT03406780	active not recruiting and Phase 2
49	heart failure with preserved ejection fraction	drug; 0.9% sodium chloride, furosemide 40 mg	Sodium transporters in urinary exosomes will be characterized and compared between HFpEF patients and controls.	NCT03837470	recruiting and early Phase 1
50	obesity, insulin resistance	Mediterranean diet, ketogenic diet, blood and adipose tissue exosomes	Signaling between organs and cells will be examined by isolating exosomes from blood and adipose tissue.	NCT04131166	recruiting and not applicable
51	thoracic surgery, video-assisted	two-lumen catheter, chest tube, plasma sample exosomes	diagnostic value and molecular characteristics of plasma exosome-derived miRNAs for these patients	NCT03230019	recruiting and not applicable
52	healthy older adults ages 65–89	blood, CSF, and serum exosomes	Different biomarkers may relate to immune health and the aging process, the risk for cognitive decline, and Alzheimer's disease.	NCT03944603	recruiting and not applicable
53	obesity, insulin resistance	blood and adipose tissue exosomes	Signaling between organs and cells will be examined by isolating exosomes from blood and adipose tissue.	NCT02706262	recruiting and not applicable
54	body weight changes	moderately high protein diet, low-fat diet, serum exosome mRNA	MicroRNAs levels in exosomes will be measured by NGS illumina Myseq at baseline and the end of the bodyweight-loss period.	NCT02737267	unknown and not applicable
55	rhinitis, allergic, perennial	exosomes from blood, saliva, serum, and plasma	Exosome isolation reagent (for plasma or serum) will compare the change in exosomes before and after treatment.	NCT02653339	unknown and not applicable
56	exosome	endometrial fluid collection, serum, blood exosomes	to describe the morphology, size distributions, and specific markers of the different vesicle's populations present endometrial fluid (i.e, DNA, RNA, proteins, lipids)	NCT02797834	unknown and not applicable
57	nonalcoholic fatty liver disease	tofogliflozin, glimepiride	changes from baseline in microRNAs and exosome contents.	NCT02649465	recruiting and Phase 4
58	chordoma	drug; afatinib blood samples	pharmacokinetic study and translational studies on EGFR pathway activation and signaling on blood and tumor samples.	NCT03083678	recruiting and Phase 2
59	minimal residual disease, recurrent acute and myelodysplasia recurrent childhood acute myeloid leukemia	daratumumab, donor lymphocyte infusion, laboratory biomarker analysis	The donor lymphocytes and monoclonal antibodies, such as daratumumab, may kill the remaining cancer cells.	NCT03537599	recruiting and Phase 1 and 2
60	dystrophic epidermolysis bullosa	AGLE-103 is an allogeneic derived exosomes product derived from healthy donor mesenchymal stem cells (MSCs), placebo	to assess the safety and effectiveness of Agle-103 vs placebo on lesions in subjects with EB	NCT04173650	not yet recruiting and Phase 1, Phase 2
61	type 1 diabetes	circulating β-cell exosomes	to diagnose the disease and its progression in type 1 diabetes	NCT04164966	not yet recruiting and not applicable
62	fasting	time-restricted feeding (TRF) with dietary counseling, blood exosomes	safety and compliance, as well as the efficacy of one specific IF intervention called time-restricted feeding	NCT04184076	not yet recruiting and Phase 2

Table 3. continued

no.	disease and conditions	interventions and exosome source	therapeutic used in the study	trial identification number	status and clinical phase
63	COPD	blood, urine, stool, saliva, serum exosomes	exosome characterization of COPD patients and healthy controls	NCT04183530	recruiting and not applicable
64	dry eye	mesenchymal stem cell-derived	umbilical mesenchymal stem cells (UMSC) derived exosomes for chronic graft versus host diseases (CGVHD) treatment	NCT04213248	not yet recruiting and Phase 1, Phase 2
65	sleep apnea, inflammation, atherosclerosis	myeloid PTP1B expression analysis, blood exosomes	to investigate myeloid PTP1B involvement in the vascular pro-inflammatory process described in OSA	NCT04235023	not yet recruiting, not applicable
66	coronavirus	MSCs-derived exosomes	efficacy and safety of aerosol inhalation of the exosomes derived from allogeneic adipose mesenchymal stem cells (MSCS-Exo)	NCT04276987	not yet recruited and Phase 1
67	coronavirus infection, pneumonia	T-cell-derived exosomes	safety and efficacy of this new targeted delivery by metered-dose inhaler	NCT04389385	active but not recruiting and Phase 1
68	pulmonary nodule	blood and alveolar lavage of lung nodules patients	study the sensitivity, specificity, and diagnostic accuracy of ctDNA and exosome combined detection in the identification of benign and malignant pulmonary nodules	NCT04182893	recruiting and not applicable
69	periodontitis	adipose-derived stem cells exosomes	the adipose stem cell exosomes are isolated autogenously from the patient to be injected locally into the periodontal pockets to evaluate their regenerative effect.	NCT04270006	recruiting and early Phase 1
70	healthy control	low level of MSCs-Exo, high level of MSCs-Exo	safety and tolerance of aerosol inhalation of the exosomes derived from allogeneic adipose mesenchymal stem cells (MSCs-exo)	NCT04313647	recruiting and Phase 1
71	healthy elderly	IkT-148009 and placebo, CNS-derived exosomes	investigates the safety tolerability movement of drug IkT-148009 in healthy elderly volunteers	NCT04350177	not yet recruiting and Phase 1
72	heart failure	exercise training, plasma exosome	Plasma exosomes will be isolated using microbead-based sorting techniques and characterized	NCT04334603	recruiting and not applicable
73	empagliflozin, hypoglycemic agents, sodium-glucose transporter 2 inhibitors	Jardiance 25 mg, plasma exosomes	determine expression of receptor and mediators of ketone metabolism in plasma exosomes	NCT03852901	recruiting and Phase 1
74	multiple system atrophy	blood, and plasma exosomes	The study is to complete the target validation of insulin resistance for future treatment trials.	NCT04250493	not yet recruiting and not applicable
75	multiple organ failure	MSC exosomes	to evaluate the safety and efficacy of exosomes from MSCs to determine clinical dosage for patients with severe MODS	NCT04356300	not yet recruiting and not applicable
76	oocyte maturation	follicular fluid exosomes	investigate the miRNA in (follicular fluid) FF exosomes in young and aged women and their relationship to egg maturation	NCT04382872	not yet recruiting and not applicable
77	coronavirus infection, COVID-19, SARS	organicell flow, placebo	safety and efficacy of intravenous infusion of organicell flow	NCT04384445	not yet recruited and Phase 1 and 2
78	coronavirus	MSCs-derived exosomes	the efficiency of aerosol inhalation of the exosomes derived from allogeneic adipose mesenchymal stem cells (MSCs-exo)	NCT04276987	complete, Phase 1
79	drug resistance	MPCs-derived exosomes	evaluate the efficacy and safety of hampc-exosome treatment with pulmonary infection caused by Gram-negative bacilli resistant to carbapenems	NCT04544215	recruiting Phase 1 and 2
80	endothelial dysfunction, obese, OSA patients	circulating exosome, mRNA analysis	evaluation of miRNA contained in exosomes	NCT04459182	not yet recruiting, not applicable
81	kidney transplantation	urine exosome analysis	urine exosome analysis after kidney transplantation	NCT03503461	complete, not applicable

Table 3. continued

no.	disease and conditions	interventions and exosome source	therapeutic used in the study	trial identification number	status and clinical phase
82	COVID-19, SARS-CoV-2 pneumonia, COVID-19	mesenchymal stem cells exosomes	Inhalation of exosomes may reduce inflammation and damage to the lung tissue and stimulate the regenerative processes.	NCT04602442	enrolled by invitation, Phase 2
83	COVID-19, SARS-CoV-2 pneumonia, COVID-19	mesenchymal stem cells exosomes	Inhalation of exosomes may reduce inflammation and damage to the lung tissue and stimulate the regenerative processes.	NCT04491240	complete, Phase 1 and 2
84	acute respiratory distress syndrome	human mesenchymal stem cell exosome	to evaluate allogeneic human mesenchymal stem cell exosomes (hMSC-Exos) in the treatment of acute respiratory distress syndrome	NCT04602104	not yet recruiting, Phase 1 and 2
85	healthy control	mesenchymal stem cells (MSCs) exosomes	evaluate aerosol inhalation's safety and tolerance of the exosomes derived from allogeneic adipose mesenchymal stem cells (MSCs-exo) in healthy volunteers	NCT04313647	recruiting, Phase 1
86	macular holes	mesenchymal stem cells (MSCs) exosomes	efficacy and safety of MSC-derived exosomes (MSC-Exos) for promoting healing of large and refractory macular holes (MHS)	NCT03437759	recruiting, early Phase 1
87	blood coagulation, platelet function	red blood-derived exosomes	to analyze the effect exosomes derived from red blood, cell units have blood coagulation and platelet function	NCT02594345	complete, not applicable
88	metabolism, acute resistance exercise	muscle exosomes	exercise-induced skeletal muscle exosomes promote adipocyte lipolysis	NCT04500769	recruiting, not applicable
89	allergic asthma, severe eosinophilic asthma	rEOS- and iEOS-derived exosomes	qualitative and quantitative selected ncrna levels in lung resident EOS- and inflammatory EOS-derived exosomes	NCT04542902	recruiting, not applicable
90	jaundice, neonatal	breast milk exosomes	analysis of breast milk exosomes miRNA for neonatal hyperbilirubinemia	NCT04527536	not recruiting yet, not applicable
91	diabetes mellitus type 2, gestational diabetes, over-weight and obese, pregnancy in diabetic, insulin resistance, insulin sensitivity, pregnancy, high risk	serum and plasma exosomes	the level, content, and bioactivity of exosomes in serum and plasma versus insulin sensitivity	NCT04617405	not yet recruiting, not applicable
92	lupus nephritis	urine and serum exosomes	analyze urine and serum exosome biomarkers	NCT04534647	recruiting, not applicable
93	acute myeloid leukemia	bone marrow and peripheral blood exosomes	analysis of exosomes and microvesicles derived from PB and bone marrow samples of AML patients	NCT04460963	not yet recruiting, not applicable
94	polycystic kidney disease, autosomal dominant	urine exosomes	changes in polycystin-1 (PC-1) and polycystin-2 (PC-2) protein levels in urinary exosomes from baseline to day 44	NCT04536688	recruiting, Phase 1
95	COVID-19	cardiosphere-derived cells (CDCs) exosomes	CDC exosome ability to be immunomodulatory, antifibrotic, and regenerative	NCT04623671	recruiting, Phase 2
96	COVID-19 ARDS pneumonia, viral	bone marrow-derived exosomes	safety and efficacy of intravenous administration of bone marrow-derived exosomes	NCT04493242	not yet recruiting, Phase 2
97	nonalcoholic fatty liver disease, metabolic syndrome, metabolically abnormal and metabolically normal obesity, obesity	liver exosomes	to determine the specific cellular and organ system, metabolic and immunologic alterations via analyzing liver exosomes	NCT01104220	recruiting, not applicable
98	severe acute respiratory syndrome (SARS)	blood exosomes	blood filtration using hemopurifier and blood exosome analysis	NCT04595903	not yet recruiting, not applicable
99	systemic autoimmune diseases	plasma and urine exosomes	exosomes for biomarker screening, gene expression analysis	NCT02890134	unknown, not applicable
100	systemic autoimmune diseases	urine and plasma exosome	exosomes for biomarker screening, gene expression analysis	NCT02890121	complete, not applicable

AC

meter-sized early stage pancreatic cancer using urine and serum exosomes (NCT03911999). We found 87 clinical trials on cancer biomarker studies, immunotherapies, or combination therapies. Unfortunately, we do not have access to finished clinical trial data that are not published publicly. The number and outcome of publicly available clinical trials are promising. Exosome-based cancer immunotherapies show very promising outcomes that can translate as clinically applicable products in the near future.

6.2. Clinical Trials Addressing Brain and Inflammation Diseases. In a brain disease and inflammation study, we found a total of 19 clinical study designs (Table 2). Penetrating the BBB and delivering drugs or active biologics is an interesting area for more more investigation because of the unique challenges. From our prior discussion, exosomes are suitable candidates for detection and drug delivery for brain diseases. For example, MSC-derived exosomes enriched with miR-124 are used in treating cerebrovascular disorders (NCT03384433). A previous study on MSC-derived exosomes shows promising data on wound healing, cell-free therapy against lung fibrosis, and skeletal muscle regeneration.[397,398] The next promising study is a biomarker study on Parkinson's disease. The study identifies LRRK2 and other novel exosomal protein expressions utilizing exosome biomarker screening (NCT01860118). Another study on Parkinson's disease estimates the prevalence of ARMD in a sample of Parkinson's patients and identifies the correlation between L-DOPA treatment and ARMD (NCT01860118). In an Alzheimer's disease study, curcumin's benefits due to the inhibition of several potential disease pathways in Alzheimer's disease and exosomes are employed in analyzing potential therapeutic applications (NCT01811381). In this trial, the investigator looked for specific blood biomarker changes due to curcumin and yoga's combined effect. Another Alzheimer's disease therapeutic application is allogenic adipose MSC-exosome safety and efficacy in Alzheimer's patients with mild to moderate dementia for improving cognitive function (NCT04388982). Investigators also look for abnormal kidney and liver function due to exosomal treatment. The next study in Table 2 focuses on using exosomes to enhance the delivery of anti-inflammatory agents and growth factors to targets by using focused transcranial ultrasound for neuralgia before intravenous infusion of exosomes (NCT04202783). In this trial, the investigator utilizes a brief pain inventory (BPI) scale to measure the pain due to transcranial ultrasound treatment.[399,400] For cancer immunotherapy of malignant glioma neoplasms, a comparative Phase 1 study with conventional treatment and a boost with immunotherapy used brain cancer-derived exosomes (NCT01550523). Scientists isolate the patient's tumor cells and treat them with an antisense molecule (IGF-1R/AS ODN) to remove a targeted tumor receptor on the tumor cells' surface. After reimplanting the treated cells in the same patients, tumor cells are activated apoptosis and released exosome-carrying tumor antigens. Because of antigen release, T-cells are activated to eliminate the tumor. By training our immune system to recognize tumors in the future, the patient will be protected from another tumor invasion via immune surveillance.[401,402] Preclinical data reveal that exosomes can cross the BBB and deliver payload within the brain. Thus, exosomes have the immense possibility of overcoming the therapeutic drawbacks of brain-related diseases.

6.3. Clinical Trials of Immune, Heart, Lung, Diabetes, Kidney, and Blood Diseases. In Table 3, we compiled multiple disease applications of exosomes either as biomarkers, diagnostics, therapeutics, or vaccine applications. We found a total of 100 clinical studies on type 2 diabetes, cardiovascular research, kidney, lung, heart diseases, ulcers, hypertension, etc. Here we will describe some essential studies to give a concise description of the clinical research. For example, for ulcer patients, investigators utilize plasma-derived exosomes on cutaneous wound healing (NCT02565264). In this trial's preclinical study, scientists found serum-derived exosomes accelerate cutaneous wound healing in the BALB/c mice model. Scientists conclude from that study that exosome supplements to cutaneous ulcer diseases such as peripheral arterial disease, decubitus, or burns have a significant therapeutic effect, and serum exosomes that will be collected from the patient's own body will have more acceptance as a therapeutic.[403,404] The following study is on umbilical cord blood MSC-derived exosomes on β-cells masses in type I diabetes mellitus (NCT02138331), now in Phase 2 and 3. Authors conclude that cell-free umbilical cord-blood-derived MSC exosomes may improve the inflammatory state and enhance β-cell mass of the pancreases along with glycemic control.[405] In the preclinical study of the trial, the authors observed that transplantation of MSC correlates to an increase in T-regulatory cells and both local and systemic reduction of autoaggressive T-cell populations, i.e., the shift of cytokine profile from pro-inflammatory to anti-inflammatory type. Furthermore, MSC transplantation increases local pancreatic cell number and increases circulating epidermal growth factor (EGF). EGF lowers blood glucose and increases insulin secretion.[406] In both a type 1 and type 2 diabetes mellitus study, circulating exosomes from β-cells were analyzed for biomarkers and therapeutic targets.[407−410] There is a study on preeclampsia, where the exosomes of peripheral blood will be compared to umbilical cord mesenchymal stem cells to identify miRNAs 136, 494, and 495 gene expression (NCT03562715, Table 3, No. 14). This specific trial is an example of biomarker screening utilizing the exosome profile. Recent data suggest that exosomes released from the placenta carry specific cargo responsible for causing preeclampsia. Isolating exosomes from the placenta and maternal blood and analyzing their biochemical and molecular mechanisms can provide important insight into the novel therapeutic intervention of preeclampsia associated with cardiovascular disease in normal and complicated pregnancies.[411−414] In another study based on exosomes, chronic kidney failure treatment is conducted using hemodiafiltration (OL-HDF), and analyzing mRNA expression of serum exosomes (NCT03202212). MicroRNA content analysis of exosomes using RT-qPCR will give insight into any inflammatory markers due to treatment against chronic kidney disease. Obesity is another significant health care burden. Exosomes have also been studied for the development of a potential obesity treatment.[415] In the current study, to determine how meal timing affects these end points differentially during the daytime and nighttime, urine exosomes will be analyzed in 12-h bins (NCT03459703, Table 3, No. 30). In this study, investigators will evaluate how mealtime influence obesity by conducting multiple behavioral studies such as mood state, retention, depression, loneliness, appetite, adherence, urine content analysis (oxalate, sodium, potassium, creatinine, nitric oxide, albumin, nephrin, KIM-1), and urine exosomeal mRNA and microRNA content.[416,417] In a COPD

study, exosome expression alteration was analyzed on epigenetic, mRNA, miRNA content using RT-qPCR and exosome profiling (NCT03049202 and NCT04183530, Table 3, Nos. 34 and 63). In both trials, the authors utilize exosomes from saliva, serum, urine, blood, and stool sources for biomarker analysis.

In preclinical studies of COPD, the authors identified either circulating exosomes content or microRNA expression (e.g., MiR-21) in analyzing specific pathways related to COPD.[418,419] These identified markers can be used as diagnostic or therapeutic targets for novel therapeutics against COPD. In HIV and tuberculosis also, clinical trials currently underway use the exosomal platforms. The study design analyzed changes in serum and tissue exosomal miRNA expression in HIV and tuberculosis patients for early detection for biomarkers (NCT03941210). In the current situation, COVID-19 has been spread worldwide, and still, outbreaks continue due to a lack of knowledge of its pathogen and vaccine absence. Scientists are working relentlessly to find a cure against SARS-CoV-2. We found four COVID-19 related clinical trials already based on the exosome platform, which confirms the exosome's versatile application and capability.

The first one seeks to evaluate the safety and potential efficacy of Organicell flow Zofin via exosome analysis (NCT04384445). Zofin is a cellular product derived from human amniotic fluid. It contains over 300 growth factors, chemokines, cytokines, and exosomes derived from epithelial and amniotic cells. Surface marker analysis reveals the presence of exosome-associated proteins CD9, CD133, CD63, and CD81, and completed sequencing revealed 102 commonly expressed miRNA. Major pro-inflammatory cytokines targeted by miRNA found in Zofin include TNF, IL-6, IL-8. Other targeted cytokines are VEGFA, IGF-1, FGF2, IL36a, CCL8, CXCL12, and IL37. Many published articles suggest that suppressing the above-mentioned pro-inflammatory cytokines cascade will reduce the severity of elevated immune response.[420−424] The next trial is in patients with severe novel coronavirus pneumonia (NCP) to evaluate the safety and efficiency of aerosol inhalation of exosomes derived from allogeneic adipose mesenchymal stem cells (MSCs-Exo) (NCT04276987). Human adipose MSCs-derived exosomes (hASCs-Exo) can stimulate T-cells in vitro and inhibit IFN-γ release and T-cell proliferation. Thus, hASCs-Exo can be considered as a therapeutic against inflammation-related diseases.[425−427] The last trial is to test the safety and efficacy of T-cell-derived exosomes following targeted delivery by metered-dose inhaler on coronavirus patients. Investigators collect donor origin COVID-19-specific T-cells and expand them via viral peptide fragments with cytokines present. This will activate the T-cells, and stimulation will cause the release of IFN-ϒ in exosomes.[428−431] All these coronavirus studies are based on vaccine development clinical trials, and hopefully, we will see commercialized vaccines based on the exosome platform. We already have the coronavirus vaccines from Moderna and Pfizer-BioNTech, and these vaccines were made available to the general public in January 2021. A third vaccine from Janssen also got emergency use authorization on February 27, 2021. However, there have been reporting of a very rare and serious blood clot in people who receive the Janssen vaccine. The Oxford COVID-19 vaccine shows a robust immune response in adults of 60−70 years old. Phase 3 studies show the vaccine to be 76% effective at preventing COVID-19 infection. Table 3 also focuses on obesity, type 1

and 2 diabetes, obesity, cardiac disease, organ failure, hypertension, atrophy, muscle dystrophy, and an exosome study on insulin resistance application. Hopefully, this section can give a proper rationale for exosome application in disease diagnosis, biomarker screening, and therapeutic application phases.

We can see that exosomes have intrinsic advantages over traditional delivery methods, biomarker analysis, diagnosis, and medical imaging application from the three tables above. Even while some polymeric nanoparticles have been commercialized, exosomes still hold a better future in drug delivery and vaccine development. Recent studies also expect exosome-based personalized medicine for patients with cancer, neurodegenerative, and inflammatory diseases. Exosomes will answer many unknowns of the multiple conditions for which proper treatment or diagnosis is not available yet.

7. LIMITATIONS OF EXOSOME RESEARCH IN THE CLINICAL SETTING

With substantial development of this field in the last two decades, exosomes bring us more possibilities in multiple deadly disease treatments and diagnosis. Although therapies are under development, we still do not know the exact mechanism of biogenesis. Isolation techniques for exosomes are tedious and hard to translate to the clinical setting. We found multiple commercial exosome isolation kits available; still, we need considerable progress in this technology. Once we identify a universal isolation method, we can correlate clinical outcomes all over the world. The validation of promising findings by scientists is impossible until we have a unified isolation and characterization method in place. In our clinical review section, we found that, as of now, 205 clinical trials have been conducted based on exosome application. However, because of complexities and variations in methodologies, the reproducibility of the exosome is widely varied, which presents difficulties for interpretation of results. Therefore, we need standard operating procedures (SOPs) for exosome isolation, storage, characterization, and analysis. With more in-depth knowledge of biogenesis and function, exosomes will open up significant opportunities in therapeutic application, and already recent studies have investigated exosomes as a biomarker and natural gene/drug delivery system. In conclusion, we urgently need an efficient and reliable isolation method to advance this research field.

8. SUMMARY AND FUTURE DIRECTIONS

Exosomes are widely disseminated and heterogeneous entities. However, exosome complexity is not thoroughly understood, especially the mechanisms responsible for sorting cargo into exosomes and releasing cargo into cells after exosome internalization. While many recent studies have focused on protein sorting in exosomes, executive functions might be associated with RNA delivery. Therefore, determining the mechanism that underlies RNA sorting in the exosomes holds excellent potential for developing various therapeutic applications. Because of their various advantages over traditional nanoparticles, exosomes are more than viable candidates for targeted drug delivery innovation. In clinical trials so far, most applications of exosomes are in their use as biomarkers. Exosomes have slowly garnered more attention in the drug delivery field due to their natural origins and the protein/lipids/receptors present on their surface. Besides, some

research groups have taken this even further by working on exosome surface modification through genetic alterations, DNA tethers, etc. However, the clinical application of current exosome research is the scope of this review. These inquiries into the exosomes provide a field ripe for further innovation and exploration. In the future, more investigations will need to be conducted into both the physiological and pathological conditions and the mechanisms that interface with the release of exosomes and impairment of exosome-mediated cell−cell communication, which may prove to be the basis of a new class of personalized therapeutics.

■ AUTHOR INFORMATION

Corresponding Authors

Md Nurunnabi − *Environmental Science & Engineering, Biomedical Engineering, and Border Biomedical Research Center, University of Texas at El Paso, El Paso, Texas 79968, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, Texas 79902, United States;* ⊙ orcid.org/0000-0003-4457-3401; Phone: 915-747-8335; Email: mnurunnabi@utep.edu

Taeho Kim − *Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States;* Email: kimtae47@msu.edu

Authors

Md Nurul Huda − *Environmental Science & Engineering, University of Texas at El Paso, El Paso, Texas 79968, United States*

Md Nafiujjaman − *Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States*

Isaac G. Deaguero − *Biomedical Engineering, University of Texas at El Paso, El Paso, Texas 79968, United States*

Jude Okonkwo − *John A. Paulson School of Engineering, Harvard University, Cambridge, Massachusetts 02138, United States*

Meghan L. Hill − *Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States*

Complete contact information is available at:
https://pubs.acs.org/10.1021/acsbiomaterials.1c00217

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

■ ABBREVIATIONS

Aβ, amyloid beta; ABC, accelerate blood clearance; BBB, blood−brain barrier; BMVEC, brain microvascular endothelial cells; CD8, cluster of differentiation 8; CDC, cardiosphere-derived cells; CRISPR, clustered regularly interspaced short palindromic repeats; CSF, cerebrospinal fluid; CT, computed tomography; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; EAAT, excitatory amino acid transporters; EGF, epidermal growth factor; ESCRT, endosomal pathways are associated with endosomal complex; GPC, gel permeation chromatography; IL-10, interleukin 10; ILV, intraluminal vesicle; MDSC, myeloid-derived suppressor cells; MHC-1, major histocompatibility complex class 1; MPS, mononuclear phagocyte system; MVBs, microvesicles; mRNA, messenger ribonucleic acid; miRNA, micro ribonucleic acid; MWCO, molecular weight cutoff; MSC, mesenchymal stromal cell; NK cell, natural killer cell; PD-L1, programmed death-ligand 1; RES, reticuloendothelial system; TEX, tumor-derived exosomes

■ REFERENCES

(1) Zhang, Y.; Liu, Y.; Liu, H.; Tang, W. H. Exosomes: Biogenesis, Biologic Function and Clinical Potential. *Cell Biosci.* 2019, 9 (1), 19.

(2) Lin, J.; Li, J.; Huang, B.; Liu, J.; Chen, X.; Chen, X.-M.; Xu, Y.-M.; Huang, L.-F.; Wang, X.-Z. Exosomes: Novel Biomarkers for Clinical Diagnosis. *Sci. World J.* 2015, 2015, 657086.

(3) Lu, M.; Yuan, S.; Li, S.; Li, L.; Liu, M.; Wan, S. The Exosome-Derived Biomarker in Atherosclerosis and Its Clinical Application. *J. Cardiovasc. Transl. Res.* 2019, 12 (1), 68−74.

(4) Lakhal, S.; Wood, M. J. A. Exosome Nanotechnology: An Emerging Paradigm Shift in Drug Delivery. *BioEssays* 2011, 33 (10), 737−741.

(5) He, C.; Zheng, S.; Luo, Y.; Wang, B. Exosome Theranostics: Biology and Translational Medicine. *Theranostics* 2018, 8 (1), 237−255.

(6) Batrakova, E. V.; Kim, M. S. Using Exosomes, Naturally-Equipped Nanocarriers, for Drug Delivery. *J. Controlled Release* 2015, 219, 396−405.

(7) Peng, Q.; Zhang, S.; Yang, Q.; Zhang, T.; Wei, X.-Q.; Jiang, L.; Zhang, C.-L.; Chen, Q.-M.; Zhang, Z.-R.; Lin, Y.-F. Preformed Albumin Corona, a Protective Coating for Nanoparticles Based Drug Delivery System. *Biomaterials* 2013, 34 (33), 8521−8530.

(8) Liechty, W. B.; Kryscio, D. R.; Slaughter, B. V.; Peppas, N. A. Polymers for Drug Delivery Systems. *Annu. Rev. Chem. Biomol. Eng.* 2010, 1, 149−173.

(9) Jang, S. C.; Kim, O. Y.; Yoon, C. M.; Choi, D.-S.; Roh, T.-Y.; Park, J.; Nilsson, J.; Lötvall, J.; Kim, Y.-K.; Gho, Y. S. Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors. *ACS Nano* 2013, 7 (9), 7698−7710.

(10) Jang, S. C.; Gho, Y. S. Could Bioengineered Exosome-Mimetic Nanovesicles Be an Efficient Strategy for the Delivery of Chemotherapeutics? *Nanomedicine* 2014, 9 (2), 177−180.

(11) Doyle, L. M.; Wang, M. Z. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. *Cells* 2019, 8 (7), 727.

(12) Wang, J.; Chen, D.; Ho, E. A. Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems. *J. Controlled Release* 2021, 329, 894.

(13) Pan, B.-T.; Johnstone, R. M. Fate of the Transferrin Receptor during Maturation of Sheep Reticulocytes in Vitro: Selective Externalization of the Receptor. *Cell* 1983, 33 (3), 967−978.

(14) Trams, E. G.; Lauter, C. J.; Norman Salem, J.; Heine, U. Exfoliation of Membrane Ecto-Enzymes in the Form of Micro-Vesicles. *Biochim. Biophys. Biochim. Biophys. Acta, Biomembr.* 1981, 645 (1), 63−70.

(15) Conlan, R. S.; Pisano, S.; Oliveira, M. I.; Ferrari, M.; Mendes Pinto, I. Exosomes as Reconfigurable Therapeutic Systems. *Trends Mol. Med.* **2017**, *23* (7), 636−650.

(16) Margolis, L.; Sadovsky, Y. The Biology of Extracellular Vesicles: The Known Unknowns. *PLoS Biol.* **2019**, *17* (7), No. e3000363.

(17) Duan, P.; Tan, J.; Miao, Y.; Zhang, Q. Potential Role of Exosomes in the Pathophysiology, Diagnosis, and Treatment of Hypoxic Diseases. *Am. J. Transl. Res.* **2019**, *11* (3), 1184−1201.

(18) Maia, J.; Caja, S.; Strano Moraes, M. C.; Couto, N.; Costa-Silva, B. Exosome-Based Cell-Cell Communication in the Tumor Micro-environment. *Front. Cell Dev. Biol.* **2018**. DOI: 10.3389/fcell.2018.00018.

(19) Mittelbrunn, M.; Gutiérrez-Vázquez, C.; Villarroya-Beltri, C.; González, S.; Sánchez-Cabo, F.; González, M. Á.; Bernad, A.; Sánchez-Madrid, F. Unidirectional Transfer of MicroRNA-Loaded Exosomes from T Cells to Antigen-Presenting Cells. *Nat. Commun.* **2011**, *2* (1), 282.

(20) Delcayre, A.; Shu, H.; Le Pecq, J.-B. Dendritic Cell-Derived Exosomes in Cancer Immunotherapy: Exploiting Nature's Antigen Delivery Pathway. *Expert Rev. Anticancer Ther.* **2005**, *5* (3), 537−547.

(21) Morishita, M.; Takahashi, Y.; Matsumoto, A.; Nishikawa, M.; Takakura, Y. Exosome-Based Tumor Antigens−Adjuvant Co-Delivery Utilizing Genetically Engineered Tumor Cell-Derived Exosomes with Immunostimulatory CpG DNA. *Biomaterials* **2016**, *111*, 55−65.

(22) Yim, N.; Ryu, S.-W.; Choi, K.; Lee, K. R.; Lee, S.; Choi, H.; Kim, J.; Shaker, M. R.; Sun, W.; Park, J.-H.; Kim, D.; Heo, W. D.; Choi, C. Exosome Engineering for Efficient Intracellular Delivery of Soluble Proteins Using Optically Reversible Protein−Protein Interaction Module. *Nat. Commun.* **2016**, *7* (1), 12277.

(23) Ferreira, J. R.; Teixeira, G. Q.; Santos, S. G.; Barbosa, M. A.; Almeida-Porada, G.; Gonçalves, R. M. Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-Conditioning. *Front. Immunol.* **2018**, *9*, 2837.

(24) Rajagopal, C.; Harikumar, K. B. The Origin and Functions of Exosomes in Cancer. *Front. Oncol.* **2018**, *8*, 66.

(25) Li, M.; Zeringer, E.; Barta, T.; Schageman, J.; Cheng, A.; Vlassov, A. V. Analysis of the RNA Content of the Exosomes Derived from Blood Serum and Urine and Its Potential as Biomarkers. *Philos. Trans. R. Soc., B* **2014**, *369* (1652), 20130502.

(26) Schorey, J. S.; Bhatnagar, S. Exosome Function: From Tumor Immunology to Pathogen Biology. *Traffic* **2008**, *9* (6), 871−881.

(27) Ha, D.; Yang, N.; Nadithe, V. Exosomes as Therapeutic Drug Carriers and Delivery Vehicles across Biological Membranes: Current Perspectives and Future Challenges. *Acta Pharm. Sin. B* **2016**, *6* (4), 287−296.

(28) Bellingham, S.; Guo, B.; Coleman, B.; Hill, A. Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases? *Front. Physiol.* **2012**, *3*, 124.

(29) Fleming, A.; Sampey, G.; Chung, M. C.; Bailey, C.; van Hoek, M. L.; Kashanchi, F.; Hakami, R. M. The Carrying Pigeons of the Cell: Exosomes and Their Role in Infectious Diseases Caused by Human Pathogens. *Pathog. Dis.* **2014**, *71* (2), 109−120.

(30) Becker, A.; Thakur, B. K.; Weiss, J. M.; Kim, H. S.; Peinado, H.; Lyden, D. Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. *Cancer Cell* **2016**, *30* (6), 836−848.

(31) Li, Y.; Zheng, Q.; Bao, C.; Li, S.; Guo, W.; Zhao, J.; Chen, D.; Gu, J.; He, X.; Huang, S. Circular RNA Is Enriched and Stable in Exosomes: A Promising Biomarker for Cancer Diagnosis. *Cell Res.* **2015**, *25* (8), 981−984.

(32) Thakur, B. K.; Zhang, H.; Becker, A.; Matei, I.; Huang, Y.; Costa-Silva, B.; Zheng, Y.; Hoshino, A.; Brazier, H.; Xiang, J.; et al. Double-Stranded DNA in Exosomes: A Novel Biomarker in Cancer Detection. *Cell Res.* **2014**, *24* (6), 766−769.

(33) Masyuk, A. I.; Masyuk, T. V.; Larusso, N. F. Exosomes in the Pathogenesis, Diagnostics and Therapeutics of Liver Diseases. *J. Hepatol.* **2013**, *59* (3), 621−625.

(34) van Balkom, B. W. M.; Pisitkun, T.; Verhaar, M. C.; Knepper, M. A. Exosomes and the Kidney: Prospects for Diagnosis and Therapy of Renal Diseases. *Kidney Int.* **2011**, *80* (11), 1138−1145.

(35) Barile, L.; Vassalli, G. Exosomes: Therapy Delivery Tools and Biomarkers of Diseases. *Pharmacol. Ther.* **2017**, *174*, 63−78.

(36) Kalra, H.; Simpson, R. J.; Ji, H.; Aikawa, E.; Altevogt, P.; Askenase, P.; Bond, V. C.; Borràs, F. E.; Breakefield, X.; Budnik, V.; Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. *PLoS Biol.* **2012**. DOI: 10.1371/journal.pbio.1001450.

(37) Keerthikumar, S.; Chisanga, D.; Ariyaratne, D.; Al Saffar, H.; Anand, S.; Zhao, K.; Samuel, M.; Pathan, M.; Jois, M.; Chilamkurti, N.; Gangoda, L.; Mathivanan, S. ExoCarta: A Web-Based Compendium of Exosomal Cargo. *J. Mol. Biol.* **2016**, *428* (4), 688−692.

(38) Tamura, R.; Uemoto, S.; Tabata, Y. Augmented Liver Targeting of Exosomes by Surface Modification with Cationized Pullulan. *Acta Biomater.* **2017**, *57*, 274−284.

(39) Khongkow, M.; Yata, T.; Boonrungsiman, S.; Ruktanonchai, U. R.; Graham, D.; Namdee, K. Surface Modification of Gold Nanoparticles with Neuron-Targeted Exosome for Enhanced Blood−Brain Barrier Penetration. *Sci. Rep.* **2019**, *9* (1), 8278.

(40) Smyth, T.; Petrova, K.; Payton, N. M.; Persaud, I.; Redzic, J. S.; Graner, M. W.; Smith-Jones, P.; Anchordoquy, T. J. Surface Functionalization of Exosomes Using Click Chemistry. *Bioconjugate Chem.* **2014**, *25* (10), 1777−1784.

(41) Wan, S.; Zhang, L.; Wang, S.; Liu, Y.; Wu, C.; Cui, C.; Sun, H.; Shi, M.; Jiang, Y.; Li, L.; Qiu, L.; Tan, W. Molecular Recognition-Based DNA Nanoassemblies on the Surfaces of Nanosized Exosomes. *J. Am. Chem. Soc.* **2017**, *139* (15), 5289−5292.

(42) Zhou, Y.; Tian, T.; Zhu, Y.; Jaffar Ali, D.; Hu, F.; Qi, Y.; Sun, B.; Xiao, Z. Exosomes Transfer Among Different Species Cells and Mediating MiRNAs Delivery. *J. Cell. Biochem.* **2017**, *118* (12), 4267−4274.

(43) Schorey, J. S.; Harding, C. V. Extracellular Vesicles and Infectious Diseases: New Complexity to an Old Story. *J. Clin. Invest.* **2016**, *126* (4), 1181−1189.

(44) Pardridge, W. M. Drug Transport across the Blood−Brain Barrier. *J. Cereb. Blood Flow Metab.* **2012**, *32* (11), 1959−1972.

(45) La-Beck, N. M.; Liu, X.; Wood, L. M. Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery. *Front. Pharmacol.* **2019**, *10*, 220.

(46) Navarro, S. M.; Darensbourg, C.; Cross, L.; Stout, R.; Coulon, D.; Astete, C. E.; Morgan, T.; Sabliov, C. M. Biodistribution of PLGA and PLGA/Chitosan Nanoparticles after Repeat-Dose Oral Delivery in F344 Rats for 7 Days. *Ther. Delivery* **2014**, *5* (11), 1191−1201.

(47) Tian, Y.; Li, S.; Song, J.; Ji, T.; Zhu, M.; Anderson, G. J.; Wei, J.; Nie, G. A Doxorubicin Delivery Platform Using Engineered Natural Membrane Vesicle Exosomes for Targeted Tumor Therapy. *Biomaterials* **2014**, *35* (7), 2383−2390.

(48) Haney, M. J.; Klyachko, N. L.; Zhao, Y.; Gupta, R.; Plotnikova, E. G.; He, Z.; Patel, T.; Piroyan, A.; Sokolsky, M.; Kabanov, A. V.; Batrakova, E. V. Exosomes as Drug Delivery Vehicles for Parkinson's Disease Therapy. *J. Controlled Release* **2015**, *207*, 18−30.

(49) Gurunathan, S.; Kang, M.-H.; Jeyaraj, M.; Qasim, M.; Kim, J.-H. Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes. *Cells* **2019**, *8* (4), 307.

(50) Schiffelers, R.; Kooijmans, S.; Vader; van Dommelen; van Solinge. Exosome Mimetics: A Novel Class of Drug Delivery Systems. *Int. J. Nanomed.* **2012**, 1525.

(51) Théry, C.; Amigorena, S.; Raposo, G.; Clayton, A. Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids. *Curr. Protoc. Cell Biol.* **2006**, *30* (1), 3.22.1−3.22.29.

(52) Rekker, K.; Saare, M.; Roost, A. M.; Kubo, A.-L.; Zarovni, N.; Chiesi, A.; Salumets, A.; Peters, M. Comparison of Serum Exosome Isolation Methods for MicroRNA Profiling. *Clin. Biochem.* **2014**, *47* (1−2), 135−138.

(53) Abdel-Haq, H. Blood Exosomes as a Tool for Monitoring Treatment Efficacy and Progression of Neurodegenerative Diseases. *Neural Regen. Res.* **2019**, *14* (1), 72−74.

(54) Feng, D.; Zhao, W.-L.; Ye, Y.-Y.; Bai, X.-C.; Liu, R.-Q.; Chang, L.-F.; Zhou, Q.; Sui, S.-F. Cellular Internalization of Exosomes Occurs Through Phagocytosis. *Traffic* **2010**, *11* (5), 675−687.

(55) Yuan, D.; Zhao, Y.; Banks, W. A.; Bullock, K. M.; Haney, M.; Batrakova, E.; Kabanov, A. V. Macrophage Exosomes as Natural Nanocarriers for Protein Delivery to Inflamed Brain. *Biomaterials* **2017**, *142*, 1−12.

(56) Pegtel, D. M.; Cosmopoulos, K.; Thorley-Lawson, D. A.; van Eijndhoven, M. A. J.; Hopmans, E. S.; Lindenberg, J. L.; de Gruijl, T. D.; Wurdinger, T.; Middeldorp, J. M. Functional Delivery of Viral MiRNAs via Exosomes. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107* (14), 6328−6333.

(57) Luan, X.; Sansanaphongpricha, K.; Myers, I.; Chen, H.; Yuan, H.; Sun, D. Engineering Exosomes as Refined Biological Nanoplatforms for Drug Delivery. *Acta Pharmacol. Sin.* **2017**, *38* (6), 754−763.

(58) Lai, C. P.; Mardini, O.; Ericsson, M.; Prabhakar, S.; Maguire, C. A.; Chen, J. W.; Tannous, B. A.; Breakefield, X. O. Dynamic Biodistribution of Extracellular Vesicles in Vivo Using a Multimodal Imaging Reporter. *ACS Nano* **2014**, *8* (1), 483−494.

(59) Ishida, T.; Kashima, S.; Kiwada, H. The Contribution of Phagocytic Activity of Liver Macrophages to the Accelerated Blood Clearance (ABC) Phenomenon of PEGylated Liposomes in Rats. *J. Controlled Release* **2008**, *126* (2), 162−165.

(60) Lai, R. C.; Yeo, R. W. Y.; Tan, K. H.; Lim, S. K. Exosomes for Drug Delivery — a Novel Application for the Mesenchymal Stem Cell. *Biotechnol. Adv.* **2013**, *31* (5), 543−551.

(61) Johnsen, K. B.; Gudbergsson, J. M.; Skov, M. N.; Pilgaard, L.; Moos, T.; Duroux, M. A Comprehensive Overview of Exosomes as Drug Delivery Vehicles — Endogenous Nanocarriers for Targeted Cancer Therapy. *Biochim. Biophys. Acta, Rev. Cancer* **2014**, *1846* (1), 75−87.

(62) Schmidt, O.; Teis, D. The ESCRT Machinery. *Curr. Biol.* **2012**, *22* (4), R116−R120.

(63) Wang, H.; Sui, H.; Zheng, Y.; Jiang, Y.; Shi, Y.; Liang, J.; Zhao, L. Curcumin-Primed Exosomes Potently Ameliorate Cognitive Function in AD Mice by Inhibiting Hyperphosphorylation of the Tau Protein through the AKT/GSK-3β Pathway. *Nanoscale* **2019**, *11* (15), 7481−7496.

(64) Huotari, J.; Helenius, A. Endosome Maturation. *EMBO J.* **2011**, *30* (17), 3481−3500.

(65) Henne, W. M.; Stenmark, H.; Emr, S. D. Molecular Mechanisms of the Membrane Sculpting ESCRT Pathway. *Cold Spring Harbor Perspect. Biol.* **2013**, *5* (9), a016766−a016766.

(66) Trajkovic, K.; Hsu, C.; Chiantia, S.; Rajendran, L.; Wenzel, D.; Wieland, F.; Schwille, P.; Brugger, B.; Simons, M. Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes. *Science (Washington, DC, U. S.)* **2008**, *319* (5867), 1244−1247.

(67) Hurley, J. H. ESCRTs Are Everywhere. *EMBO J.* **2015**, *34* (19), 2398−2407.

(68) Kowal, J.; Tkach, M.; Théry, C. Biogenesis and Secretion of Exosomes. *Curr. Opin. Cell Biol.* **2014**, *29*, 116−125.

(69) Colombo, M.; Moita, C.; van Niel, G.; Kowal, J.; Vigneron, J.; Benaroch, P.; Manel, N.; Moita, L. F.; Théry, C.; Raposo, G. Analysis of ESCRT Functions in Exosome Biogenesis, Composition and Secretion Highlights the Heterogeneity of Extracellular Vesicles. *J. Cell Sci.* **2013**, *126* (24), 5553−5565.

(70) Hessvik, N. P.; Llorente, A. Current Knowledge on Exosome Biogenesis and Release. *Cell. Mol. Life Sci.* **2018**, *75* (2), 193−208.

(71) McAndrews, K. M.; Kalluri, R. Mechanisms Associated with Biogenesis of Exosomes in Cancer. *Mol. Cancer* **2019**, *18* (1), 52.

(72) Tamai, K.; Tanaka, N.; Nakano, T.; Kakazu, E.; Kondo, Y.; Inoue, J.; Shiina, M.; Fukushima, K.; Hoshino, T.; Sano, K.; Ueno, Y.; Shimosegawa, T.; Sugamura, K. Exosome Secretion of Dendritic Cells Is Regulated by Hrs, an ESCRT-0 Protein. *Biochem. Biophys. Res. Commun.* **2010**, *399* (3), 384−390.

(73) Piper, R. C.; Katzmann, D. J. Biogenesis and Function of Multivesicular Bodies. *Annu. Rev. Cell Dev. Biol.* **2007**, *23* (1), 519−547.

(74) Wollert, T.; Wunder, C.; Lippincott-Schwartz, J.; Hurley, J. H. Membrane Scission by the ESCRT-III Complex. *Nature* **2009**, *458* (7235), 172−177.

(75) Zhu, H.; Guariglia, S.; Yu, R. Y. L.; Li, W.; Brancho, D.; Peinado, H.; Lyden, D.; Salzer, J.; Bennett, C.; Chow, C.-W. Mutation of SIMPLE in Charcot−Marie−Tooth 1C Alters Production of Exosomes. *Mol. Biol. Cell* **2013**, *24* (11), 1619−1637.

(76) Baietti, M. F.; Zhang, Z.; Mortier, E.; Melchior, A.; Degeest, G.; Geeraerts, A.; Ivarsson, Y.; Depoortere, F.; Coomans, C.; Vermeiren, E.; Zimmermann, P.; David, G. Syndecan−Syntenin−ALIX Regulates the Biogenesis of Exosomes. *Nat. Cell Biol.* **2012**, *14* (7), 677−685.

(77) Friand, V.; David, G.; Zimmermann, P. Syntenin and Syndecan in the Biogenesis of Exosomes. *Biol. Cell* **2015**, *107* (10), 331−341.

(78) Brügger, B.; Bankaitis, V. A. Lipids and Vesicular Transport. *Biochim. Biophys. Acta, Mol. Cell Biol. Lipids* **2012**, *1821* (8), 1039.

(79) Haucke, V.; Di Paolo, G. Lipids and Lipid Modifications in the Regulation of Membrane Traffic. *Curr. Opin. Cell Biol.* **2007**, *19* (4), 426−435.

(80) McMahon, H. T.; Boucrot, E. Membrane Curvature at a Glance. *J. Cell Sci.* **2015**, *128* (6), 1065−1070.

(81) Skotland, T.; Sandvig, K.; Llorente, A. Lipids in Exosomes: Current Knowledge and the Way Forward. *Prog. Lipid Res.* **2017**, *66*, 30−41.

(82) Skotland, T.; Hessvik, N. P.; Sandvig, K.; Llorente, A. Exosomal Lipid Composition and the Role of Ether Lipids and Phosphoinositides in Exosome Biology. *J. Lipid Res.* **2019**, *60* (1), 9−18.

(83) Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Takeshita, F.; Matsuki, Y.; Ochiya, T. Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells. *J. Biol. Chem.* **2010**, *285* (23), 17442−17452.

(84) Costa Verdera, H.; Gitz-Francois, J. J.; Schiffelers, R. M.; Vader, P. Cellular Uptake of Extracellular Vesicles Is Mediated by Clathrin-Independent Endocytosis and Macropinocytosis. *J. Controlled Release* **2017**, *266*, 100−108.

(85) Nakase, I.; Noguchi, K.; Aoki, A.; Takatani-Nakase, T.; Fujii, I.; Futaki, S. Arginine-Rich Cell-Penetrating Peptide-Modified Extracellular Vesicles for Active Macropinocytosis Induction and Efficient Intracellular Delivery. *Sci. Rep.* **2017**, *7* (1), 1991.

(86) Webber, J.; Steadman, R.; Mason, M. D.; Tabi, Z.; Clayton, A. Cancer Exosomes Trigger Fibroblast to Myofibroblast Differentiation. *Cancer Res.* **2010**, *70* (23), 9621−9630.

(87) Phuyal, S.; Hessvik, N. P.; Skotland, T.; Sandvig, K.; Llorente, A. Regulation of Exosome Release by Glycosphingolipids and Flotillins. *FEBS J.* **2014**, *281* (9), 2214−2227.

(88) Raposo, G.; Stoorvogel, W. Extracellular Vesicles: Exosomes, Microvesicles, and Friends. *J. Cell Biol.* **2013**, *200* (4), 373−383.

(89) Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J. P.; Primdal-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Théry, C. Proteomic Comparison Defines Novel Markers to Characterize Heterogeneous Populations of Extracellular Vesicle Subtypes. *Proc. Natl. Acad. Sci. U. S. A.* **2016**, *113* (8), E968−E977.

(90) Stuffers, S.; Sem Wegner, C.; Stenmark, H.; Brech, A. Multivesicular Endosome Biogenesis in the Absence of ESCRTs. *Traffic* **2009**, *10* (7), 925−937.

(91) Skotland, T.; Sagini, K.; Sandvig, K.; Llorente, A. An Emerging Focus on Lipids in Extracellular Vesicles. *Adv. Drug Delivery Rev.* **2020**, *159*, 308.

(92) Verderio, C.; Gabrielli, M.; Giussani, P. Role of Sphingolipids in the Biogenesis and Biological Activity of Extracellular Vesicles. *J. Lipid Res.* **2018**, *59* (8), 1325−1340.

(93) Burrello, J.; Biemmi, V.; Dei Cas, M.; Amongero, M.; Bolis, S.; Lazzarini, E.; Bollini, S.; Vassalli, G.; Paroni, R.; Barile, L. Sphingolipid Composition of Circulating Extracellular Vesicles after Myocardial Ischemia. *Sci. Rep.* **2020**, *10* (1), 16182.

(94) Kobayashi, T.; Beuchat, M.-H.; Chevallier, J.; Makino, A.; Mayran, N.; Escola, J.-M.; Lebrand, C.; Cosson, P.; Kobayashi, T.; Gruenberg, J. Separation and Characterization of Late Endosomal Membrane Domains. *J. Biol. Chem.* **2002**, *277* (35), 32157−32164.

(95) White, I. J.; Bailey, L. M.; Aghakhani, M. R.; Moss, S. E.; Futter, C. E. EGF Stimulates Annexin 1-Dependent Inward Vesiculation in a Multivesicular Endosome Subpopulation. *EMBO J.* **2006**, *25* (1), 1−12.

(96) Buschow, S. I.; van Balkom, B. W. M.; Aalberts, M.; Heck, A. J. R.; Wauben, M.; Stoorvogel, W. MHC Class II-Associated Proteins in B-Cell Exosomes and Potential Functional Implications for Exosome Biogenesis. *Immunol. Cell Biol.* **2010**, *88* (8), 851−856.

(97) Li, S.; Lin, Z.; Jiang, X.; Yu, X. Exosomal Cargo-Loading and Synthetic Exosome-Mimics as Potential Therapeutic Tools. *Acta Pharmacol. Sin.* **2018**, *39* (4), 542−551.

(98) Ghossoub, R.; Lembo, F.; Rubio, A.; Gaillard, C. B.; Bouchet, J.; Vitale, N.; Slavík, J.; Machala, M.; Zimmermann, P. Syntenin-ALIX Exosome Biogenesis and Budding into Multivesicular Bodies Are Controlled by ARF6 and PLD2. *Nat. Commun.* **2014**. DOI: 10.1038/ncomms4477.

(99) Kanemoto, S.; Nitani, R.; Murakami, T.; Kaneko, M.; Asada, R.; Matsuhisa, K.; Saito, A.; Imaizumi, K. Multivesicular Body Formation Enhancement and Exosome Release during Endoplasmic Reticulum Stress. *Biochem. Biophys. Res. Commun.* **2016**, *480* (2), 166−172.

(100) Baixauli, F.; López-Otín, C.; Mittelbrunn, M. Exosomes and Autophagy: Coordinated Mechanisms for the Maintenance of Cellular Fitness. *Front. Immunol.* **2014**, *5*, 403.

(101) Hoshino, D.; Kirkbride, K. C.; Costello, K.; Clark, E. S.; Sinha, S.; Grega-Larson, N.; Tyska, M. J.; Weaver, A. M. Exosome Secretion Is Enhanced by Invadopodia and Drives Invasive Behavior. *Cell Rep.* **2013**, *5*, 1159.

(102) van Niel, G.; Porto-Carreiro, I.; Simoes, S.; Raposo, G. Exosomes: A Common Pathway for a Specialized Function. *J. Biochem.* **2006**, *140* (1), 13−21.

(103) Qu, Y.; Franchi, L.; Nunez, G.; Dubyak, G. R. Nonclassical IL-1β Secretion Stimulated by P2 × 7 Receptors Is Dependent on Inflammasome Activation and Correlated with Exosome Release in Murine Macrophages. *J. Immunol.* **2007**, *179* (3), 1913−1925.

(104) Barros, F. M.; Carneiro, F.; Machado, J. C.; Melo, S. A. Exosomes and Immune Response in Cancer: Friends or Foes? *Front. Immunol.* **2018**, *9*, 730.

(105) Carmeliet, P.; Jain, R. K. Molecular Mechanisms and Clinical Applications of Angiogenesis. *Nature* **2011**, *473* (7347), 298−307.

(106) Tan, A.; Rajadas, J.; Seifalian, A. M. Exosomes as Nano-Theranostic Delivery Platforms for Gene Therapy. *Adv. Drug Delivery Rev.* **2013**, *65* (3), 357−367.

(107) Bobrie, A.; Colombo, M.; Krumeich, S.; Raposo, G.; Théry, C. Diverse Subpopulations of Vesicles Secreted by Different Intracellular Mechanisms Are Present in Exosome Preparations Obtained by Differential Ultracentrifugation. *J. Extracell. Vesicles* **2012**, *1* (1), 18397.

(108) Novak, J. P.; Nickerson, C.; Franzen, S.; Feldheim, D. L. Purification of Molecularly Bridged Metal Nanoparticle Arrays by Centrifugation and Size Exclusion Chromatography. *Anal. Chem.* **2001**, *73* (23), 5758−5761.

(109) Mamer, O. A. Medical Applications of Mass Spectrometry. In *Encyclopedia of Spectroscopy and Spectrometry*; Elsevier, 2017; pp 772−780. DOI: 10.1016/B978-0-12-803224-4.00199-0.

(110) Greening, D. W.; Xu, R.; Ji, H.; Tauro, B. J.; Simpson, R. J. A Protocol for Exosome Isolation and Characterization: Evaluation of Ultracentrifugation, Density-Gradient Separation, and Immunoaffinity Capture Methods. In *Methods in Molecular Biology*; Springer: Clifton, NJ, United States, 2015; Vol. 1295, pp 179−209. DOI: 10.1007/978-1-4939-2550-6_15.

(111) Li, P.; Kaslan, M.; Lee, S. H.; Yao, J.; Gao, Z. Progress in Exosome Isolation Techniques. *Theranostics* **2017**, *7* (3), 789−804.

(112) Lobb, R. J.; Becker, M.; Wen Wen, S.; Wong, C. S. F.; Wiegmans, A. P.; Leimgruber, A.; Möller, A. Optimized Exosome Isolation Protocol for Cell Culture Supernatant and Human Plasma. *J. Extracell. Vesicles* **2015**, *4* (1), 27031.

(113) Deregibus, M. C.; Figliolini, F.; D'antico, S.; Manzini, P. M.; Pasquino, C.; De Lena, M.; Tetta, C.; Brizzi, M. F.; Camussi, G.

Charge-Based Precipitation of Extracellular Vesicles. *Int. J. Mol. Med.* **2016**, *38* (5), 1359−1366.

(114) Wang, Z.; Wu, H.; Fine, D.; Schmulen, J.; Hu, Y.; Godin, B.; Zhang, J. X. J.; Liu, X. Ciliated Micropillars for the Microfluidic-Based Isolation of Nanoscale Lipid Vesicles. *Lab Chip* **2013**, *13* (15), 2879.

(115) Konoshenko, M. Y.; Lekchnov, E. A.; Vlassov, A. V.; Laktionov, P. P. Isolation of Extracellular Vesicles: General Methodologies and Latest Trends. *BioMed Res. Int.* **2018**, *2018*, 1−27.

(116) Sharma, A.; Sharma, U. S.; Stuffers, S.; Sem Wegner, C.; Stenmark, H.; Brech, A.; Date, A. A.; Joshi, M. D.; Patravale, V. B.; Lee, K. S. Isolation of Exosomes by Differential Centrifugation: Theoretical Analysis of a Commonly Used Protocol. *J. Controlled Release* **2015**, *5* (31), 1697−1704.

(117) Helwa, I.; Cai, J.; Drewry, M. D.; Zimmerman, A.; Dinkins, M. B.; Khaled, M. L.; Seremwe, M.; Dismuke, W. M.; Bieberich, E.; Stamer, W. D.; Hamrick, M. W.; Liu, Y. A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents. *PLoS One* **2017**, *12* (1), No. e0170628.

(118) Chapter 7 - Preparative and Analytical Ultracentrifugation;- Trautman, R.; Cowan, K. M. In *Methods in Immunology and Immunochemistry*; Williams, C. A., Chase, M. W., Williams, C. A., Eds.; Academic Press, 1968; Vol. 2, pp 81−118. DOI: 10.1016/B978-1-4831-9796-8.50008-0.

(119) Livshits, M. A.; Khomyakova, E.; Evtushenko, E. G.; Lazarev, V. N.; Kulemin, N. A.; Semina, S. E.; Generozov, E. V.; Govorun, V. M. Isolation of Exosomes by Differential Centrifugation: Theoretical Analysis of a Commonly Used Protocol. *Sci. Rep.* **2015**, DOI: 10.1038/srep17319.

(120) Denzer, K.; Kleijmeer, M. J.; Heijnen, H. F.; Stoorvogel, W.; Geuze, H. J. Exosome: From Internal Vesicle of the Multivesicular Body to Intercellular Signaling Device. *J. Cell Sci.* **2000**, *113* (19), 3365−3374.

(121) Tian, T.; Zhang, H.-X.; He, C.-P.; Fan, S.; Zhu, Y.-L.; Qi, C.; Huang, N.-P.; Xiao, Z.-D.; Lu, Z.-H.; Tannous, B. A.; Gao, J. Surface Functionalized Exosomes as Targeted Drug Delivery Vehicles for Cerebral Ischemia Therapy. *Biomaterials* **2018**, *150*, 137−149.

(122) Feng, Y.; Huang, W.; Wani, M.; Yu, X.; Ashraf, M. Ischemic Preconditioning Potentiates the Protective Effect of Stem Cells through Secretion of Exosomes by Targeting Mecp2 via MiR-22. *PLoS One* **2014**, *9* (2), No. e88685.

(123) Batas, B.; Chaudhuri, J. B. Protein Refolding at High Concentration Using Size-Exclusion Chromatography. *Biotechnol. Bioeng.* **1996**, *50* (1), 16−23.

(124) Prendergast, E. N.; de Souza Fonseca, M. A.; Dezem, F. S.; Lester, J.; Karlan, B. Y.; Noushmehr, H.; Lin, X.; Lawrenson, K. Optimizing Exosomal RNA Isolation for RNA-Seq Analyses of Archival Sera Specimens. *PLoS One* **2018**, *13* (5), No. e0196913.

(125) Kennedy, J. A.; Taylor, A. W. Analysis of Proanthocyanidins by High-Performance Gel Permeation Chromatography. *J. Chromatogr. A* **2003**, *995* (1−2), 99−107.

(126) Chen, C.; Skog, J.; Hsu, C.-H.; Lessard, R. T.; Balaj, L.; Wurdinger, T.; Carter, B. S.; Breakefield, X. O.; Toner, M.; Irimia, D. Microfluidic Isolation and Transcriptome Analysis of Serum Microvesicles. *Lab Chip* **2010**, *10* (4), 505−511.

(127) Clayton, A.; Court, J.; Navabi, H.; Adams, M.; Mason, M. D.; Hobot, J. A.; Newman, G. R.; Jasani, B. Analysis of Antigen Presenting Cell Derived Exosomes, Based on Immuno-Magnetic Isolation and Flow Cytometry. *J. Immunol. Methods* **2001**, *247* (1−2), 163−174.

(128) Tauro, B. J.; Greening, D. W.; Mathias, R. A.; Ji, H.; Mathivanan, S.; Scott, A. M.; Simpson, R. J. Comparison of Ultracentrifugation, Density Gradient Separation, and Immunoaffinity Capture Methods for Isolating Human Colon Cancer Cell Line LIM1863-Derived Exosomes. *Methods* **2012**, *56* (2), 293−304.

(129) Taylor, D. D.; Zacharias, W.; Gercel-Taylor, C. Exosome Isolation for Proteomic Analyses and RNA Profiling. In *Methods in Molecular Biology*; Springer, 2011; pp 235−246. DOI: 10.1007/978-1-61779-068-3_15.

(130) Serrano-Pertierra, E.; Oliveira-Rodríguez, M.; Rivas, M.; Oliva, P.; Villafani, J.; Navarro, A.; Blanco-López, M.; Cernuda-Morollón, E.

Characterization of Plasma-Derived Extracellular Vesicles Isolated by Different Methods: A Comparison Study. *Bioengineering* **2019**, *6* (1), 8.

(131) Tang, Y.-T.; Huang, Y.-Y.; Zheng, L.; Qin, S.-H.; Xu, X.-P.; An, T.-X.; Xu, Y.; Wu, Y.-S.; Hu, X.-M.; Ping, B.-H.; Wang, Q. Comparison of Isolation Methods of Exosomes and Exosomal RNA from Cell Culture Medium and Serum. *Int. J. Mol. Med.* **2017**, *40* (3), 834−844.

(132) Enderle, D.; Spiel, A.; Coticchia, C. M.; Berghoff, E.; Mueller, R.; Schlumpberger, M.; Sprenger-Haussels, M.; Shaffer, J. M.; Lader, E.; Skog, J.; et al. Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. *PLoS One* **2015**, *10* (8), No. e0136133.

(133) Ding, M.; Wang, C.; Lu, X.; Zhang, C.; Zhou, Z.; Chen, X.; Zhang, C.-Y.; Zen, K.; Zhang, C. Comparison of Commercial Exosome Isolation Kits for Circulating Exosomal MicroRNA Profiling. *Anal. Bioanal. Chem.* **2018**, *410* (16), 3805−3814.

(134) Sokolova, V.; Ludwig, A.-K.; Hornung, S.; Rotan, O.; Horn, P. A.; Epple, M.; Giebel, B. Characterisation of Exosomes Derived from Human Cells by Nanoparticle Tracking Analysis and Scanning Electron Microscopy. *Colloids Surf., B* **2011**, *87* (1), 146−150.

(135) Petersen, K. E.; Manangon, E.; Hood, J. L.; Wickline, S. A.; Fernandez, D. P.; Johnson, W. P.; Gale, B. K. A Review of Exosome Separation Techniques and Characterization of B16-F10 Mouse Melanoma Exosomes with AF4-UV-MALS-DLS-TEM. *Anal. Bioanal. Chem.* **2014**, *406* (30), 7855−7866.

(136) Conde-Vancells, J.; Rodriguez-Suarez, E.; Embade, N.; Gil, D.; Matthiesen, R.; Valle, M.; Elortza, F.; Lu, S. C.; Mato, J. M.; Falcon-Perez, J. M. Characterization and Comprehensive Proteome Profiling of Exosomes Secreted by Hepatocytes. *J. Proteome Res.* **2008**, *7* (12), 5157−5166.

(137) Fernández-Llama, P.; Khositseth, S.; Gonzales, P. A.; Star, R. A.; Pisitkun, T.; Knepper, M. A. Tamm-Horsfall Protein and Urinary Exosome Isolation. *Kidney Int.* **2010**, *77* (8), 736−742.

(138) Bandu, R.; Oh, J. W.; Kim, K. P. Mass Spectrometry-Based Proteome Profiling of Extracellular Vesicles and Their Roles in Cancer Biology. *Exp. Mol. Med.* **2019**, *51* (3), 30.

(139) Dragovic, R. A.; Gardiner, C.; Brooks, A. S.; Tannetta, D. S.; Ferguson, D. J.P.; Hole, P.; Carr, B.; Redman, C. W.G.; Harris, A. L.; Dobson, P. J.; Harrison, P.; Sargent, I. L. Sizing and Phenotyping of Cellular Vesicles Using Nanoparticle Tracking Analysis. *Nanomedicine* **2011**, *7* (6), 780−788.

(140) Encarnación, S.; Hernández, M.; Martínez-Batallar, G.; Contreras, S.; del Vargas, M. C.; Mora, J. Comparative Proteomics Using 2-D Gel Electrophoresis and Mass Spectrometry as Tools to Dissect Stimulons and Regulons in Bacteria with Sequenced or Partially Sequenced Genomes. *Biol. Proced. Online* **2005**, *7*, 117−135.

(141) Kreimer, S.; Belov, A. M.; Ghiran, I.; Murthy, S. K.; Frank, D. A.; Ivanov, A. R. Mass-Spectrometry-Based Molecular Characterization of Extracellular Vesicles: Lipidomics and Proteomics. *J. Proteome Res.* **2015**, *14* (6), 2367−2384.

(142) Chen, Y.; Xie, Y.; Xu, L.; Zhan, S.; Xiao, Y.; Gao, Y.; Wu, B.; Ge, W. Protein Content and Functional Characteristics of Serum-Purified Exosomes from Patients with Colorectal Cancer Revealed by Quantitative Proteomics. *Int. J. Cancer* **2017**, *140* (4), 900−913.

(143) Yang, C.; Guo, W.-b.; Zhang, W.-s.; Bian, J.; Yang, J.-k.; Zhou, Q.-z.; Chen, M.-k.; Peng, W.; Qi, T.; Wang, C.-y.; Liu, C.-d. Comprehensive Proteomics Analysis of Exosomes Derived from Human Seminal Plasma. *Andrology* **2017**, *5* (5), 1007−1015.

(144) Li, X.; Corbett, A. L.; Taatizadeh, E.; Tasnim, N.; Little, J. P.; Garnis, C.; Daugaard, M.; Guns, E.; Hoorfar, M.; Li, I. T. S. Challenges and Opportunities in Exosome Research—Perspectives from Biology, Engineering, and Cancer Therapy. *APL Bioeng.* **2019**, *3* (1), No. 011503.

(145) Bunggulawa, E. J.; Wang, W.; Yin, T.; Wang, N.; Durkan, C.; Wang, Y.; Wang, G. Recent Advancements in the Use of Exosomes as Drug Delivery Systems. *J. Nanobiotechnol.* **2018**, DOI: 10.1186/s12951-018-0403-9.

(146) Fu, S.; Wang, Y.; Xia, X.; Zheng, J. C. Exosome Engineering: Current Progress in Cargo Loading and Targeted Delivery. *Nano-Impact* **2020**, *20*, 100261.

(147) Kim, M. S.; Haney, M. J.; Zhao, Y.; Mahajan, V.; Deygen, I.; Klyachko, N. L.; Inskoe, E.; Piroyan, A.; Sokolsky, M.; Okolie, O.; Hingtgen, S. D.; Kabanov, A. V.; Batrakova, E. V. Development of Exosome-Encapsulated Paclitaxel to Overcome MDR in Cancer Cells. *Nanomedicine* **2016**, *12* (3), 655−664.

(148) Bellavia, D.; Raimondo, S.; Calabrese, G.; Forte, S.; Cristaldi, M.; Patinella, A.; Memeo, L.; Manno, M.; Raccosta, S.; Diana, P.; Cirrincione, G.; Giavaresi, G.; Monteleone, F.; Fontana, S.; De Leo, G.; Alessandro, R. Interleukin 3- Receptor Targeted Exosomes Inhibit *in Vitro* and *in Vivo* Chronic Myelogenous Leukemia Cell Growth. *Theranostics* **2017**, *7* (5), 1333−1345.

(149) Yang, Z.; Shi, J.; Xie, J.; Wang, Y.; Sun, J.; Liu, T.; Zhao, Y.; Zhao, X.; Wang, X.; Ma, Y. Large-Scale Generation of Functional MRNA-Encapsulating Exosomes via Cellular Nanoporation. *Nat. Biomed. Eng.* **2020**, *4* (1), 69−83.

(150) Li, Z.; Zhou, X.; Wei, M.; Gao, X.; Zhao, L.; Shi, R.; Sun, W.; Duan, Y.; Yang, G.; Yuan, L. In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with MiRNA or CRISPR/DCas9. *Nano Lett.* **2019**, *19* (1), 19−28.

(151) Yang, Y.; Hong, Y.; Nam, G.-H.; Chung, J. H.; Koh, E.; Kim, I.-S. Virus-Mimetic Fusogenic Exosomes for Direct Delivery of Integral Membrane Proteins to Target Cell Membranes. *Adv. Mater.* **2017**, *29* (13), 1605604.

(152) Lamichhane, T. N.; Raiker, R. S.; Jay, S. M. Exogenous DNA Loading into Extracellular Vesicles via Electroporation Is Size-Dependent and Enables Limited Gene Delivery. *Mol. Pharmaceutics* **2015**, *12* (10), 3650−3657.

(153) Johnsen, K. B.; Gudbergsson, J. M.; Skov, M. N.; Christiansen, G.; Gurevich, L.; Moos, T.; Duroux, M. Evaluation of Electroporation-Induced Adverse Effects on Adipose-Derived Stem Cell Exosomes. *Cytotechnology* **2016**, *68* (5), 2125−2138.

(154) Wahlgren, J.; Statello, L.; Skogberg, G.; Telemo, E.; Valadi, H. Delivery of Small Interfering RNAs to Cells via Exosomes BT. In *SiRNA Delivery Methods: Methods and Protocols*; Shum, K., Rossi, J., Eds.; Springer: New York, NY, 2016; pp 105−125. DOI: 10.1007/978-1-4939-3112-5_10.

(155) Fuhrmann, G.; Serio, A.; Mazo, M.; Nair, R.; Stevens, M. M. Saponins as Cytotoxic Agents: A Review. *J. Controlled Release* **2015**, *205*, 35−44.

(156) Fuhrmann, G.; Serio, A.; Mazo, M.; Nair, R.; Stevens, M. M. Active Loading into Extracellular Vesicles Significantly Improves the Cellular Uptake and Photodynamic Effect of Porphyrins. *J. Controlled Release* **2015**, *205*, 35−44.

(157) Jeyaram, A.; Lamichhane, T. N.; Wang, S.; Zou, L.; Dahal, E.; Kronstadt, S. M.; Levy, D.; Parajuli, B.; Knudsen, D. R.; Chao, W.; Jay, S. M. Enhanced Loading of Functional MiRNA Cargo via PH Gradient Modification of Extracellular Vesicles. *Mol. Ther.* **2020**, *28* (3), 975−985.

(158) Xu, M.; Yang, Q.; Sun, X.; Wang, Y. Recent Advancements in the Loading and Modification of Therapeutic Exosomes. *Front. Bioeng. Biotechnol.* **2020**, *8*, 586130.

(159) Wang, J.; Chen, D.; Ho, E. A. Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems. *J. Controlled Release* **2021**, *329*, 894−906.

(160) Li, X.-B.; Zhang, Z.-R.; Schluesener, H. J.; Xu, S.-Q. Role of Exosomes in Immune Regulation. *J. Cell. Mol. Med.* **2006**, *10* (2), 364−375.

(161) Greening, D. W.; Gopal, S. K.; Xu, R.; Simpson, R. J.; Chen, W. Exosomes and Their Roles in Immune Regulation and Cancer. *Semin. Cell Dev. Biol.* **2015**, *40*, 72−81.

(162) Lema, D. A.; Burlingham, W. J. Role of Exosomes in Tumour and Transplant Immune Regulation. *Scand. J. Immunol.* **2019**, *90* (5), No. e12807.

(163) Utsugi-Kobukai, S.; Fujimaki, H.; Hotta, C.; Nakazawa, M.; Minami, M. MHC Class I-Mediated Exogenous Antigen Presentation

by Exosomes Secreted from Immature and Mature Bone Marrow Derived Dendritic Cells. *Immunol. Lett.* **2003**, *89* (2-3), 125−131.

(164) Smith, V. L.; Cheng, Y.; Bryant, B. R.; Schorey, J. S. Exosomes Function in Antigen Presentation during an in Vivo Mycobacterium Tuberculosis Infection. *Sci. Rep.* **2017**, *7* (1), 43578.

(165) Zhang, H.-G.; Kim, H.; Liu, C.; Yu, S.; Wang, J.; Grizzle, W. E.; Kimberly, R. P.; Barnes, S. Curcumin Reverses Breast Tumor Exosomes Mediated Immune Suppression of NK Cell Tumor Cytotoxicity. *Biochim. Biophys. Acta, Mol. Cell Res.* **2007**, *1773* (7), 1116−1123.

(166) Ning, Y.; Shen, K.; Wu, Q.; Sun, X.; Bai, Y.; Xie, Y.; Pan, J.; Qi, C. Tumor Exosomes Block Dendritic Cells Maturation to Decrease the T Cell Immune Response. *Immunol. Lett.* **2018**, *199*, 36−43.

(167) Piper, R. C.; Luzio, J. P. Late Endosomes: Sorting and Partitioning in Multivesicular Bodies. *Traffic* **2001**, *2* (9), 612−621.

(168) Anand, P. K. Exosomal Membrane Molecules Are Potent Immune Response Modulators. *Commun. Integr. Biol.* **2010**, *3* (5), 405−408.

(169) Zhu, M.; Tian, X.; Song, X.; Li, Y.; Tian, Y.; Zhao, Y.; Nie, G. Nanoparticle-Induced Exosomes Target Antigen-Presenting Cells to Initiate Th1-Type Immune Activation. *Small* **2012**, *8* (18), 2841−2848.

(170) Brinton, L. T.; Sloane, H. S.; Kester, M.; Kelly, K. A. Formation and Role of Exosomes in Cancer. *Cell. Mol. Life Sci.* **2015**, *72* (4), 659−671.

(171) Alexander, M.; Hu, R.; Runtsch, M. C.; Kagele, D. A.; Mosbruger, T. L.; Tolmachova, T.; Seabra, M. C.; Round, J. L.; Ward, D. M.; O'Connell, R. M. Exosome-Delivered MicroRNAs Modulate the Inflammatory Response to Endotoxin. *Nat. Commun.* **2015**, *6* (1), 7321.

(172) Tran, T.-H.; Mattheolabakis, G.; Aldawsari, H.; Amiji, M. Exosomes as Nanocarriers for Immunotherapy of Cancer and Inflammatory Diseases. *Clin. Immunol.* **2015**, *160* (1), 46−58.

(173) Nojehdehi, S.; Soudi, S.; Hesampour, A.; Rasouli, S.; Soleimani, M.; Hashemi, S. M. Immunomodulatory Effects of Mesenchymal Stem Cell−Derived Exosomes on Experimental Type-1 Autoimmune Diabetes. *J. Cell. Biochem.* **2018**, *119* (11), 9433−9443.

(174) Zhao, H.; Shang, Q.; Pan, Z.; Bai, Y.; Li, Z.; Zhang, H.; Zhang, Q.; Guo, C.; Zhang, L.; Wang, Q. Exosomes From Adipose-Derived Stem Cells Attenuate Adipose Inflammation and Obesity Through Polarizing M2Macrophages and Beiging in White Adipose Tissue. *Diabetes* **2018**, *67* (2), 235−247.

(175) Xiao, T.; Zhang, W.; Jiao, B.; Pan, C.-Z.; Liu, X.; Shen, L. The Role of Exosomes in the Pathogenesis of Alzheimer' Disease. *Transl. Neurodegener.* **2017**, *6*, 3.

(176) Yáñez-Mó, M.; Siljander, P. R. M.; Andreu, Z.; Bedina Zavec, A.; Borràs, F. E.; Buzas, E. I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J. Biological Properties of Extracellular Vesicles and Their Physiological Functions. *J. Extracell. Vesicles* **2015**, *4* (1), 27066.

(177) Yuan, Y.; Du, W.; Liu, J.; Ma, W.; Zhang, L.; Du, Z.; Cai, B. Stem Cell-Derived Exosome in Cardiovascular Diseases: Macro Roles of Micro Particles. *Front. Pharmacol.* **2018**, *9*, 547.

(178) Wang, L.; Jia, Q.; Xinnong, C.; Xie, Y.; Yang, Y.; Zhang, A.; Liu, R.; Zhuo, Y.; Zhang, J. Role of Cardiac Progenitor Cell-derived Exosome-mediated MicroRNA-210 in Cardiovascular Disease. *J. Cell. Mol. Med.* **2019**, *23* (11), 7124−7131.

(179) Wu, R.; Gao, W.; Yao, K.; Ge, J. Roles of Exosomes Derived From Immune Cells in Cardiovascular Diseases. *Front. Immunol.* **2019**, *10*, 648.

(180) Hough, K. P.; Chanda, D.; Duncan, S. R.; Thannickal, V. J.; Deshane, J. S. Exosomes in Immunoregulation of Chronic Lung Diseases. *Allergy* **2017**, *72* (4), 534−544.

(181) Robbins, P. D.; Morelli, A. E. Regulation of Immune Responses by Extracellular Vesicles. *Nat. Rev. Immunol.* **2014**, *14* (3), 195−208.

(182) Johnstone, R. M. Exosomes Biological Significance: A Concise Review. *Blood Cells, Mol., Dis.* **2006**, *36* (2), 315−321.

(183) Chen, G.; Huang, A. C.; Zhang, W.; Zhang, G.; Wu, M.; Xu, W.; Yu, Z.; Yang, J.; Wang, B.; Sun, H. Exosomal PD-L1 Contributes to Immunosuppression and Is Associated with Anti-PD-1 Response. *Nature* **2018**, *560* (7718), 382−386.

(184) Porto-Carreiro, I.; Février, B.; Paquet, S.; Vilette, D.; Raposo, G. Prions and Exosomes: From PrPc Trafficking to PrPsc Propagation. *Blood Cells, Mol., Dis.* **2005**, *35* (2), 143−148.

(185) Taylor, D. D.; Akyol, S.; Gercel-Taylor, C. Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling. *J. Immunol.* **2006**, *176* (3), 1534−1542.

(186) Taylor, D. D.; Gerçel-Taylor, C. Tumour-Derived Exosomes and Their Role in Cancer-Associated T-Cell Signalling Defects. *Br. J. Cancer* **2005**, *92* (2), 305−311.

(187) Whiteside, T. L. Immune Modulation of T-Cell and NK (Natural Killer) Cell Activities by TEXs (Tumour-Derived Exosomes). *Biochem. Soc. Trans.* **2013**, *41* (1), 245−251.

(188) Dong, H.; Strome, S. E.; Salomao, D. R.; Tamura, H.; Hirano, F.; Flies, D. B.; Roche, P. C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V. A.; Celis, E.; Chen, L. Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. *Nat. Med.* **2002**, *8* (8), 793−800.

(189) Chen, L.; Han, X. Anti-PD-1/PD-L1 Therapy of Human Cancer: Past, Present, and Future. *J. Clin. Invest.* **2015**, *125* (9), 3384−3391.

(190) Akinleye, A.; Rasool, Z. Immune Checkpoint Inhibitors of PD-L1 as Cancer Therapeutics. *J. Hematol. Oncol.* **2019**, *12* (1), 92.

(191) Arellano, B.; Graber, D. J.; Sentman, C. L. Regulatory T Cell-Based Therapies for Autoimmunity. *Discovery Med.* **2016**, *22* (119), 73−80.

(192) Dejaco, C.; Duftner, C.; Grubeck-Loebenstein, B.; Schirmer, M. Imbalance of Regulatory T Cells in Human Autoimmune Diseases. *Immunology* **2006**, *117* (3), 289−300.

(193) Anel, A.; Gallego-Lleyda, A.; de Miguel, D.; Naval, J.; Martínez-Lostao, L. Role of Exosomes in the Regulation of T-Cell Mediated Immune Responses and in Autoimmune Disease. *Cells* **2019**, *8* (2), 154.

(194) Huang, Y.; Li, R.; Ye, S.; Lin, S.; Yin, G.; Xie, Q. Recent Advances in the Use of Exosomes in Sjögren's Syndrome. *Front. Immunol.* **2020**, *11*, 1509.

(195) Zhang, B.; Yeo, R. W. Y.; Lai, R. C.; Sim, E. W. K.; Chin, K. C.; Lim, S. K. Mesenchymal Stromal Cell Exosome-Enhanced Regulatory T-Cell Production through an Antigen-Presenting Cell-Mediated Pathway. *Cytotherapy* **2018**, *20* (5), 687−696.

(196) Daneman, R.; Prat, A. The Blood−Brain Barrier. *Cold Spring Harbor Perspect. Biol.* **2015**, *7* (1), a020412.

(197) Griep, L. M.; Wolbers, F.; de Wagenaar, B.; ter Braak, P. M.; Weksler, B. B.; Romero, I. A.; Couraud, P. O.; Vermes, I.; van der Meer, A. D.; van den Berg, A. BBB ON CHIP: Microfluidic Platform to Mechanically and Biochemically Modulate Blood-Brain Barrier Function. *Biomed. Microdevices* **2013**, *15* (1), 145−150.

(198) Kabat-Zinn, J.; Lipworth, L.; Burney, R. The Clinical Use of Mindfulness Meditation for the Self-Regulation of Chronic Pain. *J. Behav. Med.* **1985**, *8* (2), 163−190.

(199) Pardridge, W. M. Transport of Small Molecules through the Blood-Brain Barrier: Biology and Methodology. *Adv. Drug Delivery Rev.* **1995**, *15* (1), 5−36.

(200) Fischer, H.; Gottschlich, R.; Seelig, A. Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion. *J. Membr. Biol.* **1998**, *165* (3), 201−211.

(201) Yang, T.; Martin, P.; Fogarty, B.; Brown, A.; Schurman, K.; Phipps, R.; Yin, V. P.; Lockman, P.; Bai, S. Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio. *Pharm. Res.* **2015**, *32* (6), 2003−2014.

(202) Wood, M. J. A.; O'Loughlin, A. J.; Lakhal, S. Exosomes and the Blood−Brain Barrier: Implications for Neurological Diseases. *Ther. Delivery* **2011**, *2* (9), 1095−1099.

(203) Chen, C. C.; Liu, L.; Ma, F.; Wong, C. W.; Guo, X. E.; Chacko, J. V.; Farhoodi, H. P.; Zhang, S. X.; Zimak, J.; Segaliny, A.; Riazifar, M.; Pham, V.; Digman, M. A.; Pone, E. J.; Zhao, W.

Elucidation of Exosome Migration Across the Blood−Brain Barrier Model In Vitro. *Cell. Mol. Bioeng.* **2016**, 9 (4), 509−529.

(204) Zhao, C.; Wang, H.; Xiong, C.; Liu, Y. Hypoxic Glioblastoma Release Exosomal VEGF-A Induce the Permeability of Blood-Brain Barrier. *Biochem. Biophys. Res. Commun.* **2018**, 502 (3), 324−331.

(205) O'Kane, R. L.; Martínez-López, I.; DeJoseph, M. R.; Viña, J. R.; Hawkins, R. A. Na + -Dependent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain Barrier. *J. Biol. Chem.* **1999**, 274 (45), 31891−31895.

(206) Barar, J.; Rafi, M. A.; Pourseif, M. M.; Omidi, Y. Blood-Brain Barrier Transport Machineries and Targeted Therapy of Brain Diseases. *BioImpacts* **2016**, 6 (4), 225−248.

(207) Upadhyay, R. K. Transendothelial Transport and Its Role in Therapeutics. *Int. Scholarly Res. Not.* **2014**, 2014, 309404.

(208) Wu, X.; Xie, C.; Zhang, Y.; Fan, Z.; Yin, Y.; Blachier, F. Glutamate−Glutamine Cycle and Exchange in the Placenta−Fetus Unit during Late Pregnancy. *Amino Acids* **2015**, 47 (1), 45−53.

(209) van Dommelen, S. M.; Vader, P.; Lakhal, S.; Kooijmans, S. A. A.; van Solinge, W. W.; Wood, M. J. A.; Schiffelers, R. M. Microvesicles and Exosomes: Opportunities for Cell-Derived Membrane Vesicles in Drug Delivery. *J. Controlled Release* **2012**, 161 (2), 635−644.

(210) Aryani, A.; Denecke, B. Exosomes as a Nanodelivery System: A Key to the Future of Neuromedicine? *Mol. Neurobiol.* **2016**, 53 (2), 818−834.

(211) Saiz, M. L.; Rocha-Perugini, V.; Sánchez-Madrid, F. Tetraspanins as Organizers of Antigen-Presenting Cell Function. *Front. Immunol.* **2018**, 9, 1074.

(212) Haqqani, A. S.; Delaney, C. E.; Tremblay, T.-L.; Sodja, C.; Sandhu, J. K.; Stanimirovic, D. B. Method for Isolation and Molecular Characterization of Extracellular Microvesicles Released from Brain Endothelial Cells. *Fluids Barriers CNS* **2013**, 10 (1), 4.

(213) Balusu, S.; Van Wonterghem, E.; De Rycke, R.; Raemdonck, K.; Stremersch, S.; Gevaert, K.; Brkic, M.; Demeestere, D.; Vanhooren, V.; Hendrix, A.; Libert, C.; Vandenbroucke, R. E Identification of a Novel Mechanism of Blood−Brain Communication during Peripheral Inflammation via Choroid Plexus-Derived Extracellular Vesicles. *EMBO Mol. Med.* **2016**, 8 (10), 1162−1183.

(214) András, I. E.; Leda, A.; Contreras, M. G.; Bertrand, L.; Park, M.; Skowronska, M.; Toborek, M. Extracellular Vesicles of the Blood-Brain Barrier: Role in the HIV-1 Associated Amyloid Beta Pathology. *Mol. Cell. Neurosci.* **2017**, 79, 12−22.

(215) Tanzi, R. E.; Gusella, J. F.; Watkins, P. C.; Bruns, G. A.; St George-Hyslop, P.; Van Keuren, M. L.; Patterson, D.; Pagan, S.; Kurnit, D. M.; Neve, R. L. Amyloid Beta Protein Gene: CDNA, MRNA Distribution, and Genetic Linkage near the Alzheimer Locus. *Science* **1987**, 235 (4791), 880−884.

(216) Badhwar, A.; Haqqani, A. S. Biomarker Potential of Brain-Secreted Extracellular Vesicles in Blood in Alzheimer's Disease. *Alzheimer's Dement. (Amsterdam, Netherlands)* **2020**, 12 (1), No. e12001.

(217) Qu, M.; Lin, Q.; Huang, L.; Fu, Y.; Wang, L.; He, S.; Fu, Y.; Yang, S.; Zhang, Z.; Zhang, L.; Sun, X. Dopamine-Loaded Blood Exosomes Targeted to Brain for Better Treatment of Parkinson's Disease. *J. Controlled Release* **2018**, 287, 156−166.

(218) Sharma, A. Liposomes in Drug Delivery: Progress and Limitations. *Int. J. Pharm.* **1997**, 154 (2), 123−140.

(219) Kumari, A.; Yadav, S. K.; Yadav, S. C. Biodegradable Polymeric Nanoparticles Based Drug Delivery Systems. *Colloids Surf., B* **2010**, 75 (1), 1−18.

(220) Tang, B. C.; Dawson, M.; Lai, S. K.; Wang, Y.-Y.; Suk, J. S.; Yang, M.; Zeitlin, P.; Boyle, M. P.; Fu, J.; Hanes, J. Biodegradable Polymer Nanoparticles That Rapidly Penetrate the Human Mucus Barrier. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, 106 (46), 19268−19273.

(221) Musyanovych, A.; Schmitz-Wienke, J.; Mailänder, V.; Walther, P.; Landfester, K. Preparation of Biodegradable Polymer Nanoparticles by Miniemulsion Technique and Their Cell Interactions. *Macromol. Biosci.* **2008**, 8 (2), 127−139.

(222) Chen, C.; Johnston, T. D.; Jeon, H.; Gedaly, R.; McHugh, P. P.; Burke, T. G.; Ranjan, D. An in Vitro Study of Liposomal Curcumin: Stability, Toxicity and Biological Activity in Human Lymphocytes and Epstein-Barr Virus-Transformed Human B-Cells. *Int. J. Pharm.* **2009**, 366, 133.

(223) Feng, S.-S.; Mu, L.; Win, K. Y.; Huang, G. Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel. *Curr. Med. Chem.* **2004**, 11 (4), 413−424.

(224) Cheng, Q.; Feng, J.; Chen, J.; Zhu, X.; Li, F. Brain Transport of Neurotoxin-I with PLA Nanoparticles through Intranasal Administration in Rats: A Microdialysis Study. *Biopharm. Drug Dispos.* **2008**, 29 (8), 431−439.

(225) Gomezgaete, C.; Tsapis, N.; Besnard, M.; Bochot, a.; Fattal, E. Encapsulation of Dexamethasone into Biodegradable Polymeric Nanoparticles. *Int. J. Pharm.* **2007**, 331 (2), 153−159.

(226) Mu, L.; Feng, S. A Novel Controlled Release Formulation for the Anticancer Drug Paclitaxel (Taxol®): PLGA Nanoparticles Containing Vitamin E TPGS. *J. Controlled Release* **2003**, 86 (1), 33−48.

(227) Vázquez-Ríos, A. J.; Molina-Crespo, Á.; Bouzo, B. L.; López-López, R.; Moreno-Bueno, G.; de la Fuente, M. Exosome-Mimetic Nanoplatforms for Targeted Cancer Drug Delivery. *J. Nanobiotechnol.* **2019**, 17 (1), 85.

(228) Damgé, C.; Maincent, P.; Ubrich, N. Oral Delivery of Insulin Associated to Polymeric Nanoparticles in Diabetic Rats. *J. Controlled Release* **2007**, 117 (2), 163−170.

(229) Goetzl, E. J.; Boxer, A.; Schwartz, J. B.; Abner, E. L.; Petersen, R. C.; Miller, B. L.; Kapogiannis, D. Altered Lysosomal Proteins in Neural-Derived Plasma Exosomes in Preclinical Alzheimer Disease. *Neurology* **2015**, 85 (1), 40−47.

(230) Calvo, P.; Gouritin, B.; Brigger, I.; Lasmezas, C.; Deslys, J.-P.; Williams, A.; Andreux, J. P.; Dormont, D.; Couvreur, P. PEGylated Polycyanoacrylate Nanoparticles as Vector for Drug Delivery in Prion Diseases. *J. Neurosci. Methods* **2001**, 111 (2), 151−155.

(231) Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, C. S.; Kim, S.-B.; Rha, S. Y.; Lee, M. Y.; Ro, J. Multicenter Phase II Trial of Genexol-PM, a Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel, in Patients with Metastatic Breast Cancer. *Breast Cancer Res. Treat.* **2008**, 108 (2), 241−250.

(232) Sercombe, L.; Veerati, T.; Moheimani, F.; Wu, S. Y.; Sood, A. K.; Hua, S. Advances and Challenges of Liposome Assisted Drug Delivery. *Front. Pharmacol.* **2015**, 6, 286.

(233) Gabizon, A.; Goren, D.; Horowitz, A. T.; Tzemach, D.; Lossos, A.; Siegal, T. Long-Circulating Liposomes for Drug Delivery in Cancer Therapy: A Review of Biodistribution Studies in Tumor-Bearing Animals. *Adv. Drug Delivery Rev.* **1997**, 24 (2-3), 337−344.

(234) Hines, D. J.; Kaplan, D. L. Poly(Lactic-Co-Glycolic) Acid-Controlled-Release Systems: Experimental and Modeling Insights. *Crit. Rev. Ther. Drug Carrier Syst.* **2013**, 30 (3), 257−276.

(235) Lü, J.-M.; Wang, X.; Marin-Muller, C.; Wang, H.; Lin, P. H.; Yao, Q.; Chen, C. Current Advances in Research and Clinical Applications of PLGA-Based Nanotechnology. *Expert Rev. Mol. Diagn.* **2009**, 9 (4), 325−341.

(236) Green, A. E.; Rose, P. G. Pegylated Liposomal Doxorubicin in Ovarian Cancer. *Int. J. Nanomed.* **2006**, 1 (3), 229−239.

(237) Piccaluga, P. P.; Visani, G.; Martinelli, G.; Isidori, A.; Malagola, M.; Rondoni, M.; Baccarani, M.; Tura, S. Liposomal Daunorubicin (DaunoXome) for Treatment of Relapsed Meningeal Acute Myeloid Leukemia. *Leukemia* **2002**, 16 (9), 1880−1881.

(238) Bayever, E.; Dhindsa, N.; Fitzgerald, J. B.; Laivins, P.; Moyo, V.; Clet Niyikiza, J. K. Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Rinotecan. US 9,339,497 B2, 2013.

(239) Chambers, C. D.; Johnson, D. L. Emerging Data on the Use of Anti-Tumor Necrosis Factor-Alpha Medications in Pregnancy. *Birth Defects Res., Part A* **2012**, 94 (8), 607−611.

(240) Molineux, G. The Design and Development of Pegfilgrastim (PEG-RmetHuG-CSF, Neulasta). *Curr. Pharm. Des.* **2004**, 10 (11), 1235−1244.

(241) Pettinati, H. M.; Anton, R. F.; Willenbring, M. L. The COMBINE Study-: An Overview of the Largest Pharmacotherapy Study to Date for Treating Alcohol Dependence. *Psychiatry (Edgmont.)* **2006**, *3* (10), 36−39.

(242) Gordon, M. S.; Kinlock, T. W.; Vocci, F. J.; Fitzgerald, T. T.; Memisoglu, A.; Silverman, B. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners. *J. Subst. Abuse Treat.* **2015**, *59*, 52−58.

(243) Samson, S. L. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. *Drugs* **2016**, *76* (13), 1235−1243.

(244) McKeage, K. Pasireotide in Acromegaly: A Review. *Drugs* **2015**, *75* (9), 1039−1048.

(245) de Smet, M.; Heijman, E.; Langereis, S.; Hijnen, N. M.; Grüll, H. Magnetic Resonance Imaging of High Intensity Focused Ultrasound Mediated Drug Delivery from Temperature-Sensitive Liposomes: An in Vivo Proof-of-Concept Study. *J. Controlled Release* **2011**, *150* (1), 102−110.

(246) Blanco, E.; Shen, H.; Ferrari, M. Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery. *Nat. Biotechnol.* **2015**, *33* (9), 941−951.

(247) Szebeni, J.; Barenholz, Y. Complement Activation, Immunogenicity and Immune Suppression as Potential Side Effects of Liposomes. In *Handbook of Harnessing Biomaterials in Nanomedicine*; Tayler & Francis Group: Milton Park, Milton, United Kingdom, 2012; pp 309−334. https://doi.org/10.1201/b11620.

(248) Ishida, T.; Harashima, H.; Kiwada, H. Liposome Clearance. *Biosci. Rep.* **2002**, *22*, 197−224.

(249) Cullis, P. R.; Chonn, A.; Semple, S. C. Interactions of Liposomes and Lipid-Based Carrier Systems with Blood Proteins: Relation to Clearance Behaviour in Vivo. *Adv. Drug Delivery Rev.* **1998**, *32* (1−2), 3−17.

(250) Inglut, C. T.; Sorrin, A. J.; Kuruppu, T.; Vig, S.; Cicalo, J.; Ahmad, H.; Huang, H.-C. Immunological and Toxicological Considerations for the Design of Liposomes. *Nanomaterials* **2020**, *10* (2), 190.

(251) Saadati, R.; Dadashzadeh, S.; Abbasian, Z.; Soleimanjahi, H. Accelerated Blood Clearance of PEGylated PLGA Nanoparticles Following Repeated Injections: Effects of Polymer Dose, PEG Coating, and Encapsulated Anticancer Drug. *Pharm. Res.* **2013**, *30* (4), 985−995.

(252) Fornaguera, C.; Calderó, G.; Mitjans, M.; Vinardell, M. P.; Solans, C.; Vauthier, C. Interactions of PLGA Nanoparticles with Blood Components: Protein Adsorption, Coagulation, Activation of the Complement System and Hemolysis Studies. *Nanoscale* **2015**, *7* (14), 6045−6058.

(253) Dams, E. T. M.; Laverman, P.; Oyen, W. J. G.; Storm, G.; Scherphof, G. L.; Van Der Meer, J. W. M.; Corstens, F. H. M.; Boerman, O. C. Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes. *J. Pharmacol. Exp. Ther.* **2000**.29210711079

(254) Moghimi, S. M.; Hunter, A. C. Capture of Stealth Nanoparticles by the Body's Defences. *Crit. Rev. Ther. Drug Carrier Syst.* **2001**, *18* (6), 527−550.

(255) Szebeni, J. Complement Activation-Related Pseudoallergy: A New Class of Drug-Induced Acute Immune Toxicity. *Toxicology* **2005**, *216* (2−3), 106−121.

(256) Prabhakar, U.; Maeda, H.; Jain, R. K.; Sevick-Muraca, E. M.; Zamboni, W.; Farokhzad, O. C.; Barry, S. T.; Gabizon, A.; Grodzinski, P.; Blakey, D. C. Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology. *Cancer Res.* **2013**, *73*, 2412−2417.

(257) Eetezadi, S.; Ekdawi, S. N.; Allen, C. The Challenges Facing Block Copolymer Micelles for Cancer Therapy: In Vivo Barriers and Clinical Translation. *Adv. Drug Delivery Rev.* **2015**, *91*, 7−22.

(258) Li, C.; Zhang, J.; Zu, Y.-J.; Nie, S.-F.; Cao, J.; Wang, Q.; Nie, S.-P.; Deng, Z.-Y.; Xie, M.-Y.; Wang, S. Biocompatible and Biodegradable Nanoparticles for Enhancement of Anti-Cancer Activities of Phytochemicals. *Chin. J. Nat. Med.* **2015**, *13* (9), 641−652.

(259) Rani, S.; Ritter, T. The Exosome - A Naturally Secreted Nanoparticle and Its Application to Wound Healing. *Adv. Mater.* **2016**, *28* (27), 5542−5552.

(260) Göran Ronquist, K. Extracellular Vesicles and Energy Metabolism. *Clin. Chim. Acta* **2019**, *488*, 116−121.

(261) Baquir, B.; Hancock, R. E. W. Exosomes, Your Body's Answer to Immune Health. *Ann. Transl. Med.* **2017**, *5* (4), 81.

(262) Fu, W.; Lei, C.; Liu, S.; Cui, Y.; Wang, C.; Qian, K.; Li, T.; Shen, Y.; Fan, X.; Lin, F.; Ding, M.; Pan, M.; Ye, X.; Yang, Y.; Hu, S. CAR Exosomes Derived from Effector CAR-T Cells Have Potent Antitumour Effects and Low Toxicity. *Nat. Commun.* **2019**, *10* (1), 4355.

(263) Agrawal, A. K.; Aqil, F.; Jeyabalan, J.; Spencer, W. A.; Beck, J.; Gachuki, B. W.; Alhakeem, S. S.; Oben, K.; Munagala, R.; Bondada, S.; Gupta, R. C. Milk-Derived Exosomes for Oral Delivery of Paclitaxel. *Nanomedicine* **2017**, *13* (5), 1627−1636.

(264) Turturici, G.; Tinnirello, R.; Sconzo, G.; Geraci, F. Extracellular Membrane Vesicles as a Mechanism of Cell-to-Cell Communication: Advantages and Disadvantages. *Am. J. Physiol. Physiol.* **2014**, *306* (7), C621−C633.

(265) Kalimuthu, S.; Gangadaran, P.; Rajendran, R. L.; Zhu, L.; Oh, J. M.; Lee, H. W.; Gopal, A.; Baek, S. H.; Jeong, S. Y.; Lee, S.-W.; Lee, J.; Ahn, B.-C. A New Approach for Loading Anticancer Drugs Into Mesenchymal Stem Cell-Derived Exosome Mimetics for Cancer Therapy. *Front. Pharmacol.* **2018**, *9*, 1116.

(266) Rani, S.; Ryan, A. E.; Griffin, M. D.; Ritter, T. Mesenchymal Stem Cell-Derived Extracellular Vesicles: Toward Cell-Free Therapeutic Applications. *Mol. Ther.* **2015**, *23* (5), 812−823.

(267) Gomzikova, M. O.; James, V.; Rizvanov, A. A. Therapeutic Application of Mesenchymal Stem Cells Derived Extracellular Vesicles for Immunomodulation. *Front. Immunol.* **2019**, *10*, 2663.

(268) van den Boorn, J. G.; Schlee, M.; Coch, C.; Hartmann, G. SiRNA Delivery with Exosome Nanoparticles. *Nat. Biotechnol.* **2011**, *29* (4), 325−326.

(269) Lin, Y.; Wu, J.; Gu, W.; Huang, Y.; Tong, Z.; Huang, L.; Tan, J. Exosome−Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. *Adv. Sci.* **2018**, *5* (4), 1700611.

(270) Sun, D.; Zhuang, X.; Xiang, X.; Liu, Y.; Zhang, S.; Liu, C.; Barnes, S.; Grizzle, W.; Miller, D.; Zhang, H.-G. A Novel Nanoparticle Drug Delivery System: The Anti-Inflammatory Activity of Curcumin Is Enhanced When Encapsulated in Exosomes. *Mol. Ther.* **2010**, *18* (9), 1606−1614.

(271) Ravindran, J.; Prasad, S.; Aggarwal, B. B. Curcumin and Cancer Cells: How Many Ways Can Curry Kill Tumor Cells Selectively? *AAPS J.* **2009**, *11* (3), 495−510.

(272) Aggarwal, B. B.; Harikumar, K. B. Potential Therapeutic Effects of Curcumin, the Anti-Inflammatory Agent, against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases. *Int. J. Biochem. Cell Biol.* **2009**, *41* (1), 40−59.

(273) Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A. B.; Aggarwal, B. B. Curcumin and Cancer: An "Old-Age" Disease with an "Age-Old" Solution. *Cancer Lett.* **2008**, *267* (1), 133−164.

(274) Lv, M.; Zhu, X.; Chen, W.; Zhong, S.; Hu, Q.; Ma, T.; Zhang, J.; Chen, L.; Tang, J.; Zhao, J. Exosomes Mediate Drug Resistance Transfer in MCF-7 Breast Cancer Cells and a Probable Mechanism Is Delivery of P-Glycoprotein. *Tumor Biol.* **2014**, *35* (11), 10773−10779.

(275) Raposo, G.; Nijman, H. W.; Stoorvogel, W.; Liejendekker, R.; Harding, C. V.; Melief, C. J.; Geuze, H J B Lymphocytes Secrete Antigen-Presenting Vesicles. *J. Exp. Med.* **1996**, *183*, 1161.

(276) Chaput, N.; Théry, C. Exosomes: Immune Properties and Potential Clinical Implementations. *Semin. Immunopathol.* **2011**, *33*, 419−440.

(277) Bianco, N. R.; Kim, S.-H.; Morelli, A. E.; Robbins, P. D. Modulation of the Immune Response Using Dendritic Cell-Derived Exosomes. *Methods Mol. Biol.* **2007**, *380*, 443−455.

(278) Chen, W.; Huang, Y.; Han, J.; Yu, L.; Li, Y.; Lu, Z.; Li, H.; Liu, Z.; Shi, C.; Duan, F.; Xiao, Y. Immunomodulatory Effects of Mesenchymal Stromal Cells-Derived Exosome. *Immunol. Res.* **2016**, *64* (4), 831−840.

(279) Chen, W.; Wang, J.; Shao, C.; Liu, S.; Yu, Y.; Wang, Q.; Cao, X. Efficient Induction of Antitumor T Cell Immunity by Exosomes Derived from Heat-Shocked Lymphoma Cells. *Eur. J. Immunol.* **2006**, *36* (6), 1598−1607.

(280) Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell Derived Exosomes. *Nat. Med.* **1998**, *4* (5), 594−600.

(281) Kaur, S.; Singh, S. P.; Elkahloun, A. G.; Wu, W.; Abu-Asab, M. S.; Roberts, D. D. CD47-Dependent Immunomodulatory and Angiogenic Activities of Extracellular Vesicles Produced by T Cells. *Matrix Biol.* **2014**, *37*, 49−59.

(282) Aucher, A.; Rudnicka, D.; Davis, D. M. MicroRNAs Transfer from Human Macrophages to Hepato-Carcinoma Cells and Inhibit Proliferation. *J. Immunol.* **2013**, *191* (12), 6250−6260.

(283) Pascucci, L.; Cocce, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Vigano, L.; Locatelli, A.; Sisto, F.; Doglia, S. M.; Parati, E.; Bernardo, M. E.; Muraca, M.; Alessandri, G.; Bondiolotti, G.; Pessina, A. Paclitaxel Is Incorporated by Mesenchymal Stromal Cells and Released in Exosomes That Inhibit in Vitro Tumor Growth: A New Approach for Drug Delivery. *J. Controlled Release* **2014**, *192*, 262−270.

(284) Yan, L.; Shen, J.; Wang, J.; Yang, X.; Dong, S.; Lu, S. Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology. *Dose-Response* **2020**, *18* (3), 155932582093616.

(285) Zhuang, X.; Xiang, X.; Grizzle, W.; Sun, D.; Zhang, S.; Axtell, R. C; Ju, S.; Mu, J.; Zhang, L.; Steinman, L.; Miller, D.; Zhang, H.-G. Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-Inflammatory Drugs from the Nasal Region to the Brain. *Mol. Ther.* **2011**, *19* (10), 1769−1779.

(286) Dhillon, N.; Aggarwal, B. B.; Newman, R. A.; Wolff, R. A.; Kunnumakkara, A. B.; Abbruzzese, J. L.; Ng, C. S.; Badmaev, V.; Kurzrock, R. Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. *Clin. Cancer Res.* **2008**, *14* (14), 4491−4499.

(287) Lai, R. C.; Arslan, F.; Lee, M. M.; Sze, N. S. K.; Choo, A.; Chen, T. S.; Salto-Tellez, M.; Timmers, L.; Lee, C. N.; El Oakley, R. M.; Pasterkamp, G.; de Kleijn, D. P.V.; Lim, S. K. Exosome Secreted by MSC Reduces Myocardial Ischemia/Reperfusion Injury. *Stem Cell Res.* **2010**, *4* (3), 214−222.

(288) Arslan, F.; Lai, R. C.; Smeets, M. B.; Akeroyd, L.; Choo, A.; Aguor, E. N.E.; Timmers, L.; van Rijen, H. V.; Doevendans, P. A.; Pasterkamp, G.; Lim, S. K.; de Kleijn, D. P. Mesenchymal Stem Cell-Derived Exosomes Increase ATP Levels, Decrease Oxidative Stress and Activate PI3K/Akt Pathway to Enhance Myocardial Viability and Prevent Adverse Remodeling after Myocardial Ischemia/Reperfusion Injury. *Stem Cell Res.* **2013**, *10* (3), 301−312.

(289) Katsuda, T.; Tsuchiya, R.; Kosaka, N.; Yoshioka, Y.; Takagaki, K.; Oki, K.; Takeshita, F.; Sakai, Y.; Kuroda, M.; Ochiya, T. Human Adipose Tissue-Derived Mesenchymal Stem Cells Secrete Functional Neprilysin-Bound Exosomes. *Sci. Rep.* **2013**, *3*, 1197.

(290) Huang, L.; Ma, W.; Ma, Y.; Feng, D.; Chen, H.; Cai, B. Exosomes in Mesenchymal Stem Cells, a New Therapeutic Strategy for Cardiovascular Diseases? *Int. J. Biol. Sci.* **2015**, *11* (2), 238−245.

(291) Sahoo, S.; Losordo, D. W. Exosomes and Cardiac Repair After Myocardial Infarction. *Circ. Res.* **2014**, *114* (2), 333−344.

(292) El-Andaloussi, S.; Lee, Y.; Lakhal-Littleton, S.; Li, J.; Seow, Y.; Gardiner, C.; Alvarez-Erviti, L.; Sargent, I. L.; Wood, M. J. A. Exosome-Mediated Delivery of SiRNA in Vitro and in Vivo. *Nat. Protoc.* **2012**, *7* (12), 2112−2126.

(293) Lee, Y.; EL Andaloussi, S.; Wood, M. J. A. Exosomes and Microvesicles: Extracellular Vesicles for Genetic Information Transfer and Gene Therapy. *Hum. Mol. Genet.* **2012**, *21* (R1), R125−R134.

(294) Shtam, T. A.; Kovalev, R. A.; Varfolomeeva, E. Y.; Makarov, E. M.; Kil, Y. V.; Filatov, M. V. Exosomes Are Natural Carriers of Exogenous SiRNA to Human Cells in Vitro. *Cell Commun. Signaling* **2013**, *11*, 88.

(295) Wahlgren, J.; De L Karlston, T.; Brisslert, M.; Vaziri Sani, F.; Telemo, E.; Sunnerhagen, P.; Valadi, H. Plasma Exosomes Can Deliver Exogenous Short Interfering RNA to Monocytes and Lymphocytes. *Nucleic Acids Res.* **2012**, *40* (17), e130−e130.

(296) Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M. J. A. Delivery of SiRNA to the Mouse Brain by Systemic Injection of Targeted Exosomes. *Nat. Biotechnol.* **2011**, *29* (4), 341−345.

(297) Yerneni, S. S.; Lathwal, S.; Shrestha, P.; Shirwan, H.; Matyjaszewski, K.; Weiss, L.; Yolcu, E. S.; Campbell, P. G.; Das, S. R. Rapid On-Demand Extracellular Vesicle Augmentation with Versatile Oligonucleotide Tethers. *ACS Nano* **2019**, *13* (9), 10555−10565.

(298) Li, J.; Liu, K.; Liu, Y.; Xu, Y.; Zhang, F.; Yang, H.; Liu, J.; Pan, T.; Chen, J.; Wu, M.; Zhou, X.; Yuan, Z. Exosomes Mediate the Cell-to-Cell Transmission of IFN-α-Induced Antiviral Activity. *Nat. Immunol.* **2013**, *14* (8), 793−803.

(299) Pitt, J. M.; Charrier, M.; Viaud, S.; André, F.; Besse, B.; Chaput, N.; Zitvogel, L. Dendritic Cell−Derived Exosomes as Immunotherapies in the Fight against Cancer. *J. Immunol.* **2014**, *193* (3), 1006−1011.

(300) Colino, J.; Snapper, C. M. Exosomes from Bone Marrow Dendritic Cells Pulsed with Diphtheria Toxoid Preferentially Induce Type 1 Antigen-Specific IgG Responses in Naive Recipients in the Absence of Free Antigen. *J. Immunol.* **2006**, *177* (6), 3757−3762.

(301) Théry, C.; Regnault, A.; Garin, J.; Wolfers, J.; Zitvogel, L.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. Molecular Characterization of Dendritic Cell-Derived Exosomes. Selective Accumulation of the Heat Shock Protein Hsc73. *J. Cell Biol.* **1999**, *147* (3), 599−610.

(302) Rosenberg, S. A.; Restifo, N. P. Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer. *Science* **2015**, *348* (6230), 62−68.

(303) Lu, Z.; Zuo, B.; Jing, R.; Gao, X.; Rao, Q.; Liu, Z.; Qi, H.; Guo, H.; Yin, H. Dendritic Cell-Derived Exosomes Elicit Tumor Regression in Autochthonous Hepatocellular Carcinoma Mouse Models. *J. Hepatol.* **2017**, *67* (4), 739−748.

(304) Geis-Asteggiante, L.; Belew, A. T.; Clements, V. K.; Edwards, N. J.; Ostrand-Rosenberg, S.; El-Sayed, N. M.; Fenselau, C. Differential Content of Proteins, MRNAs, and MiRNAs Suggests That MDSC and Their Exosomes May Mediate Distinct Immune Suppressive Functions. *J. Proteome Res.* **2018**, *17* (1), 486−498.

(305) Di Bonito, P.; Accardi, L.; Galati, L.; Ferrantelli, F.; Federico, M. Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. *Cancers* **2019**, *11*, 138.

(306) McElroy, A. K.; Akondy, R. S.; Davis, C. W.; Ellebedy, A. H.; Mehta, A. K.; Kraft, C. S.; Lyon, G. M.; Ribner, B. S.; Varkey, J.; Sidney, J.; Sette, A.; Campbell, S.; Stroher, U.; Damon, I.; Nichol, S. T.; Spiropoulou, C. F.; Ahmed, R. Human Ebola Virus Infection Results in Substantial Immune Activation. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112* (15), 4719−4724.

(307) Wu, X.-M.; Liao, Y.-W.; Wang, H.-Y.; Ji, K.-Q.; Li, G.-F.; Zang, B. Integrin Alphavbeta6 Is Involved in Measles Protein-Induced Airway Immune Suppression. *Cytokine+* **2012**, *59* (1), 59−64.

(308) Li, X.; Li, J.-J.; Yang, J.-Y.; Wang, D.-S.; Zhao, W.; Song, W.-J.; Li, W.-M.; Wang, J.-F.; Han, W.; Zhang, Z.-C.; Yu, Y.; Cao, D.-Y.; Dou, K.-F. Tolerance Induction by Exosomes from Immature Dendritic Cells and Rapamycin in a Mouse Cardiac Allograft Model. *PLoS One* **2012**, *7* (8), No. e44045.

(309) Song, J.; Huang, J.; Chen, X.; Teng, X.; Song, Z.; Xing, Y.; Wang, M.; Chen, K.; Wang, Z.; Yang, P.; Hu, S. Donor-Derived Exosomes Induce Specific Regulatory T Cells to Suppress Immune Inflammation in the Allograft Heart. *Sci. Rep.* **2016**, *6* (1), 20077.

(310) Califf, R. M. Biomarker Definitions and Their Applications. *Exp. Biol. Med. (London, U. K.)* 2018, 243 (3), 213−221.

(311) Mirzakhani, M.; Shahbazi, M.; Oliaei, F.; Mohammadnia-Afrouzi, M. Immunological Biomarkers of Tolerance in Human Kidney Transplantation: An Updated Literature Review. *J. Cell. Physiol.* 2019, 234 (5), 5762−5774.

(312) Kennel, P. J.; Saha, A.; Maldonado, D. A.; Givens, R.; Brunjes, D. L.; Castillero, E.; Zhang, X.; Ji, R.; Yahi, A.; George, I.; Mancini, D. M.; Koller, A.; Fine, B.; Zorn, E.; Colombo, P. C.; Tatonetti, N.; Chen, E. I.; Schulze, P. C. Serum Exosomal Protein Profiling for the Non-Invasive Detection of Cardiac Allograft Rejection. *J. Hear. Lung Transplant.* 2018, 37 (3), 409−417.

(313) Stickney, Z.; Losacco, J.; McDevitt, S.; Zhang, Z.; Lu, B. Development of Exosome Surface Display Technology in Living Human Cells. *Biochem. Biophys. Res. Commun.* 2016, 472 (1), 53−59.

(314) Jeyaram, A.; Jay, S. M. Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications. *AAPS J.* 2018, 20 (1), 1.

(315) Logozzi, M.; De Milito, A.; Lugini, L.; Borghi, M.; Calabrò, L.; Spada, M.; Perdicchio, M.; Marino, M. L.; Federici, C.; Iessi, E. High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. *PLoS One* 2009, 4 (4), e5219−e5219.

(316) Lu, J.; Li, J.; Liu, S.; Wang, T.; Ianni, A.; Bober, E.; Braun, T.; Xiang, R.; Yue, S. Exosomal Tetraspanins Mediate Cancer Metastasis by Altering Host Microenvironment. *Oncotarget* 2017, 8 (37), 62803−62815.

(317) Welker, M.-W.; Reichert, D.; Susser, S.; Sarrazin, C.; Martinez, Y.; Herrmann, E.; Zeuzem, S.; Piiper, A.; Kronenberger, B. Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity. *PLoS One* 2012, 7 (2), e30796−e30796.

(318) Ashraf Malik, M.; Ishtiyaq Ali Mirza, J.; Umar, M.; Manzoor, S. CD81(+) Exosomes Play a Pivotal Role in the Establishment of Hepatitis C Persistent Infection and Contribute Toward the Progression of Hepatocellular Carcinoma. *Viral Immunol.* 2019, 32 (10), 453−462.

(319) Chettimada, S.; Lorenz, D. R.; Misra, V.; Dillon, S. T.; Reeves, R. K.; Manickam, C.; Morgello, S.; Kirk, G. D.; Mehta, S. H.; Gabuzda, D. Exosome Markers Associated with Immune Activation and Oxidative Stress in HIV Patients on Antiretroviral Therapy. *Sci. Rep.* 2018, 8 (1), 7227.

(320) Sandfeld-Paulsen, B.; Jakobsen, K. R.; Bæk, R.; Folkersen, B. H.; Rasmussen, T. R.; Meldgaard, P.; Varming, K.; Jørgensen, M. M.; Sorensen, B. S. Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. *J. Thorac. Oncol.* 2016, 11 (10), 1701−1710.

(321) Melo, S. A.; Luecke, L. B.; Kahlert, C.; Fernandez, A. F.; Gammon, S. T.; Kaye, J.; LeBleu, V. S.; Mittendorf, E. A.; Weitz, J.; Rahbari, N.; Reissfelder, C.; Pilarsky, C.; Fraga, M. F.; Piwnica-Worms, D.; Kalluri, R. Glypican-1 Identifies Cancer Exosomes and Detects Early Pancreatic Cancer. *Nature* 2015, 523 (7559), 177−182.

(322) Azmi, A. S.; Bao, B.; Sarkar, F. H. Exosomes in Cancer Development, Metastasis, and Drug Resistance: A Comprehensive Review. *Cancer Metastasis Rev.* 2013, 32 (3−4), 623−642.

(323) Zhou, H.; Yuen, P. S. T.; Pisitkun, T.; Gonzales, P. A.; Yasuda, H.; Dear, J. W.; Gross, P.; Knepper, M. A.; Star, R. A. Collection, Storage, Preservation, and Normalization of Human Urinary Exosomes for Biomarker Discovery. *Kidney Int.* 2006, 69 (8), 1471−1476.

(324) Knepper, M. A. Common Sense Approaches to Urinary Biomarker Study Design. *J. Am. Soc. Nephrol.* 2009, 20 (6), 1175−1178.

(325) Gonzales, P. A.; Pisitkun, T.; Hoffert, J. D.; Tchapyjnikov, D.; Star, R. A.; Kleta, R.; Wang, N. S.; Knepper, M. A. Large-Scale Proteomics and Phosphoproteomics of Urinary Exosomes. *J. Am. Soc. Nephrol.* 2009, 20 (2), 363−379.

(326) Alvarez, M. L.; Khosroheidari, M.; Kanchi Ravi, R.; DiStefano, J. K. Comparison of Protein, MicroRNA, and MRNA Yields Using Different Methods of Urinary Exosome Isolation for the Discovery of Kidney Disease Biomarkers. *Kidney Int.* 2012, 82 (9), 1024−1032.

(327) Zhou, H.; Cheruvanky, A.; Hu, X.; Matsumoto, T.; Hiramatsu, N.; Cho, M. E.; Berger, A.; Leelahavanichkul, A.; Doi, K.; Chawla, L. S.; Illei, G. G.; Kopp, J. B.; Balow, J. E.; Austin, H. A.; Yuen, P. S.T.; Star, R. A. Urinary Exosomal Transcription Factors, a New Class of Biomarkers for Renal Disease. *Kidney Int.* 2008, 74 (5), 613−621.

(328) Wang, Z.; Hill, S.; Luther, J. M.; Hachey, D. L.; Schey, K. L. Proteomic Analysis of Urine Exosomes by Multidimensional Protein Identification Technology (MudPIT). *Proteomics* 2012, 12 (2), 329−338.

(329) Miranda, K. C.; Bond, D. T.; McKee, M.; Skog, J.; Pǎunescu, T. G.; Da Silva, N.; Brown, D.; Russo, L. M. Nucleic Acids within Urinary Exosomes/Microvesicles Are Potential Biomarkers for Renal Disease. *Kidney Int.* 2010, 78 (2), 191−199.

(330) Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J. W. W.; Comber, H.; Forman, D.; Bray, F. Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012. *Eur. J. Cancer* 2013, 49 (6), 1374−1403.

(331) Wu, L.; Zhang, X.; Zhang, B.; Shi, H.; Yuan, X.; Sun, Y.; Pan, Z.; Qian, H.; Xu, W. Exosomes Derived from Gastric Cancer Cells Activate NF-KB Pathway in Macrophages to Promote Cancer Progression. *Tumor Biol.* 2016, 37 (9), 12169−12180.

(332) Ohshima, K.; Inoue, K.; Fujiwara, A.; Hatakeyama, K.; Kanto, K.; Watanabe, Y.; Muramatsu, K.; Fukuda, Y.; Ogura, S.-i.; Yamaguchi, K.; Mochizuki, T. Let-7 MicroRNA Family Is Selectively Secreted into the Extracellular Environment via Exosomes in a Metastatic Gastric Cancer Cell Line. *PLoS One* 2010, 5 (10), e13247−e13247.

(333) Manterola, L.; Guruceaga, E.; Gállego Pérez-Larraya, J.; González-Huarriz, M.; Jauregui, P.; Tejada, S.; Diez-Valle, R.; Segura, V.; Samprón, N.; Barrena, C. A Small Noncoding RNA Signature Found in Exosomes of GBM Patient Serum as a Diagnostic Tool. *Neuro. Oncol.* 2014, 16 (4), 520−527.

(334) Saadatpour, L.; Fadaee, E.; Fadaei, S.; Nassiri Mansour, R.; Mohammadi, M.; Mousavi, S. M.; Goodarzi, M.; Verdi, J.; Mirzaei, H. Glioblastoma: Exosome and MicroRNA as Novel Diagnosis Biomarkers. *Cancer Gene Ther.* 2016, 23 (12), 415−418.

(335) Masoudi, M. S.; Mehrabian, E.; Mirzaei, H. MiR-21: A Key Player in Glioblastoma Pathogenesis. *J. Cell. Biochem.* 2018, 119 (2), 1285−1290.

(336) Huang, S.-W.; Ali, N.; Zhong, L.; Shi, J. MicroRNAs as Biomarkers for Human Glioblastoma: Progress and Potential. *Acta Pharmacol. Sin.* 2018, 39 (9), 1405−1413.

(337) Joyce, D. P.; Kerin, M. J.; Dwyer, R. M. Exosome-Encapsulated MicroRNAs as Circulating Biomarkers for Breast Cancer. *Int. J. Cancer* 2016, 139 (7), 1443−1448.

(338) Rodriguez-Martinez, A.; de Miguel-Perez, D.; Ortega, F. G.; Garcia-Puche, J. L.; Robles-Fernandez, I.; Exposito, J.; Martorell-Marugan, J.; Carmona-Saez, P.; Garrido-Navas, M. d. C.; Rolfo, C.; Ilyine, H.; Lorente, J. A.; Legueren, M.; Serrano, M. J. Exosomal MiRNA Profile as Complementary Tool in the Diagnostic and Prediction of Treatment Response in Localized Breast Cancer under Neoadjuvant Chemotherapy. *Breast Cancer Res.* 2019, 21 (1), 21.

(339) Zhu, L.; Liu, J.; Dao, J.; Lu, K.; Li, H.; Gu, H.; Liu, J.; Feng, X.; Cheng, G. Molecular Characterization of S. Japonicum Exosome-like Vesicles Reveals Their Regulatory Roles in Parasite-Host Interactions. *Sci. Rep.* 2016, 6 (1), 25885.

(340) Wang, Y.; Yuan, W.; Kimber, M.; Lu, M.; Dong, L. Rapid Differentiation of Host and Parasitic Exosome Vesicles Using Microfluidic Photonic Crystal Biosensor. *ACS Sensors* 2018, 3 (9), 1616−1621.

(341) Wu, Z.; Wang, L.; Li, J.; Wang, L.; Wu, Z.; Sun, X. Extracellular Vesicle-Mediated Communication Within Host-Parasite Interactions. *Front. Immunol.* 2019, 9, 3066.

(342) Harding, C.; Heuser, J.; Stahl, P. Receptor-Mediated Endocytosis of Transferrin and Recycling of the Transferrin Receptor in Rat Reticulocytes. *J. Cell Biol.* 1983, 97 (2), 329−339.

(343) Kamerkar, S.; LeBleu, V. S.; Sugimoto, H.; Yang, S.; Ruivo, C. F.; Melo, S. A.; Lee, J. J.; Kalluri, R. Exosomes Facilitate Therapeutic

Targeting of Oncogenic KRAS in Pancreatic Cancer. *Nature* **2017**, *546* (7659), 498−503.

(344) Betzer, O.; Barnoy, E.; Sadan, T.; Elbaz, I.; Braverman, C.; Liu, Z.; Popovtzer, R. Advances in Imaging Strategies for in Vivo Tracking of Exosomes. *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.* **2020**, *12* (2), No. e1594.

(345) Gangadaran, P.; Hong, C. M.; Ahn, B.-C. An Update on in Vivo Imaging of Extracellular Vesicles as Drug Delivery Vehicles. *Front. Pharmacol.* **2018**, *9*, 169.

(346) Stuker, F.; Ripoll, J.; Rudin, M. Fluorescence Molecular Tomography: Principles and Potential for Pharmaceutical Research. *Pharmaceutics* **2011**, *3* (2), 229−274.

(347) Gangadaran, P.; Hong, C. M.; Ahn, B.-C. Current Perspectives on In Vivo Noninvasive Tracking of Extracellular Vesicles with Molecular Imaging. *BioMed Res. Int.* **2017**, *2017*, 9158319.

(348) Chuo, S. T.-Y.; Chien, J. C.-Y.; Lai, C. P.-K. Imaging Extracellular Vesicles: Current and Emerging Methods. *J. Biomed. Sci.* **2018**, *25* (1), 91.

(349) Smyth, T.; Kullberg, M.; Malik, N.; Smith-Jones, P.; Graner, M. W.; Anchordoquy, T. J. Biodistribution and Delivery Efficiency of Unmodified Tumor-Derived Exosomes. *J. Controlled Release* **2015**, *199*, 145−155.

(350) Close, D. M.; Xu, T.; Sayler, G. S.; Ripp, S. In Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living Animals. *Sensors* **2011**, *11* (1), 180−206.

(351) Takahashi, Y.; Nishikawa, M.; Shinotsuka, H.; Matsui, Y.; Ohara, S.; Imai, T.; Takakura, Y. Visualization and in Vivo Tracking of the Exosomes of Murine Melanoma B16-BL6 Cells in Mice after Intravenous Injection. *J. Biotechnol.* **2013**, *165* (2), 77−84.

(352) Kim, T.; Lee, N.; Arifin, D. R.; Shats, I.; Janowski, M.; Walczak, P.; Hyeon, T.; Bulte, J. W. M. In Vivo Micro-CT Imaging of Human Mesenchymal Stem Cells Labeled with Gold-Poly-l-Lysine Nanocomplexes. *Adv. Funct. Mater.* **2017**, *27* (3), 1604213.

(353) Perets, N.; Betzer, O.; Shapira, R.; Brenstein, S.; Angel, A.; Sadan, T.; Ashery, U.; Popovtzer, R.; Offen, D. Golden Exosomes Selectively Target Brain Pathologies in Neurodegenerative and Neurodevelopmental Disorders. *Nano Lett.* **2019**, *19* (6), 3422−3431.

(354) Betzer, O.; Perets, N.; Angel, A.; Motiei, M.; Sadan, T.; Yadid, G.; Offen, D.; Popovtzer, R. In Vivo Neuroimaging of Exosomes Using Gold Nanoparticles. *ACS Nano* **2017**, *11* (11), 10883−10893.

(355) Weber, J.; Beard, P. C.; Bohndiek, S. E. Contrast Agents for Molecular Photoacoustic Imaging. *Nat. Methods* **2016**, *13* (8), 639−650.

(356) Hu, L.; Wickline, S. A.; Hood, J. L. Magnetic Resonance Imaging of Melanoma Exosomes in Lymph Nodes. *Magn. Reson. Med.* **2015**, *74* (1), 266−271.

(357) Jung, K. O.; Jo, H.; Yu, J. H.; Gambhir, S. S.; Pratx, G. Development and MPI Tracking of Novel Hypoxia-Targeted Theranostic Exosomes. *Biomaterials* **2018**, *177*, 139−148.

(358) Cao, Y.; Wu, T.; Zhang, K.; Meng, X.; Dai, W.; Wang, D.; Dong, H.; Zhang, X. Engineered Exosome-Mediated Near-Infrared-II Region V2C Quantum Dot Delivery for Nucleus-Target Low-Temperature Photothermal Therapy. *ACS Nano* **2019**, *13* (2), 1499−1510.

(359) Srivastava, P. Interaction of Heat Shock Proteins with Peptides and Antigen Presenting Cells: Chaperoning of the Innate and Adaptive Immune Responses. *Annu. Rev. Immunol.* **2002**, *20*, 395−425.

(360) Gastpar, R.; Gehrmann, M.; Bausero, M. A.; Asea, A.; Gross, C.; Schroeder, J. A.; Multhoff, G. Heat Shock Protein 70 Surface-Positive Tumor Exosomes Stimulate Migratory and Cytolytic Activity of Natural Killer Cells. *Cancer Res.* **2005**, *65* (12), 5238−5247.

(361) Perez-Hernandez, D.; Gutiérrez-Vázquez, C.; Jorge, I.; López-Martín, S.; Ursa, A.; Sánchez-Madrid, F.; Vázquez, J.; Yáñez-Mó, M. The Intracellular Interactome of Tetraspanin-Enriched Microdomains Reveals Their Function as Sorting Machineries toward Exosomes. *J. Biol. Chem.* **2013**, *288* (17), 11649−11661.

(362) Ahmed, W.; Philip, P. S.; Attoub, S.; Khan, G. Epstein−Barr Virus-Infected Cells Release Fas Ligand in Exosomal Fractions and Induce Apoptosis in Recipient Cells via the Extrinsic Pathway. *J. Gen. Virol.* **2015**, *96* (12), 3646−3659.

(363) Gutiérrez-Vázquez, C.; Villarroya-Beltri, C.; Mittelbrunn, M.; Sánchez-Madrid, F. Transfer of Extracellular Vesicles during Immune Cell-Cell Interactions. *Immunol. Rev.* **2013**, *251* (1), 125−142.

(364) Wen, C.; Seeger, R. C.; Fabbri, M.; Wang, L.; Wayne, A. S.; Jong, A. Y. Biological Roles and Potential Applications of Immune Cell-Derived Extracellular Vesicles. *J. Extracell. Vesicles* **2017**, *6* (1), 1400370.

(365) Assil, S.; Webster, B.; Dreux, M. Regulation of the Host Antiviral State by Intercellular Communications. *Viruses* **2015**, *7* (8), 4707−4733.

(366) Qian, C.; Cao, X. Dendritic Cells in the Regulation of Immunity and Inflammation. *Semin. Immunol.* **2018**, *35*, 3−11.

(367) van Hezel, M. E.; Nieuwland, R.; van Bruggen, R.; Juffermans, N. P. The Ability of Extracellular Vesicles to Induce a Pro-Inflammatory Host Response. *Int. J. Mol. Sci.* **2017**, *18* (6), 1285.

(368) Wang, M.; Zhao, J.; Zhang, L.; Wei, F.; Lian, Y.; Wu, Y.; Gong, Z.; Zhang, S.; Zhou, J.; Cao, K.; Li, X.; Xiong, W.; Li, G.; Zeng, Z.; Guo, C. Role of Tumor Microenvironment in Tumorigenesis. *J. Cancer* **2017**, *8* (5), 761−773.

(369) Becker, A.; Thakur, B. K.; Weiss, J. M.; Kim, H. S.; Peinado, H.; Lyden, D. Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. *Cancer Cell* **2016**, *30*, 836.

(370) Desrochers, L. M.; Antonyak, M. A.; Cerione, R. A. Extracellular Vesicles: Satellites of Information Transfer in Cancer and Stem Cell Biology. *Dev. Cell* **2016**, *37* (4), 301−309.

(371) McAllister, S. S.; Weinberg, R. A. The Tumour-Induced Systemic Environment as a Critical Regulator of Cancer Progression and Metastasis. *Nat. Cell Biol.* **2014**, *16* (8), 717−727.

(372) Noy, R.; Pollard, J. W. Tumor-Associated Macrophages: From Mechanisms to Therapy. *Immunity* **2014**, *41* (1), 49−61.

(373) Sisquella, X.; Ofir-Birin, Y.; Pimentel, M. A.; Cheng, L.; Abou Karam, P.; Sampaio, N. G.; Penington, J. S.; Connolly, D.; Giladi, T.; Scicluna, B. J.; Malaria Parasite DNA-Harbouring Vesicles Activate Cytosolic Immune Sensors. *Nat. Commun.* **2017**, 1985. .

(374) Schorey, J. S.; Cheng, Y.; Singh, P. P.; Smith, V. L. Exosomes and Other Extracellular Vesicles in Host-Pathogen Interactions. *EMBO Rep.* **2015**, *16* (1), 24−43.

(375) Pejawar-Gaddy, S.; Finn, O. J. Cancer Vaccines: Accomplishments and Challenges. *Crit. Rev. Oncol. Hematol.* **2008**, *67* (2), 93−102.

(376) Hartman, Z. C.; Wei, J.; Glass, O. K.; Guo, H.; Lei, G.; Yang, X.-Y.; Osada, T.; Hobeika, A.; Delcayre, A.; Le Pecq, J.-B.; Morse, M. A.; Clay, T. M.; Lyerly, H. K. Increasing Vaccine Potency through Exosome Antigen Targeting. *Vaccine* **2011**, *29* (50), 9361−9367.

(377) Peters, P. J.; Geuze, H. J.; Van der Donk, H. A.; Slot, J. W.; Griffith, J. M.; Stam, N. J.; Clevers, H. C.; Borst, J. Molecules Relevant for T Cell-Target Cell Interaction Are Present in Cytolytic Granules of Human T Lymphocytes. *Eur. J. Immunol.* **1989**, *19* (8), 1469−1475.

(378) Peters, P. J.; Borst, J.; Oorschot, V.; Fukuda, M.; Krähenbühl, O.; Tschopp, J.; Slot, J. W.; Geuze, H. J. Cytotoxic T Lymphocyte Granules Are Secretory Lysosomes, Containing Both Perforin and Granzymes. *J. Exp. Med.* **1991**, *173* (5), 1099−1109.

(379) Li, Y.; Liu, Y.; Xiu, F.; Wang, J.; Cong, H.; He, S.; Shi, Y.; Wang, X.; Li, X.; Zhou, H. Characterization of Exosomes Derived from Toxoplasma Gondii and Their Functions in Modulating Immune Responses. *Int. J. Nanomed.* **2018**, *13*, 467−477.

(380) Roier, S.; Blume, T.; Klug, L.; Wagner, G. E.; Elhenawy, W.; Zangger, K.; Prassl, R.; Reidl, J.; Daum, G.; Feldman, M. F.; Schild, S. A Basis for Vaccine Development: Comparative Characterization of Haemophilus Influenzae Outer Membrane Vesicles. *Int. J. Med. Microbiol.* **2015**, *305* (3), 298−309.

(381) Rajabi, M.; Mousa, S. A. The Role of Angiogenesis in Cancer Treatment. *Biomedicines* **2017**, *5* (2), 34.

(382) Teleanu, R. I.; Chircov, C.; Grumezescu, A. M.; Teleanu, D. M. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. *J. Clin. Med.* **2020**, *9* (1), 84.

(383) Zhang, C.; Ji, Q.; Yang, Y.; Li, Q.; Wang, Z. Exosome: Function and Role in Cancer Metastasis and Drug Resistance. *Technol. Cancer Res. Treat.* **2018**, *17*, 1533033818763450.

(384) Manier, S.; Liu, C.-J.; Avet-Loiseau, H.; Park, J.; Shi, J.; Campigotto, F.; Salem, K. Z.; Huynh, D.; Glavey, S. V.; Rivotto, B.; Sacco, A.; Roccaro, A. M.; Bouyssou, J.; Minvielle, S.; Moreau, P.; Facon, T.; Leleu, X.; Weller, E.; Trippa, L.; Ghobrial, I. M. Prognostic Role of Circulating Exosomal MiRNAs in Multiple Myeloma. *Blood* **2017**, *129* (17), 2429–2436.

(385) Yuwen, D.; Ma, Y.; Wang, D.; Gao, J.; Li, X.; Xue, W.; Fan, M.; Xu, Q.; Shen, Y.; Shu, Y. Prognostic Role of Circulating Exosomal MiR-425–3p for the Response of NSCLC to Platinum-Based Chemotherapy. *Cancer Epidemiol., Biomarkers Prev.* **2019**, *28* (1), 163–173.

(386) Al-Nedawi, K.; Meehan, B.; Kerbel, R. S.; Allison, A. C.; Rak, J. Endothelial Expression of Autocrine VEGF upon the Uptake of Tumor-Derived Microvesicles Containing Oncogenic EGFR. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106* (10), 3794–3799.

(387) Al-Nedawi, K.; Meehan, B.; Micallef, J.; Lhotak, V.; May, L.; Guha, A.; Rak, J. Intercellular Transfer of the Oncogenic Receptor EGFRvIII by Microvesicles Derived from Tumour Cells. *Nat. Cell Biol.* **2008**, *10* (5), 619–624.

(388) Lucero, R.; Zappulli, V.; Sammarco, A.; Murillo, O. D.; Cheah, P. S.; Srinivasan, S.; Tai, E.; Ting, D. T.; Wei, Z.; Roth, M. E.; Laurent, L. C.; Krichevsky, A. M.; Breakefield, X. O.; Milosavljevic, A. Glioma-Derived MiRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells. *Cell Rep.* **2020**, *30* (7), 2065–2074.

(389) Todorova, D.; Simoncini, S.; Lacroix, R.; Sabatier, F.; Dignat-George, F. Extracellular Vesicles in Angiogenesis. *Circ. Res.* **2017**, *120* (10), 1658–1673.

(390) Mamdani, H.; Ahmed, S.; Armstrong, S.; Mok, T.; Jalal, S. I. Blood-Based Tumor Biomarkers in Lung Cancer for Detection and Treatment. *Transl. Lung Cancer Res.* **2017**, *6* (6), 648–660.

(391) NCT03581435. A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients (EXOGBC001).

(392) Shao, Y.; Shen, Y.; Chen, T.; Xu, F.; Chen, X.; Zheng, S. The Functions and Clinical Applications of Tumor-Derived Exosomes. *Oncotarget* **2016**, *7* (37), 60736–60751.

(393) Fu, M.; Gu, J.; Jiang, P.; Qian, H.; Xu, W.; Zhang, X. Exosomes in Gastric Cancer: Roles, Mechanisms, and Applications. *Mol. Cancer* **2019**, *18* (1), 41.

(394) Sun, Z.; Shi, K.; Yang, S.; Liu, J.; Zhou, Q.; Wang, G.; Song, J.; Li, Z.; Zhang, Z.; Yuan, W. Effect of Exosomal MiRNA on Cancer Biology and Clinical Applications. *Mol. Cancer* **2018**, *17* (1), 147.

(395) Wu, Q.; Wu, X.; Ying, X.; Zhu, Q.; Wang, X.; Jiang, L.; Chen, X.; Wu, Y.; Wang, X. Suppression of Endothelial Cell Migration by Tumor Associated Macrophage-Derived Exosomes Is Reversed by Epithelial Ovarian Cancer Exosomal LncRNA. *Cancer Cell Int.* **2017**, *17* (1), 62.

(396) Mannavola, F.; Salerno, T.; Passarelli, A.; Tucci, M.; Internò, V.; Silvestris, F. Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now? *Front. Oncol.* **2019**, *9*, 521.

(397) Li, T.; Yan, Y.; Wang, B.; Qian, H.; Zhang, X.; Shen, L.; Wang, M.; Zhou, Y.; Zhu, W.; Li, W.; Xu, W. Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Liver Fibrosis. *Stem Cells Dev.* **2013**, *22* (6), 845–854.

(398) Nakamura, Y.; Miyaki, S.; Ishitobi, H.; Matsuyama, S.; Nakasa, T.; Kamei, N.; Akimoto, T.; Higashi, Y.; Ochi, M. Mesenchymal-Stem-Cell-Derived Exosomes Accelerate Skeletal Muscle Regeneration. *FEBS Lett.* **2015**, *589* (11), 1257–1265.

(399) Zhang, B.; Yeo, R. W. Y.; Tan, K. H.; Lim, S. K. Focus on Extracellular Vesicles: Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles. *Int. J. Mol. Sci.* **2016**, *17* (2), 174.

(400) Balbi, C.; Piccoli, M.; Barile, L.; Papait, A.; Armirotti, A.; Principi, E.; Reverberi, D.; Pascucci, L.; Becherini, P.; Varesio, L.; Mogni, M.; Coviello, D.; Bandiera, T.; Pozzobon, M.; Cancedda, R.; Bollini, S. First Characterization of Human Amniotic Fluid Stem Cell Extracellular Vesicles as a Powerful Paracrine Tool Endowed with Regenerative Potential. *Stem Cells Transl. Med.* **2017**, *6* (5), 1340–1355.

(401) Andrews, D. W.; Resnicoff, M.; Flanders, A. E.; Kenyon, L.; Curtis, M.; Merli, G.; Baserga, R.; Iliakis, G.; Aiken, R. D. Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed against the Insulin-like Growth Factor Type I Receptor in Malignant Astrocytomas. *J. Clin. Oncol.* **2001**, *19* (8), 2189–2200.

(402) Cage, T. A.; Lamborn, K. R.; Ware, M. L.; Frankfurt, A.; Chakalian, L.; Berger, M. S.; McDermott, M. W. Adjuvant Enoxaparin Therapy May Decrease the Incidence of Postoperative Thrombotic Events Though Does Not Increase the Incidence of Postoperative Intracranial Hemorrhage in Patients with Meningiomas. *J. Neuro-Oncol.* **2009**, *93* (1), 151–156.

(403) Ma, T.; Fu, B.; Yang, X.; Xiao, Y.; Pan, M. Adipose Mesenchymal Stem Cell-Derived Exosomes Promote Cell Proliferation, Migration, and Inhibit Cell Apoptosis via Wnt/β-Catenin Signaling in Cutaneous Wound Healing. *J. Cell. Biochem.* **2019**, *120* (6), 10847–10854.

(404) Wang, X.; Jiao, Y.; Pan, Y.; Zhang, L.; Gong, H.; Qi, Y.; Wang, M.; Gong, H.; Shao, M.; Wang, X.; Jiang, D. Fetal Dermal Mesenchymal Stem Cell-Derived Exosomes Accelerate Cutaneous Wound Healing by Activating Notch Signaling. *Stem Cells Int.* **2019**, *2019*, 2402916.

(405) Ezquer, F.; Ezquer, M.; Contador, D.; Ricca, M.; Simon, V.; Conget, P. The Antidiabetic Effect of Mesenchymal Stem Cells Is Unrelated to Their Transdifferentiation Potential but to Their Capability to Restore Th1/Th2 Balance and to Modify the Pancreatic Microenvironment. *Stem Cells* **2012**, *30* (8), 1664–1674.

(406) Lee, H. Y.; Yea, K.; Kim, J.; Lee, B. D.; Chae, Y. C.; Kim, H. S.; Lee, D.-W.; Kim, S.-H.; Cho, J.-H.; Jin, C. J.; Koh, D.-S.; Park, K. S.; Suh, P.-G.; Ryu, S. H. Epidermal Growth Factor Increases Insulin Secretion and Lowers Blood Glucose in Diabetic Mice. *J. Cell. Mol. Med.* **2008**, *12* (5A), 1593–1604.

(407) Xiao, Y.; Zheng, L.; Zou, X.; Wang, J.; Zhong, J.; Zhong, T. Extracellular Vesicles in Type 2 Diabetes Mellitus: Key Roles in Pathogenesis, Complications, and Therapy. *J. Extracell. Vesicles* **2019**, *8* (1), 1625677.

(408) Ge, Q.; Xie, X. X.; Xiao, X.; Li, X. Exosome-Like Vesicles as New Mediators and Therapeutic Targets for Treating Insulin Resistance and β-Cell Mass Failure in Type 2 Diabetes Mellitus. *J. Diabetes Res.* **2019**, *2019*, 3256060.

(409) Chidester, S.; Livinski, A. A.; Fish, A. F.; Joseph, P. V. The Role of Extracellular Vesicles in β-Cell Function and Viability: A Scoping Review. *Front. Endocrinol.* **2020**, *11*, 375.

(410) Garcia-Contreras, M.; Brooks, R. W.; Boccuzzi, L.; Robbins, P. D.; Ricordi, C. Exosomes as Biomarkers and Therapeutic Tools for Type 1 Diabetes Mellitus. *Eur. Rev. Med. Pharmacol. Sci.* **2017**, *21* (12), 2940–2956.

(411) Czernek, L.; Düchler, M. Exosomes as Messengers Between Mother and Fetus in Pregnancy. *Int. J. Mol. Sci.* **2020**, *21* (12), 4264.

(412) Pillay, P.; Moodley, K.; Moodley, J.; Mackraj, I. Placenta-Derived Exosomes: Potential Biomarkers of Preeclampsia. *Int. J. Nanomed.* **2017**, *12*, 8009–8023.

(413) Salomon, C.; Guanzon, D.; Scholz-Romero, K.; Longo, S.; Correa, P.; Illanes, S. E.; Rice, G. E. Placental Exosomes as Early Biomarker of Preeclampsia: Potential Role of Exosomal MicroRNAs Across Gestation. *J. Clin. Endocrinol. Metab.* **2017**, *102* (9), 3182–3194.

(414) Mitchell, M. D.; Peiris, H. N.; Kobayashi, M.; Koh, Y. Q.; Duncombe, G.; Illanes, S. E.; Rice, G. E.; Salomon, C. Placental Exosomes in Normal and Complicated Pregnancy. *Am. J. Obstet. Gynecol.* **2015**, *213* (4, Supplement), S173–S181.

(415) Hruby, A.; Hu, F. B. The Epidemiology of Obesity: A Big Picture. *PharmacoEconomics* **2015**, *33* (7), 673–689.

(416) Castaño, C.; Kalko, S.; Novials, A.; Párrizas, M. Obesity-Associated Exosomal MiRNAs Modulate Glucose and Lipid

Metabolism in Mice. *Proc. Natl. Acad. Sci. U. S. A.* **2018**, *115* (48), 12158−12163.

(417) Ji, C.; Guo, X. The Clinical Potential of Circulating MicroRNAs in Obesity. *Nat. Rev. Endocrinol.* **2019**, *15* (12), 731−743.

(418) Tan, D. B. A.; Armitage, J.; Teo, T.-H.; Ong, N. E.; Shin, H.; Moodley, Y. P. Elevated Levels of Circulating Exosome in COPD Patients Are Associated with Systemic Inflammation. *Respir. Med.* **2017**, *132*, 261−264.

(419) Xu, H.; Ling, M.; Xue, J.; Dai, X.; Sun, Q.; Chen, C.; Liu, Y.; Zhou, L.; Liu, J.; Luo, F.; Bian, Q.; Liu, Q. Exosomal MicroRNA-21 Derived from Bronchial Epithelial Cells Is Involved in Aberrant Epithelium-Fibroblast Cross-Talk in COPD Induced by Cigarette Smoking. *Theranostics* **2018**, *8* (19), 5419−5433.

(420) Abd El-Kader, S. M.; Al-Shreef, F. M. Inflammatory Cytokines and Immune System Modulation by Aerobic versus Resisted Exercise Training for Elderly. *Afr. Health Sci.* **2018**, *18* (1), 120−131.

(421) Xu, X.; Gao, X. Immunological Responses against SARS-Coronavirus Infection in Humans. *Cell. Mol. Immunol.* **2004**, *1* (2), 119−122.

(422) Tufan, A.; Avanoğlu Güler, A.; Matucci-Cerinic, M. COVID-19, Immune System Response, Hyperinflammation and Repurposing Antirheumatic Drugs. *Turkish J. Med. Sci.* **2020**, *50* (SI-1), 620−632.

(423) Wilk, A. J.; Rustagi, A.; Zhao, N. Q.; Roque, J.; Martinez-Colon, G. J.; McKechnie, J. L.; Ivison, G. T.; Ranganath, T.; Vergara, R.; Hollis, T.; Simpson, L. J.; Grant, P.; Subramanian, A.; Rogers, A. J.; Blish, C. A. A Single-Cell Atlas of the Peripheral Immune Response in Patients with Severe COVID-19. *Nat. Med.* **2020**, *26* (7), 1070−1076.

(424) Liu, J.; Li, S.; Liu, J.; Liang, B.; Wang, X.; Wang, H.; Li, W.; Tong, Q.; Yi, J.; Zhao, L. Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients. *EBioMedicine* **2020**, *55*, 102763.

(425) Blazquez, R.; Sanchez-Margallo, F. M.; de la Rosa, O.; Dalemans, W.; Álvarez, V.; Tarazona, R.; Casado, J. G. Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on in Vitro Stimulated T Cells. *Front. Immunol.* **2014**, *5*, 556.

(426) Alzahrani, F. A.; Saadeldin, I. M.; Ahmad, A.; Kumar, D.; Azhar, E. I.; Siddiqui, A. J.; Kurdi, B.; Sajini, A.; Alrefaei, A. F.; Jahan, S. The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients. *Stem Cells Int.* **2020**, *2020*, 8835986.

(427) Maqsood, M.; Kang, M.; Wu, X.; Chen, J.; Teng, L.; Qiu, L. Adult Mesenchymal Stem Cells and Their Exosomes: Sources, Characteristics, and Application in Regenerative Medicine. *Life Sci.* **2020**, *256*, 118002.

(428) Rosendahl Huber, S.; van Beek, J.; de Jonge, J.; Luytjes, W.; van Baarle, D. T Cell Responses to Viral Infections - Opportunities for Peptide Vaccination. *Front. Immunol.* **2014**, *5*, 171.

(429) Cox, M. A.; Kahan, S. M.; Zajac, A. J. Anti-Viral CD8 T Cells and the Cytokines That They Love. *Virology* **2013**, *435* (1), 157−169.

(430) Vella, L. A.; Herati, R. S.; Wherry, E. J. CD4(+) T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective. *Trends Mol. Med.* **2017**, *23* (12), 1072−1087.

(431) Schmidt, M. E.; Varga, S. M. The CD8 T Cell Response to Respiratory Virus Infections. *Front. Immunol.* **2018**, *9*, 678.